Document:

Exhibit 10.1	EXECUTION COPY

 

 

 

CREDIT
AGREEMENT

 

between

 

APOLLO
MEDICAL HOLDINGS, INC.

 

and

 

NNA
OF NEVADA, INC.

 

$7,000,000
Term Loan

 

$1,000,000
Revolving Line of Credit

 

March
28, 2014

 

 

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

	 	Page
	 	 
	 	ARTICLE I	 
	 	 	 
	 	DEFINITIONS	 
	 	 	 
	1.1	Defined Terms	1
	1.2	Accounting Terms	16
	1.3	Singular/Plural	16
	1.4	Other Terms	16
	 	 	 
	 	ARTICLE II	 
	 	 	 
	 	AMOUNTS AND TERMS OF THE LOANS	 
	 	 	 
	2.1	Commitments	16
	2.2	Repayments; Maturity of Loans	17
	2.3	Interest	18
	2.4	Fees	19
	2.5	Termination or Reduction of Commitments	19
	2.6	General Provisions as to Payments	19
	2.7	Disbursement of Loan Proceeds	19
	2.8	Use of Proceeds	20
	2.9	Taxes	20
	2.10	Basis for Determining Interest Rate Inadequate or Unfair	20
	2.11	Illegality	20
	2.12	Increased Cost and Reduced Return	21
	2.13	Application and Allocation of Payments	21
	2.14	Warrants	22
	 	 	 
	 	ARTICLE III	 
	 	 	 
	 	CLOSING; CONDITIONS OF CLOSING AND BORROWING	 
	 	 	 
	3.1	Conditions of Initial Loans	22
	3.2	Conditions to all Loans	26
	3.3	Post-Closing	26
	 	 	 
	 	ARTICLE IV	 
	 	 	 
	 	REPRESENTATIONS AND WARRANTIES	 
	 	 	 
	4.1	Corporate Organization and Power	27
	4.2	Authorization; Enforceability	27
	4.3	No Violation	27
	4.4	Governmental and Third-Party Authorization; Permits	28
	4.5	Litigation	28

 

    	 

    	 

    

 

	4.6	Taxes	28
	4.7	Capitalization	29
	4.8	Full Disclosure	30
	4.9	Margin Regulations	30
	4.10	No Material Adverse Effect	30
	4.11	Financial Matters	30
	4.12	Ownership of Properties	31
	4.13	ERISA	32
	4.14	Environmental Matters	32
	4.15	Compliance with Laws	33
	4.16	Intellectual Property	33
	4.17	Investment Company Act	33
	4.18	Insurance	33
	4.19	Material Contracts	33
	4.20	Security Documents	34
	4.21	Labor Relations	34
	4.22	No Burdensome Restrictions	34
	4.23	OFAC; Anti-Terrorism Laws	34
	4.24	Investment Documents	35
	 	 	 
	 	ARTICLE V	 
	 	 	 
	 	AFFIRMATIVE COVENANTS	 
	 	 	 
	5.1	Financial Statements	35
	5.2	Other Business and Financial Information	36
	5.3	Existence; Franchises; Maintenance of Properties	38
	5.4	Compliance with Laws	38
	5.5	Payment of Obligations	39
	5.6	Insurance	39
	5.7	Maintenance of Books and Records; Inspection	39
	5.8	Permitted Acquisitions	40
	5.9	Creation or Acquisition of Subsidiaries	41
	5.10	Additional Security	43
	5.11	Environmental Laws	44
	5.12	PATRIOT Act Compliance	44
	5.13	Securities Filings	44
	5.14	Further Assurances	44
	5.15	Board Rights	44
	5.16	Immaterial Subsidiaries	45
	 	 	 
	 	ARTICLE VI	 
	 	 	 
	 	FINANCIAL COVENANTS	 
	 	 	 
	6.1	Consolidated EBITDA	45
	6.2	Leverage Ratio	45
	6.3	Fixed Charge Coverage Ratio	45

 

    	ii

    	 

    

 

	6.4	Consolidated Tangible Net Worth	45
	 	 	 
	 	ARTICLE VII	 
	 	 	 
	 	NEGATIVE COVENANTS	 
	 	 	 
	7.1	Merger; Consolidation	46
	7.2	Indebtedness	47
	7.3	Liens	49
	7.4	Asset Dispositions	50
	7.5	Investments	51
	7.6	Restricted Payments	52
	7.7	Transactions with Affiliates	53
	7.8	Lines of Business	54
	7.9	Sale-Leaseback Transactions	54
	7.10	Certain Amendments	55
	7.11	Limitation on Certain Restrictions	55
	7.12	No Other Negative Pledges	55
	7.13	Fiscal Year	56
	7.14	Accounting Changes	56
	 	 	 
	 	ARTICLE VIII	 
	 	 	 
	 	EVENTS OF DEFAULT; REMEDIES	 
	 	 	 
	8.1	Events of Default	56
	8.2	Remedies	59
	 	 	 
	 	ARTICLE IX	 
	 	 	 
	 	MISCELLANEOUS	 
	 	 	 
	9.1	Costs, Expenses and Taxes	59
	9.2	Indemnification	60
	9.3	Consent to Jurisdiction; Waiver of Jury Trial	61
	9.4	Notices	61
	9.5	Continuing Obligations	62
	9.6	Confidential Information	62
	9.7	Controlling Law	63
	9.8	Successors and Assigns	63
	9.9	Assignment and Sale	63
	9.10	Entire Agreement	63
	9.11	Amendment	64
	9.12	Severability	64
	9.13	Counterparts	64
	9.14	Captions	64
	9.15	Termination of Existing Credit Agreement	64
	9.16	Public Announcements	64

 

    	iii

    	 

    

 

	EXHIBITS:	 
	Exhibit A	Form of Compliance Certificate
	Exhibit B	Form of Notice of Borrowing
	Exhibit C	Form of Intercompany Note

  

	SCHEDULES:	 
	Schedule 1.1	Immaterial Subsidiaries
	Schedule 4.1	Credit Party Jurisdictions
	Schedule 4.4	Consents
	Schedule 4.7(b)	Capitalization
	Schedule 4.7(d)	Subsidiaries
	Schedule 4.12	Realty; Registry
	Schedule 4.14	Environmental Matters
	Schedule 4.16	Intellectual Property
	Schedule 4.18	Insurance
	Schedule 4.19	Material Contracts
	Schedule 7.2	Indebtedness
	Schedule 7.3	Liens
	Schedule 7.4(vii)	Asset Disposition
	Schedule 7.5	Investments
	Schedule 7.6(a)(iv)	Restricted Payments
	Schedule 7.7	Transactions with Affiliates

 

    	iv

    	 

    

 

CREDIT AGREEMENT

 

THIS CREDIT AGREEMENT, dated as of
March 28, 2014, is made and entered into between Apollo Medical Holdings, Inc., a Delaware corporation (“Borrower”),
and NNA of Nevada, Inc. (“Lender”).

 

BACKGROUND STATEMENT

 

A.           The
Borrower and the Lender are party to a Credit Agreement, dated as of October 15, 2013, as amended by the First Amendment To Credit
Agreement, dated as of December 20, 2013 (as so amended, the “Existing Credit Agreement”).

 

 

B.           The
Borrower has applied to the Lender for a term loan in the principal amount of $7,000,000 to refinance the outstanding principal
balance of the loans under the Existing Credit Agreement and provide additional working capital, and to be advanced by the Lender
pursuant to the terms and conditions hereof. 

 

C.           The
Borrower has also requested that the Lender extend a $1,000,000 revolving line of credit to the Borrower, to be advanced by the
Lender pursuant to the terms and conditions hereof.

 

D.           The
Lender is willing to extend the term loan and revolving line of credit described above upon the terms and subject to the conditions
set forth in this Credit Agreement.

 

 

AGREEMENT

 

NOW, THEREFORE, in consideration
of the premises, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and
in order to induce the Lender to make the loans described herein, the parties hereto hereby agree as follows:

 

ARTICLE
I

 

DEFINITIONS

 

1.1           Defined
Terms.   In addition to the words and terms defined elsewhere in this Agreement, the following terms when used herein shall have
the following respective meanings:

 

“Acquisition” means any
transaction or series of related transactions, consummated on or after the date hereof, by which the Borrower or any of its Subsidiaries,
(i) acquires all or substantially all of the assets of any Person or any going business, division thereof or line of business,
whether through purchase of assets, merger or otherwise, (ii) acquires Capital Stock of any Person having at least a majority
of combined voting power of the then outstanding Capital Stock of such Person or (iii) enters into a Physician Practice Management
Agreement, some other physician practice management agreement or such other agreement with another Person and the effect of which
is to cause such Person to be consolidated with the Borrower in accordance with GAAP.

 

    	 

    	 

    

 

“Acquisition Amount”
means, with respect to any Acquisition, the sum (without duplication) of (i) the amount of cash paid as purchase price by
the Borrower and its Subsidiaries in connection with such Acquisition, (ii) the value of all Capital Stock of the Borrower
issued or given as purchase price in connection with such Acquisition (as determined by the parties thereto under the definitive
acquisition agreement and, if no such determination is made, as determined in good faith by the Board of Directors of the Borrower),
(iii) the amount (determined by using the face amount or the amount payable at maturity, whichever is greater) of all Indebtedness
assumed or acquired by the Borrower and its Subsidiaries in connection with such Acquisition, (iv) the maximum amount of any
Contingent Purchase Price Obligations payable in connection with such Acquisition, as determined in good faith by the Borrower,
(v) all amounts paid in respect of noncompetition agreements, consulting agreements and similar arrangements entered into
in connection with such Acquisition, and (vi) the aggregate fair market value of all other real, mixed or personal property
paid as purchase price by the Borrower and its Subsidiaries in connection with such Acquisition.

 

“Adjusted LIBOR” means
a rate per annum equal to the sum of (i) LIBOR and (ii) six percent (6%).

 

“Affiliate” means, as
to any Person, (i) any other Person which directly, or indirectly through one or more intermediaries, controls such Person or is
consolidated with such Person in accordance with GAAP, (ii) any other Person which directly, or indirectly through one or more
intermediaries, is controlled by or is under common control with such Person, or (iii) any other Person of which such Person owns,
directly or indirectly, ten percent (10%) or more of the common stock or equivalent equity interests. As used herein, the term
“control” means possession, directly or indirectly, of the power to direct or cause the direction of the management
or policies of a Person, whether through the ownership of voting securities or otherwise.

 

“Affiliated Physician Practice
Entity” means any of Maverick Medical Group, Inc., ApolloMed Care Clinic, ApolloMed Hospitalists, and any other physician
practice group that from time to time is consolidated with the Borrower in accordance with GAAP and (i) that is a party to a Physician
Practice Management Agreement with the Borrower or any Subsidiary and (ii) for which the owner(s) of at least seventy five percent
(75%) of its outstanding Capital Stock have entered into a Physician Shareholder Agreement.

 

“Agreement” means this
Credit Agreement and all schedules and exhibits hereto, together with any amendments, modifications, replacements and supplements
hereto, any substitutes herefor, and any replacements, renewals or extensions hereof, in whole or in part, and shall refer to this
Agreement as the same may be in effect at the time such reference becomes operative.

 

“Aligned Purchase Agreement”
means the Stock Purchase Agreement, dated as of February 15, 2011, as amended by the First Amendment to Stock Purchase Agreement,
dated as of July 8, 2011, among the Borrower, Aligned Healthcare Group LLC, Aligned Healthcare Group – California, Inc. and
the other parties thereto.

 

    	2

    	 

    

 

“Asset Disposition” means
any sale, assignment, lease, conveyance, transfer or other disposition by any Credit Party (whether in one or a series of transactions)
of all or any of its assets, business or other properties (including Capital Stock of Subsidiaries), other than pursuant to a Casualty
Event.

 

“Bankruptcy Code” means
Title 11 of the United States Code, as amended, and any successor statute or statutes having substantially the same function.

 

“Borrower” has the meaning
set forth in the introductory paragraph hereof.

 

“Borrowing” means any
borrowing hereunder consisting of the Term Loan or a Revolving Loan made to the Borrower pursuant to Article II.

 

“Business Day” means
any day of the year on which banks are open for business in Waltham, Massachusetts and, in respect of any determination relevant
to the determination or payment of interest determined based on LIBOR, the term “Business Day” shall also exclude any
day on which banks in London, England are not open for dealings in United States dollar deposits in the London interbank market.

 

“Capital Expenditures”
means, during any period, the sum of all amounts paid during such period that would, in accordance with GAAP, be included on the
consolidated statement of cash flows of the Borrower and its Subsidiaries as an acquisition of fixed assets or improvements, replacements,
substitutions or additions thereto.

 

“Capital Stock” means
(i) with respect to any Person that is a corporation, any and all shares, interests or equivalents in capital stock (whether voting
or nonvoting, and whether common or preferred) of such corporation, and (ii) with respect to any Person that is not a corporation,
any and all partnership, membership, limited liability company or other equity interests of such Person; and in each case, any
and all warrants, rights or options to purchase any of the foregoing.

 

“Capitalized Lease” means
any lease or similar arrangement which is of a nature that payment obligations of the lessee or obligor thereunder at the time
are or should be capitalized and shown as liabilities (other than current liabilities) upon a balance sheet of such lessee or obligor
prepared in accordance with GAAP.

 

“Capitalized Lease Obligations”
means, with respect to any Capitalized Lease, the amount of the obligation of the lessee thereunder that would, in accordance with
GAAP, appear on a balance sheet of such lessee with respect to such Capitalized Lease.

 

“Cash Equivalents” means
(i) securities issued or unconditionally guaranteed or insured by the United States of America or any agency or instrumentality
thereof, backed by the full faith and credit of the United States of America and maturing within one year from the date of acquisition,
(ii) commercial paper issued by any Person organized under the laws of the United States of America, maturing within 180 days from
the date of acquisition and, at the time of acquisition, having a rating of at least A-1 or the equivalent thereof by Standard
& Poor’s Ratings Services or at least P-1 or the equivalent thereof by Moody’s Investors Service, Inc., (iii) time
deposits and certificates of deposit maturing within 180 days from the date of issuance and issued by a bank or trust company organized
under the laws of the United States of America or any state thereof (y) that has combined capital and surplus of at least $500,000,000
or (z) that has (or is a subsidiary of a bank holding company that has) a long-term unsecured debt rating of at least A or the
equivalent thereof by Standard & Poor’s Ratings Services or at least A2 or the equivalent thereof by Moody’s Investors
Service, Inc., (iv) repurchase obligations with a term not exceeding thirty (30) days with respect to underlying securities of
the types described in clause (i) above entered into with any bank or trust company meeting the qualifications specified in clause
(iii) above, (v) money market funds at least ninety-five percent (95%) of the assets of which are continuously invested in securities
of the foregoing types, and (vi) cash balances in accounts deposited with banks or other financial institutions in the United
States.

 

    	3

    	 

    

 

“Casualty Event” means,
with respect to any property (including any interest in property) of any Credit Party, any loss of, damage to, or condemnation
or other taking of, such property for which such Credit Party receives insurance proceeds, proceeds of a condemnation award or
other compensation.

 

“Change of Law” means
the adoption of any applicable law, rule or regulation, or any change therein or any existing or future law, rule or regulation,
or any change in the interpretation or administration thereof, by any Governmental Authority, or compliance by the Lender with
any request or directive (whether or not having the force of law) of any Governmental Authority.

 

“Closing Date” means
the date upon which the initial extensions of credit are made pursuant to this Agreement, which shall be the date upon which each
of the conditions set forth in Sections 3.1 and 3.2 shall have been satisfied or waived in accordance with the terms
of this Agreement.

 

“Code” means the Internal
Revenue Code of 1986, as amended, or any successor federal tax code. Any reference to any provision of the Code shall also include
the income tax regulations promulgated thereunder, whether final, temporary or proposed.

 

“Compliance Certificate”
means a fully completed and duly executed certificate in the form of Exhibit A, together with a Covenant Compliance Worksheet.

 

“Confidential Information”
means, with respect to a party hereto or any of its Affiliates (the “Disclosing Party”), any and all confidential
or proprietary information and material disclosed by the Disclosing Party to the other party hereto or any of its Affiliates (the
“Receiving Party”) or obtained by the Receiving Party through inspection or observation of the Disclosing Party’s
property or facilities (whether in writing, or in oral, graphic, electronic or any other form), whether disclosed or obtained before,
on or after the date hereof, including any (a) trade secret, know-how, idea, invention, process, technique, algorithm, program
(whether in source code or object code form), hardware, device, design, schematic, drawing, formula, data, plan, strategy and forecast
of, and (b) technical, engineering, manufacturing, product, marketing, servicing, financial, personnel, log-in or identification
passwords and other information and materials of, the Disclosing Party and its employees, consultants, investors, Affiliates, licensors,
suppliers, vendors, customers, clients and other Persons, provided, that Confidential Information shall not include any
such information which (a) was in the public domain on the Closing Date or comes into the public domain other than through the
fault or negligence of the other party hereto (the “Receiving Party”) or any of its Affiliates, (b) was lawfully
obtained by the Receiving Party from a third party, but only to the extent that such source is not known by the Receiving Party
to be bound by a confidentiality agreement with, or other contractual, legal or fiduciary obligation of confidentiality to, the
Disclosing Party or any other party with respect to such information, (c) was known to the Receiving Party or any of its Affiliates
at the time of disclosure of such Confidential Information to the Receiving Party by the Disclosing Party, provided that
the Receiving Party was not, at such time, subject to any confidentiality obligation to the Disclosing Party with respect thereto,
or (d) was independently developed by the Receiving Party without making use of any Confidential Information. For the avoidance
of doubt, it is expressly agreed and understood that (i) financial projections of the Borrower were disclosed by the Borrower to
the Lender (or any person on behalf of the Lender) on March 4, 2014, on March 11, 2014 and on March 24, 2014 (collectively, the
“Projections”) as required by the Lender and the Projections were prior to the date hereof subject to the confidentiality
provisions of Section 9.6 of the Existing Credit Agreement, (ii) information that was subject to the confidentiality provisions
of Section 9.6 of the Existing Credit Agreement, including the Projections, shall be deemed Confidential Information and subject
to the confidentiality provisions of Section 9.6, and (iii) the Lender acknowledges that the Projections have only been
used to determine the financial covenants herein and in the Convertible Note and shall not be used for any other purpose.  

 

    	4

    	 

    

 

“Consolidated EBITDA”
means, for the Borrower for any period, the aggregate of (i) Consolidated Net Income of the Borrower for such period, plus (ii)
the sum of interest expense, income tax expense, depreciation and amortization, and minus (iii) interest income, all to the extent
taken into account in the calculation of Consolidated Net Income of the Borrower for such period.

 

“Consolidated Entities”
means the Borrower and the Subsidiaries of the Borrower.

 

“Consolidated Funded Debt”
means, without duplication, any of the following types of Indebtedness of the Borrower and its Subsidiaries, as determined on consolidated
basis in accordance with GAAP:

 

(i)          all
obligations for borrowed money, whether current or long-term (including the Obligations hereunder), and all obligations evidenced
by bonds, debentures, notes, loan agreements or similar instruments;

 

(ii)         all
purchase money Indebtedness (including indebtedness and obligations in respect of conditional sales and title retention arrangements,
except for customary conditional sales and title retention arrangements with suppliers that are entered into in the ordinary course
of business) and all Indebtedness and obligations in respect of deferred purchase price of property or services (other than trade
payables incurred in the ordinary course of business on terms customary in the trade and not past due other than as a result of
a bona fide dispute pursuant to Section 5.5);

 

(iii)        the
principal amount of capital leases;

 

(iv)         any
non-contingent obligations with respect to preferred stock and comparable equity interests providing for mandatory redemption,
sinking fund or other like payments; and

 

    	5

    	 

    

 

(v)          any
of the foregoing types of Indebtedness of any partnership or joint venture or other similar entity which any such Person is a
general partner or joint venture, and, as such, has personal liability for such obligations, but only to the extent there is recourse
to such Person for payment thereof.

 

“Consolidated Net Income”
means, for the Borrower for any period, the net income (or loss) of the Borrower and its Subsidiaries, as determined on consolidated
basis in accordance with GAAP, but excluding extraordinary gains and losses and any other non-operating gains and losses.

 

“Consolidated Tangible Net Worth”
means, at any date, (i) the Borrower’s total stockholders’ equity at such date determined for the Borrower and its
Subsidiaries on consolidated basis in accordance with GAAP minus (ii) the amount of intangible assets of the Borrower and
its Subsidiaries at such date, including without limitation, goodwill (whether representing the excess of cost over book value
of assets acquired, or otherwise), capitalized expenses, patents, trademarks, tradenames, copyrights, franchises, licenses and
deferred charges, all determined for the Borrower and its Subsidiaries on a consolidated basis in accordance with GAAP; provided,
however, that the Borrower and the Lender may mutually agree in writing, in each such party’s sole discretion and
without any obligation to do so, to add-back to the calculation of “Consolidated Tangible Net Worth” certain goodwill
relating to one or more acquisitions.

 

“Contingent Purchase Price Obligations”
means any earnout obligations or similar deferred or contingent purchase price obligations of the Borrower or any of its Subsidiaries
incurred or created in connection with an Acquisition.

 

“Controlled Group” means
all members of a controlled group of corporations and all trades or businesses (whether or not incorporated) under common control
which, together with the Borrower, are treated as a single employer under Section 414 of the Code.

 

“Convertible Note” means
the 8% initial Convertible Note issued by the Borrower pursuant to the Investment Agreement, providing an option for the Borrower
to borrow an original principal amount of $2,000,000, as such Convertible Secured Note is in effect on the Closing Date and as
the same may be supplemented, amended, restated, extended, renewed, replaced or otherwise modified from time to time in accordance
with the terms hereof and thereof.

 

“Costs” has the meaning
set forth in Section 9.2.

 

“Covenant Compliance Worksheet”
means a fully completed worksheet in the form of Attachment A to Exhibit A.

 

“Credit Documents” means
and collectively refer to this Agreement, the Intercompany Notes, the Security Documents, the Warrants, the Shareholders Agreement,
the Registration Rights Agreement and any and all other agreements, instruments and documents now or hereafter executed by or in
behalf of the Borrower or any Subsidiary or delivered to the Lender with respect to this Agreement or with respect to the transactions
contemplated by this Agreement, and in each case, together with any amendments, modifications and supplements thereto, any replacements,
renewals, extensions and restatements thereof, and any substitutes therefor, in whole or in part.

    	6

    	 

    

 

“Credit Parties” means
the Borrower and the Subsidiary Guarantors.

 

“Default” means any event
which with the giving of notice, lapse of time, or both, would become an Event of Default.

 

“Default Rate” means
an interest rate equal to the sum of (i) the rate otherwise in effect for the Term Loan or Revolving Loans, as the case may be,
and (ii) six percent (6.0%).

 

“Dollar” or “$”
means dollars in lawful currency of the United States of America.

 

“Environmental Claims”
means any and all administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, allegations, notices
of noncompliance or violation, investigations by a Governmental Authority, or proceedings (including administrative, regulatory
and judicial proceedings) relating in any way to any Hazardous Substance, any actual or alleged violation of or liability under
any Environmental Law or any permit issued, or any approval given, under any Environmental Law (collectively, “Claims”),
including (i) any and all Claims by Governmental Authorities for enforcement, cleanup, removal, response, remedial or other
actions or damages pursuant to any applicable Environmental Law and (ii) any and all Claims by any third party seeking damages,
contribution, indemnification, cost recovery, compensation or injunctive relief resulting from any Hazardous Substance or arising
from alleged injury or threat of injury to human health or the environment.

 

“Environmental Laws”
means any and all federal, state and local laws, statutes, ordinances, rules, regulations, permits, licenses, approvals, rules
of common law and orders of courts or Governmental Authorities, relating to the protection of human health, occupational safety
with respect to exposure to Hazardous Substances, or the environment, now or hereafter in effect, and in each case as amended from
time to time, including requirements pertaining to the manufacture, processing, distribution, use, treatment, storage, disposal,
transportation, handling, reporting, licensing, permitting, investigation or remediation of Hazardous Substances.

 

“ERISA” means the Employee
Retirement Income Security Act of 1974, and all rules and regulations from time to time promulgated thereunder.

 

“ERISA Affiliate” means
any trade or business (whether or not incorporated) that, together with any Consolidated Entity, is treated as (i) a single
employer under Section 414(b), (c), (m) or (o) of the Code or (ii) a member of the same controlled group under Section 4001(a)(14)
of ERISA.

 

    	7

    	 

    

 

“ERISA Event” means any
of the following: (i) a “reportable event” as defined in Section 4043(c) of ERISA with respect to a Plan
or, if any Consolidated Entity or any ERISA Affiliate has received notice, a Multiemployer Plan, for which the requirement to give
notice has not been waived by the PBGC (provided, however, that a failure to meet the minimum funding standard of
Section 412 of the Code shall be considered a “reportable event” regardless of the issuance of any waiver), (ii) the
application by any Consolidated Entity or any ERISA Affiliate for a funding waiver pursuant to Section 412 of the Code, (iii) the
incurrence by any Consolidated Entity or any ERISA Affiliate of any Withdrawal Liability, or the receipt by any Consolidated Entity
or any ERISA Affiliate of notice from a Multiemployer Plan that it is in reorganization or insolvency pursuant to Section 4241
or 4245 of ERISA or that it intends to terminate or has terminated under Section 4041A of ERISA, (iv) the distribution by
any Consolidated Entity or any ERISA Affiliate under Section 4041 or 4041A of ERISA of a notice of intent to terminate any Plan
or the taking of any action to terminate any Plan, (v) the commencement of proceedings by the PBGC under Section 4042 of ERISA
for the termination of, or the appointment of a trustee to administer, any Plan, or the receipt by any Consolidated Entity or any
ERISA Affiliate of a notice from any Multiemployer Plan that such action has been taken by the PBGC with respect to such Multiemployer
Plan, (vi) the institution of a proceeding by any fiduciary of any Multiemployer Plan against any Consolidated Entity or any
ERISA Affiliate to enforce Section 515 of ERISA, which proceeding is not dismissed within 30 days, (vii) the imposition upon
any Consolidated Entity or any ERISA Affiliate of any liability under Title IV of ERISA, other than for PBGC premiums due but not
delinquent under Section 4007 of ERISA, or the imposition or threatened imposition of any Lien upon any assets of any Consolidated
Entity or any ERISA Affiliate as a result of any alleged failure to comply with the Code or ERISA with respect to any Plan, or
(viii) the engaging in or otherwise becoming liable for a Prohibited Transaction by any Consolidated Entity or any ERISA Affiliate.

 

“Event of Default” has
the meaning set forth in Article VIII.

 

“Exchange Act” means
the Securities Exchange Act of 1934, as amended from time to time, and any successor statute, and all rules and regulations from
time to time promulgated thereunder.

 

“Excluded Asset Disposition”
means any Asset Disposition permitted under Section 7.4(i), (ii), (iii) or (iv).

 

“Executive Employment Agreements”
has the meaning set forth in Section 3.1(o).

 

“Existing Credit Agreement”
has the meaning set forth in the Background Statement hereof.

 

“Existing Notes” means
the 9% Promissory Convertible Notes, as in effect as of the date hereof, scheduled to mature on February 15, 2015 and with an aggregate
outstanding principal balance of $1,100,000 as of the Closing Date.

 

“Financial Officer” means,
with respect to any Person, the chief financial officer, vice president - finance, principal accounting officer or treasurer of
such Person.

 

“fiscal quarter” means
a fiscal quarter of the Borrower and its Subsidiaries.

 

“fiscal year” means a
fiscal year of the Borrower and its Subsidiaries.

 

    	8

    	 

    

 

“Fixed Charge Coverage Ratio”
means, as of the last day of any fiscal quarter, for the Borrower and its Subsidiaries as determined on consolidated basis in accordance
with GAAP, the ratio of (i) Consolidated EBITDA for the period of four consecutive fiscal quarters ending as of such day, to (ii)
the sum of (A) all interest expense to the extent paid (or required to be paid) in cash for the period of four consecutive
fiscal quarters ending as of such day, (B) all scheduled payments of principal of Consolidated Funded Debt for the 12-month period
immediately following such period, (C) all taxes to the extent paid in cash during the period of four consecutive fiscal quarters
ending as of such day, (D) all rent expense to the extent paid in cash during the period of four consecutive fiscal quarters ending
as of such day and (E) all payments made by the Borrower and its Subsidiaries for purchases of shares of Capital Stock permitted
by Section 7.6(a)(iv) during the period of four consecutive fiscal quarters ending as of such day.

 

“GAAP” means generally
accepted accounting principles, as recognized by the American Institute of Certified Public Accountants, consistently applied and
maintained on a consistent basis for the Borrower and its Subsidiaries on a consolidated basis throughout the period indicated
and consistent with the financial practice of the Borrower and its Subsidiaries prior to the date hereof.

 

“Governmental Authority”
means any nation or government, any state, department, agency or other political subdivision thereof, and any entity exercising
executive, legislative, judicial, regulatory or administrative functions of or pertaining to any government, and any corporation
or other entity owned or controlled (through stock or capital ownership or otherwise) by any of the foregoing.

 

“Guaranty” means a guaranty
agreement, dated as of the date hereof, made by the Subsidiary Guarantors in favor of the Lender, as amended, modified, restated
or supplemented from time to time.

 

“Hazardous Substance”
means any substance or material meeting any one or more of the following criteria: (i) it is or contains a substance designated
as a hazardous waste, hazardous substance, hazardous material, pollutant, contaminant or toxic substance under any Environmental
Law, (ii) it is toxic, explosive, corrosive, ignitable, infectious, radioactive, mutagenic or otherwise hazardous to human
health or the environment and is or becomes regulated by any Governmental Authority, (iii) its presence may require investigation
or response under any Environmental Law, (iv) it constitutes a nuisance, trespass or health or safety hazard to Persons or
neighboring properties, or (v) it is or contains, without limiting the foregoing, asbestos, polychlorinated biphenyls, urea
formaldehyde foam insulation, petroleum hydrocarbons, petroleum derived substances or wastes, crude oil, nuclear fuel, natural
gas or synthetic gas.

 

“Hedge Agreement” means
any interest or foreign currency rate swap, cap, collar, option, hedge, forward rate or other similar agreement or arrangement
designed to protect against fluctuations in interest rates or currency exchange rates.

 

“Immaterial Subsidiary”
means, at any date of determination, (i) Los Angeles Lung Center and Eli E. Hendel, M.D. and (ii) (A) until financial statements
are delivered pursuant to Section 5.1(b) for the Borrower’s fiscal year ended in 2016, those subsidiaries listed on
Schedule 1.1, as such schedule may be updated from time to time as mutually agreed by the Borrower and the Lender, and (B)
commencing upon the Borrower’s delivery of the financial statements pursuant to Section 5.1(b) for the Borrower’s
fiscal year ended in 2016, any Subsidiary, together with its Subsidiaries and each other Subsidiary which the Borrower is treating
as an “Immaterial Subsidiary” for purposes of this clause (ii)(B) (and, for the avoidance of doubt, excluding
Los Angeles Lung Center and Eli E. Hendel, M.D., which shall remain Immaterial Subsidiaries pursuant to clause (i) of this definition),
including their Subsidiaries and without duplication, that contributed less than an aggregate of 5% of Consolidated EBITDA for
the fiscal year of the Borrower most recently ended prior to such date of determination.

 

    	9

    	 

    

 

“Indebtedness” means,
for any Person, without duplication (i) obligations of such Person for borrowed money; (ii) obligations of such Person evidenced
by bonds, debentures, notes or other similar instruments; (iii) obligations of such Person in respect of the deferred purchase
price of property or services (other than trade payables incurred in the ordinary course of business on terms customary in the
trade and not past due other than as a result of a bona fide dispute pursuant to Section 5.5); (iv) obligations of such
Person under any conditional sale or other title retention agreement(s) relating to property acquired by such Person; (v) Capitalized
Lease Obligations of such Person; (vi) obligations, contingent or otherwise, of such Person in respect of letters of credit, acceptances
or similar extensions of credit (whether or not drawn upon and in the stated amount thereof); (vii) guaranties by such Person of
the type of indebtedness described in clauses (i) through (vi) above; (viii) all indebtedness of a third party secured by any Lien
on property owned by such Person, whether or not such indebtedness has been assumed by such Person; (ix) all obligations of
such Person, contingent or otherwise, to purchase, redeem, retire or otherwise acquire for value any common stock of such Person;
(x) off-balance sheet liability retained in connection with asset securitization programs, synthetic leases, sale and leaseback
transactions or other similar obligations arising with respect to any other transaction which is the functional equivalent of or
takes the place of borrowing but which does not constitute a liability on the consolidated balance sheet of such Person and its
Subsidiaries; and (xi) obligations under any Hedge Agreement.

 

“Intellectual Property”
means (i) all inventions (whether or not patentable and whether or not reduced to practice), all improvements thereto, and all
patents, patent applications, and patent disclosures, together with all reissues, continuations, continuations-in-part, divisions,
revisions, extensions, and reexaminations thereof, (ii) all trademarks, service marks, trade dress, logos, trade names, and corporate
names, together with all goodwill associated therewith, and all applications, registrations, and renewals in connection therewith,
(iii) all copyrightable works and all copyrights (registered and unregistered), (iv) all trade secrets and confidential information
(including, without limitation, financial, business and marketing plans and customer and supplier lists and related information),
(v) all computer software and software systems (including, without limitation, data, databases and related documentation), (vi)
all Internet web sites and domain names, (vii) all technology, know-how, processes and other proprietary rights, and (viii) all
licenses or other agreements to or from third parties regarding any of the foregoing.

 

“Intercompany Loan Agreement”
means any intercompany loan agreement between the Borrower or a Subsidiary, on the one hand, and an Affiliated Physician Practice
Entity, on the other hand, on terms and conditions satisfactory to the Lender, including without limitation (i) that certain Intercompany
Revolving Loan Agreement, dated July 31, 2013, by and between ApolloMed Care Clinic and Apollo Medical Management, Inc., as amended
on March 28, 2014, (ii) that certain Intercompany Revolving Loan Agreement, dated September 30, 2013, by and between ApolloMed
Hospitalists and Apollo Medical Management, Inc., as amended on March 28, 2014, and (iii) that certain Intercompany Revolving Loan
Agreement, dated February 1, 2013, by and between Apollo Medical Management, Inc. and Maverick Medical Group, Inc., as amended
on March 28, 2014.

 

    	10

    	 

    

 

“Intercompany Note” means
the intercompany note substantially in the form of Exhibit C.

 

“Investment Agreement”
means that certain Investment Agreement, dated as of the Closing Date, between the Borrower, as issuer, and NNA of Nevada, Inc.,
as purchaser, with respect to the Convertible Note, the Capital Stock of the Borrower purchased thereunder and the warrants granted
thereunder, as in effect on the Closing Date, as supplemented, amended, restated, extended, renewed, replaced or otherwise modified
from time to time in accordance with the terms hereof and thereof.

 

“Investment Documents”
means the Convertible Note, the Investment Agreement, the warrants issued pursuant to the Investment Agreement, including the Warrants,
and all other documents executed and delivered with respect to the Investment Agreement, the Convertible Note, the Capital Stock
of the Borrower purchased thereunder and the warrants issued thereunder, in each case, as in effect on the Closing Date, as supplemented,
amended, restated, extended, renewed, replaced or otherwise modified from time to time in accordance with the terms hereof and
thereof.

 

“Investments” has the
meaning set forth in Section 7.5.

 

“Lender” has the meaning
set forth in the introductory paragraph hereof.

 

“Leverage Ratio” means,
as of the last day of any fiscal quarter, the ratio of (i) the amount of Consolidated Funded Debt on such day to (ii) Consolidated
EBITDA for the period of four consecutive fiscal quarters ending as of such day.

 

“LIBOR “ means, for any
day, the offered rate as published by Bloomberg L.P. (or any other generally recognized financial information page
or service designated by Lender) for deposits in U.S. Dollars in the London interbank deposit market with a maturity of three (3)
months, determined approximately 11:00 A.M. (London time) two Business Days before commencement of each calendar quarter; provided,
that if no such LIBOR Rate is available, the applicable LIBOR Rate shall instead be the rate determined by Lender to be the rate
at which Bank of America, N.A., or one of its affiliates banks, offers to place deposits in U.S. Dollars with first class banks
in the London interbank market at approximately 11:00 A.M. (London time) two Business Days before the commencement of each calendar
quarter.

 

“Lien” means any interest
in property securing an obligation owed to, or claim by, a Person other than the owner of such property, whether such interest
arises by virtue of contract, statute or common law, including but not limited to the lien or security interest arising from a
mortgage, security agreement, pledge, lease, conditional sale, consignment or bailment for security purposes or from attachment,
judgment or execution. The term “Lien” shall include any easements, covenants, restrictions, conditions, encroachments,
reservations, rights-of-way, leases and other title exceptions and encumbrances affecting real property. For the purpose of this
Agreement, the Borrower or any Subsidiary shall be deemed to own, subject to a Lien, any proceeds of a sale with recourse of accounts
receivable, any asset leased under any “sale and lease back” or similar arrangement and any asset which it has
acquired or holds subject to the interest of a vendor or lessor under any conditional sale agreement, financing lease or other
title retention agreement relating to such asset.

 

    	11

    	 

    

 

“Loans” means, collectively,
the Term Loan and the Revolving Loans.

 

“Margin Stock” has the
meaning given to such term in Regulation U.

 

“Material Adverse Effect”
or “Material Adverse Change” means a material adverse effect upon, or a material adverse change in, any of (i)
the financial condition, operations, business or properties of the Borrower and its Subsidiaries, taken as a whole; (ii) the ability
of the Borrower or any Subsidiary to perform under this Agreement or any other Credit Document in any material respect or any other
material contract in any material respect to which any one or more of them is a party; (iii) the legality, validity or enforceability
of this Agreement or any other Credit Document; or (iv) the perfection or priority of the Liens of the Lender granted under this
Agreement or any other Credit Document or the rights and remedies of the Lender under this Agreement or any other Credit Document
(other than a change resulting from any act or omission by the Lender).

 

“Material Contracts”
has the meaning set forth in Section 4.19.

 

“Maturity Date” means
March 28, 2019.

 

“Multiemployer Plan”
means any “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA.

 

“Net Cash Proceeds” means,
in the case of any Casualty Event or Asset Disposition, the aggregate cash proceeds received by any Credit Party in respect thereof
(including, in the case of a Casualty Event, insurance proceeds and condemnation awards), minus the sum of (i) reasonable
fees and out-of-pocket expenses payable by such Credit Party in connection therewith, (ii) taxes paid or payable as a result
thereof, and (iii) the amount required to retire Indebtedness to the extent such Indebtedness is secured by Permitted Liens
on the subject property; it being understood that the term “Net Cash Proceeds” shall include, as and when received,
any cash received upon the sale or other disposition of any non-cash consideration received by any Credit Party in respect of any
of the foregoing events.

 

“Notice of Borrowing”
has the meaning set forth in Section 3.2(a).

 

“Obligations” means (i)
the Loans, indebtedness, liabilities, obligations, covenants and duties owing, arising, due or payable from the Borrower or any
Subsidiary to the Lender of any kind or nature, present or future, arising under this Agreement or the other Credit Documents,
whether direct or indirect (including those acquired by assignment), absolute or contingent, primary or secondary, due or to become
due, now existing or hereafter arising and however acquired; and (ii) all interest (including to the extent permitted by law, all
post-petition interest), charges, expenses, fees, attorneys’ fees and any other sums payable by the Borrower or any Subsidiary
to the Lender under this Agreement or any of the other Credit Documents.

 

    	12

    	 

    

 

“OFAC” means the U.S.
Department of the Treasury’s Office of Foreign Assets Control, and any successor thereto.

 

“OTCQB” has the meaning
set forth in Section 4.7(c).

 

“PATRIOT Act” means the
Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (USA PATRIOT Act
of 2001), as amended from time to time, and any successor statute, and all rules and regulations from time to time promulgated
thereunder.

 

“PBGC” means the Pension
Benefit Guaranty Corporation established pursuant to Subtitle A of Title IV of ERISA, and any successor thereto.

 

“Permitted Acquisition”
means any Acquisition for which the Acquisition Amount is less than $500,000 and any other Acquisition to which the Lender shall
have given its prior written consent (which consent may be in its sole discretion and may be given subject to such additional terms
and conditions as it shall establish).

 

“Permitted Liens” has
the meaning set forth in Section 7.3.

 

“Person” means an individual,
a corporation, a partnership, a limited liability company, an association, a trust or any other entity or organization, including
a government or political subdivision or an agency or instrumentality thereof.

 

“Physician Practice Management
Agreement” means a Physician Practice Management Agreement between an Affiliated Physician Practice Entity and a Subsidiary
or the Borrower, as manager, and providing for the management of the non-medical aspects of such Affiliated Physician Practice
Entity on terms and conditions satisfactory to the Lender.

 

“Physician Shareholder Agreement”
means a Physician Shareholder Agreement, by and between owners of at least seventy five percent (75%) of the Capital Stock issued
by an Affiliated Physician Practice Entity, the Subsidiary or the Borrower that is the manager pursuant to the Physician Practice
Management Agreement to which such Affiliated Physician Practice Entity is a party, such Affiliated Physician Practice Entity,
and the Borrower (if not already party thereto as manager) and on terms and conditions satisfactory to the Lender.

 

“Plan” means any “employee
pension benefit plan” within the meaning of Section 3(2) of ERISA that is subject to the provisions of Title IV of ERISA
(other than a Multiemployer Plan) and to which any Consolidated Entity or any ERISA Affiliate may have any liability.

 

“Pledge and Security Agreement”
means a Pledge and Security Agreement, dated as of the date hereof, made by the Borrower and the Subsidiaries of the Borrower party
thereto in favor of the Lender, as amended, modified, restated or supplemented from time to time.

 

“Prohibited Transaction”
means any transaction described in (i) Section 406 of ERISA that is not exempt by reason of Section 408 of ERISA
or by reason of a Department of Labor prohibited transaction individual or class exemption or (ii) Section 4975(c) of the
Code that is not exempt by reason of Section 4975(c)(2) or 4975(d) of the Code.

 

    	13

    	 

    

 

“Projections” has the
meaning set forth in the definition of Confidential Information.

 

“Realty” means the real
property owned by the Borrower or a Subsidiary Guarantor and set forth on Schedule 4.12.

 

“Reference Period” with
respect to any date of determination, means (except as may be otherwise expressly provided herein) the period of twelve consecutive
fiscal months of the Borrower immediately preceding such date or, if such date is the last day of a fiscal quarter, the period
of four consecutive fiscal quarters ending on such date.

 

“Registration Rights Agreement”
has the meaning set forth in Section 3.1(a)(viii).

 

“Requirement of Law”
means, with respect to any Person, the charter, articles or certificate of organization or incorporation and bylaws or other organizational
or governing documents of such Person, and any statute, law, treaty, rule, regulation, order, decree, writ, injunction or determination
of any arbitrator or court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its
property or to which such Person or any of its property is subject or otherwise pertaining to any or all of the transactions contemplated
by this Agreement and the other Credit Documents.

 

“Responsible Officer”
means, with respect to any Person, the president, the chief executive officer, the chief financial officer, any executive officer,
or any other Financial Officer of such Person, and any other officer or similar official thereof responsible for the administration
of the obligations of such Person in respect of this Agreement or any other Credit Document.

 

“Revolving Credit Commitment”
has the meaning set forth in Section 2.1.

 

“Revolving Credit Termination Date”
means the date of the earliest to occur of the (i) Maturity Date and (ii) such earlier date of termination of the Revolving Credit
Commitments pursuant to Section 2.5 or 8.2(a).

 

“Revolving Loans” has
the meaning set forth in Section 2.1.

 

“Sanctioned Country”
means a country subject to a sanctions program identified on the list maintained by OFAC and available at http://www.treas.gov/offices/eotffc/ofac/sanctions/index/html,
or as otherwise published from time to time.

 

“Sanctioned Person”
means (i) a Person named on the list of Specially Designated Nationals or Blocked Persons maintained by OFAC available at http://www.treas.gov/offices/eotffc/ofac/sdn/index/html,
or as otherwise published from time to time, or (ii) (A) an agency of the government of a Sanctioned Country, (B) an organization
controlled by a Sanctioned Country, or (C) a Person resident in a Sanctioned Country, to the extent subject to a sanctions program
administered by OFAC.

 

“Securities Act” means
the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

    	14

    	 

    

 

“Security Documents”
means the Pledge and Security Agreement, the Guaranty, the collateral assignments referred to in Section 3.1(o), and all other
pledge or security agreements, assignments or other similar agreements or instruments executed and delivered by the Borrower or
any of its Subsidiaries pursuant to the terms of this Agreement or otherwise in connection with the transactions contemplated hereby,
in each case as amended, modified or supplemented from time to time.

 

“Shareholders Agreement”
has the meaning set forth in Section 3.1(a)(vii).

 

“Solvent” means as to
any Person on any particular date, that such Person (i) does not have unreasonably small capital to carry on its business as now
conducted and as presently proposed to be conducted, (ii) is able to pay its debts as they become due in the ordinary course of
business, and (iii) has assets with a present fair saleable value greater than its total stated liabilities and identified contingent
liabilities, including any amounts necessary to satisfy preferential rights of shareholders.

 

“Subsidiary” means any
corporation, partnership, limited liability company, association or other business entity (i) of which the Borrower owns, directly
or indirectly, more than fifty percent (50%) of the voting securities thereof or (ii) the management of which is otherwise controlled,
directly or indirectly through one or more intermediaries, by the Borrower and is consolidated with the Borrower in accordance
with GAAP.

 

“Subsidiary Guarantor”
means any Subsidiary of the Borrower that is a guarantor of the Obligations under the Guaranty (or under another guaranty agreement
in form and substance satisfactory to the Lender) and has granted to the Lender a Lien upon and security interest in its personal
property assets pursuant to the Pledge and Security Agreement.

 

“Target” has the meaning
set forth in Section 5.8(a)(i).

 

“Term Loan” has the meaning
set forth in Section 2.1(a).

 

“Unfunded Pension Liability”
means, with respect to any Plan, the excess of its benefit liabilities under Section 4001(a)(16) of ERISA over the current value
of its assets, determined in accordance with the applicable assumptions used for funding under Section 412 of the Code for the
applicable plan year.

 

“2012 Equity Incentive Plan”
means the 2012 Equity Incentive Plan of Apollomed Accountable Care Organization, Inc. as in effect on the Closing Date.

 

“Warrants” has the meaning
set forth in Section 3.1(a)(vi).

 

“Wholly Owned” means,
with respect to any Subsidiary of any Person, that 100% of the outstanding Capital Stock of such Subsidiary is owned, directly
or indirectly, by such Person.

 

    	15

    	 

    

 

1.2           Accounting
Terms. Except as specifically provided otherwise in this Agreement, all accounting terms used herein that are not specifically
defined shall have the meanings customarily given them in accordance with GAAP. Notwithstanding anything to the contrary in this
Agreement, for purposes of calculation of the financial covenants set forth in Article VI, all accounting determinations
and computations hereunder shall be made in accordance with GAAP as in effect as of the date of this Agreement applied on a basis
consistent with the application used in preparing the most recent financial statements of the Borrower referred to in Section 4.11(a).
In the event that any changes in GAAP after such date are required to be applied to the Borrower and would affect the computation
of the financial covenants contained in Article VI, such changes shall be followed only from and after the date this Agreement
shall have been amended to take into account any such changes.

 

1.3           Singular/Plural.
Unless the context otherwise requires, words in the singular include the plural and words in the plural include the singular.

 

1.4           Other
Terms. All other terms contained in this Agreement shall, when the context so indicates, have the meanings provided for by
the Uniform Commercial Code of the State of New York to the extent the same are used or defined therein.

 

ARTICLE
II

 

AMOUNTS
AND TERMS OF THE LOANS

 

2.1           Commitments.

 

(a)          Prior
to the Closing Date the Lender made revolving loans to the Borrower under the Existing Credit Agreement, of which a principal amount
of $3,311,878.00 remains outstanding as of the Closing Date, and together with all accrued and unpaid interest and fees of $16,032.07
(such outstanding principal, interest and fees, the “Outstanding Obligations”). Each of the Borrower and the
Lender acknowledges and agrees, subject to the terms and conditions set forth herein, that the Outstanding Obligations shall be
deemed funded by the Lender on the Closing Date as part of the Term Loan under this Section 2.1(a), and such funding shall
be deemed to refinance hereunder the Outstanding Obligations under the Existing Credit Agreement. In addition, the Lender agrees,
subject to the terms and conditions set forth herein, to make a term loan to the Borrower on the Closing Date in a principal amount
of $3,672,089.93 (and together with the Outstanding Obligations, the “Term Loan”). To the extent repaid, the
Term Loan may not be reborrowed.

 

(b)          The
Lender agrees, on the terms and conditions set forth herein, to make loans (each, a “Revolving Loan,” and collectively,
the “Revolving Loans”) to the Borrower, from time to time before the Revolving Credit Termination Date; provided
that, immediately after each Revolving Loan is made, the aggregate outstanding principal amount of the Revolving Loans by the Lender
shall not exceed $1,000,000 (as such figure may be reduced from time to time as provided in this Agreement, the “Revolving
Credit Commitment”). Subject to Section 3.2, the Borrower may borrow under this Section 2.1(b), repay
or prepay Revolving Loans and reborrow under this Section 2.1(b) at any time before the Revolving Credit Termination Date,
and any such repayment or prepayment may be made in whole or in part and without premium or penalty.

 

    	16

    	 

    

 

2.2           Repayments;
Maturity of Loans.

 

(a)          The
principal amount of the Term Loan shall be repaid on the last Business Day of each calendar quarter, commencing on the first such
day to occur after the Closing Date (and which shall count as Calendar Quarter 1 below), in accordance with the following amortization
schedule:

 

	Calendar 
 Quarter	 	Quarterly Principal Payment	 
	1 – 4	 	$	87,500	 
	5 - 8	 	$	122,500	 
	9 – 12	 	$	122,500	 
	13 – 16	 	$	175,000	 
	17 – 19	 	$	210,000	 

 

In any event, the Term Loan shall be due
and payable in full on the earlier of (i) the Maturity Date and (ii) the occurrence of any Event of Default and acceleration thereof
by the Lender pursuant to Article VIII hereof.

 

(b)          The
Borrower shall repay the Revolving Loans:

 

(i)          In
full, on the Revolving Credit Termination Date;

 

(ii)         In
the event that, at any time, the aggregate principal amount of Revolving Loans shall exceed the aggregate Revolving Credit Commitments
at such time, the Borrower will immediately prepay the outstanding principal amount of Revolving Loans in the amount of such excess;
and

 

(iii)        In
full, upon the occurrence of any Event of Default and acceleration thereof by the Lender pursuant to Article VIII hereof.

 

(c)          At
any time and from time to time, the Borrower shall have the right to prepay the Term Loan, in whole or in part and without premium
or penalty, upon written notice given to the Lender not later than 11:00 a.m., Massachusetts time, at least one (1) Business Day
prior to each intended prepayment of principal, provided that each partial prepayment of the Term Loan shall be in an aggregate
principal amount of not less than $250,000 or, if greater, an integral multiple of $50,000 in excess thereof. Each such notice
shall specify the proposed date of such prepayment and the aggregate principal amount to be prepaid, and shall be irrevocable and
shall bind the Borrower to make such prepayment on the terms specified therein. Each prepayment of the Term Loan pursuant to this
Section 2.2(c) shall be applied to the remaining amortization payments in the inverse order of maturity.

 

    	17

    	 

    

 

(d)          Not
later than 90 days after receipt by any Credit Party of any proceeds of insurance, condemnation award or other compensation in
respect of any Casualty Event (or, if earlier, upon its determination not to repair or replace any property subject to such Casualty
Event or to acquire assets used or useable in the business of the Credit Parties), the Borrower will (i) prepay the outstanding
principal amount of the Term Loan in an amount equal to 100% of the Net Cash Proceeds from such Casualty Event (less any amounts
theretofore applied (or contractually committed to be applied) to the repair or replacement of property subject to such Casualty
Event or to acquire assets used or useable in the business of the Credit Parties) and will deliver to the Lender, concurrently
with such prepayment, a certificate signed by a Financial Officer of the Borrower in form and substance satisfactory to the Lender
and setting forth the calculation of such Net Cash Proceeds and (ii) if any such Net Cash Proceeds remain following the prepayment
of the outstanding principal amount of the Term Loan in full, the remaining Net Cash Proceeds from such Casualty Event shall be
used to reduce the principal amount of the Revolving Loans. Notwithstanding the foregoing, nothing in this Section 2.2(d)
shall be deemed to permit any Asset Disposition not expressly permitted under Section 7.4.

 

(e)          Not
later than 90 days after receipt by any Credit Party of proceeds in respect of any Asset Disposition other than an Excluded Asset
Disposition (or, if earlier, upon its determination not to apply such proceeds to the acquisition of assets used or useable in
the business of the Borrower and its Subsidiaries), the Borrower will (i) prepay the outstanding principal amount of the Term Loan
in an amount equal to 100% of the Net Cash Proceeds from such Asset Disposition (less any amounts theretofore applied (or contractually
committed to be applied) to acquire assets used or useable in the business of the Credit Parties) and will deliver to the Lender,
concurrently with such prepayment, a certificate signed by a Financial Officer of the Borrower in form and substance satisfactory
to the Lender and setting forth the calculation of such Net Cash Proceeds and (ii) if any such Net Cash Proceeds remain following
the prepayment of the Term Loan in full, the remaining Net Cash Proceeds from such Asset Disposition shall be used to reduce the
principal amount of the Revolving Loans. Notwithstanding the foregoing, nothing in this Section 2.2(e) shall be deemed
to permit any Asset Disposition not expressly permitted under Section 7.4.

 

2.3           Interest.

 

(a)          The
Term Loan shall bear, and the Borrower shall pay, interest from the Closing Date on the unpaid principal balance thereof at a rate
per annum equal to eight percent (8%).

 

(b)          Each
Revolving Loan shall bear, and the Borrower shall pay, interest from the date such Revolving Loan is made on the unpaid principal
balance thereof at a rate equal to Adjusted LIBOR.

 

(c)          Interest
on the outstanding principal balance of each Loan shall be due and payable (i) monthly on the last Business Day of each successive
month, in arrears, commencing with April 30, 2014, and at each month-end thereafter until the entire principal amount of the Loans
plus interest thereon is paid in full and (ii) on each date when all or any amount of the unpaid principal balance of each such
Loan shall be due (whether at maturity, by optional or mandatory prepayment, by acceleration or otherwise), but only to the extent
accrued.

 

(d)          Interest
on the Loans and fees shall be computed on the basis of a 360-day year and the actual number of days elapsed.

 

    	18

    	 

    

 

(e)          Nothing
contained in this Agreement shall be deemed to establish or require the payment of interest to the Lender at a rate in excess of
the maximum rate permitted by governing law. In the event that the rate of interest required to be paid under this Agreement exceeds
the maximum rate permitted by governing law, the rate of interest required to be paid hereunder shall be automatically reduced
to the maximum rate permitted by governing law and any amounts collected in excess of the permissible amount shall be deemed a
prepayment of principal hereunder.

 

(f)          Notwithstanding
any other provision of this Agreement to the contrary, upon and during the continuance of any Event of Default under this Agreement,
at the option of the Lender without any required notice to the Borrower, the outstanding principal amount of the Loans, and to
the full extent permitted by law, all interest accrued on the Loans, shall bear interest at the Default Rate, and such default
interest shall be payable on demand.

 

2.4           Fees.

 

(a)          The
Borrower agrees to pay to the Lender an upfront fee of $80,000.00, which shall be due and payable in full on the Closing Date if
the Closing Date occurs.

 

(b)          The
Borrower agrees to pay to the Lender a facility fee on the last Business Day of each month, commencing on April 30, 2014, and on
the Revolving Credit Termination Date at a per annum rate of 1.0% of the average daily unused portion of the Revolving Credit Commitment
for such month. Such unused facility fee shall be contingent on and accrue from and including the Closing Date to (but excluding)
the Revolving Credit Termination Date.

 

2.5           Termination
or Reduction of Commitments.

 

(a)          The
Borrower may, upon at least three (3) Business Days’ written notice to the Lender, terminate or proportionately reduce the
unused portion of the Revolving Credit Commitment from time to time by an aggregate amount of at least $100,000 or any larger integral
multiple of $25,000. If the Revolving Credit Commitment is terminated in its entirety, all accrued fees (as provided under Section
2.4(b)) shall be due and payable on the effective date of such termination.

 

(b)          Each
prepayment of Revolving Loans pursuant to Section 2.2(d) and (e) shall permanently reduce the amount of the Revolving
Credit Commitment. 

 

2.6           General
Provisions as to Payments. All payments (including prepayments) by the Borrower on account of principal, interest and fees
on the Loans shall be made in immediately available funds to the Lender at its offices as set forth in Section 9.4, prior
to 2:00 p.m., Massachusetts time, on the date payment is due, or at such other place as is designated in writing by the Lender.

 

2.7           Disbursement
of Loan Proceeds. The Borrower hereby authorizes and directs the Lender to disburse, for and on behalf of the Borrower and
for the Borrower’s account, the proceeds of the Loans made by the Lender pursuant to this Agreement (i) to such Person or
Persons as the Borrower shall direct, whether orally or in writing and (ii) to pay the Lender any interest, fees, costs and expenses
payable pursuant to Section 9.1 hereof.

 

    	19

    	 

    

  

2.8           Use
of Proceeds.

 

(a)          The
proceeds of the Term Loan shall be used by the Borrower solely (i) to pay fees and expenses in connection with the transactions
contemplated by this Agreement, (ii) to provide working capital for the Borrower, and (iii) to finance acquisitions and joint ventures
as permitted by this Agreement.

 

(b)          The
proceeds of the Revolving Loans shall be used by the Borrower solely to provide working capital for the Borrower.

 

2.9           Taxes.
All payments of principal, interest and fees and all other amounts to be made by the Borrower pursuant to this Agreement with respect
to the Loans or fees relating thereto shall be paid without deduction for, and free from, any tax, imposts, levies, duties, deductions,
or withholdings of any nature now or at any time hereafter imposed on or measured by any governmental authority or by any taxing
authority thereof, or therein, excluding (i) taxes imposed on or measured by the Lender’s net income and (ii) franchise taxes
imposed on the Lender by the jurisdiction under the laws of which the Lender is organized or the Lender’s location set forth
in Section 9.4 or any political subdivision thereof. In the event that the Borrower is required by applicable law to make
any such withholding or deduction of taxes with respect to the Loans or fee or other amount, the Borrower shall pay such deduction
or withholding to the applicable taxing authority, shall promptly furnish to the Lender all receipts and other additional amounts
as may be necessary in order that the amount received by the Lender after the required withholding or other payment shall equal
the amount the Lender would have received had no such withholding or other payment been made.

 

2.10         Basis
for Determining Interest Rate Inadequate or Unfair. If on or prior to the first day of any Borrowing of Revolving Loans, (i)
the Lender determines that deposits in U.S. Dollars (in the applicable amounts) are not being offered in the relevant market, or
(ii) the Lender determines that LIBOR will not adequately and fairly reflect the cost to the Lender of funding a Revolving Loan,
the Lender shall forthwith give notice thereof to the Borrower, whereupon until the Lender notifies the Borrower that the circumstances
giving rise to such suspension no longer exist the obligation of the Lender to fund Revolving Loans shall be suspended unless the
Borrower and the Lender can mutually agree upon a different formulation for the interest rate applicable to such Borrowing.

 

2.11         Illegality.
If, after the date hereof, any Change of Law, or any change in interpretation or administration thereof by any Governmental Authority,
or compliance by the Lender with any request or directive (whether or not having the force of law) by any Governmental Authority,
shall make it unlawful or impossible for the Lender to make, maintain or fund Revolving Loans, then the Lender shall so notify
the Borrower, whereupon until the Lender notifies the Borrower that the circumstances giving rise to such suspension no longer
exist, the obligation of the Lender to fund Revolving Loans shall be suspended. If the Lender shall determine that it may not lawfully
continue to maintain and fund Loans to maturity and shall so specify in such notice, the Borrower shall immediately prepay in full
the then outstanding principal amount of the Loans.

 

    	20

    	 

    

 

2.12         Increased
Cost and Reduced Return.

 

(a)          If
after the date hereof, a Change of Law or compliance by the Lender with any request or directive (whether or not having the force
of law) of any Governmental Authority:

 

(i)          shall
impose, modify or deem applicable any reserve, special deposit or similar requirement (including, without limitation, any such
requirement imposed by the Board of Governors of the Federal Reserve System) against assets of, deposits with or for the account
of, or credit extended by, the Lender; or

 

(ii)         shall
impose on the Lender or on the United States market for certificates of deposit or the London interbank market any other condition
affecting Loans or its obligation to make Revolving Loans;

 

and the result of any of the foregoing is to increase the cost
to the Lender of making or maintaining any Loan, or to reduce the amount of any sum received or receivable by the Lender under
this Agreement with respect thereto, by an amount deemed by the Lender to be material, then, within fifteen (15) days after demand
by the Lender, the Borrower shall pay to the Lender such additional amount or amounts as will compensate the Lender for such increased
cost or reduction.

 

(b)          If
the Lender shall have determined that after the date hereof, any Change of Law, or any change in the interpretation or administration
thereof, or compliance by the Lender with any request or directive regarding capital adequacy (whether or not having the force
of law) by any Governmental Authority, has or would have the effect of reducing the rate of return on the Lender’s capital
as a consequence of its obligations hereunder to a level below that which the Lender could have achieved but for such adoption,
change or compliance (taking into consideration the Lender’s policies with respect to capital adequacy) by an amount deemed
by the Lender to be material, then from time to time, within fifteen (15) days after demand by the Lender, the Borrower shall pay
to the Lender such additional amount or amounts as will compensate the Lender for such reduction.

 

(c)          The
Lender will promptly notify the Borrower of any event of which it has knowledge, occurring after the date hereof, which will entitle
the Lender to compensation pursuant to this Section. A certificate of the Lender claiming compensation under this Section and setting
forth the additional amount or amounts to be paid to it hereunder shall be conclusive in the absence of manifest error. In determining
such amount, the Lender may use any reasonable averaging and attribution methods.

 

(d)          The
provisions of this Section 2.12 shall be applicable with respect to any participant, assignee or other transferee, and any
calculations required by such provisions shall be made based upon the circumstances of such participant, assignee or other transferee.

 

2.13         Application
and Allocation of Payments.

 

(a)          Payments
made by the Borrower hereunder shall be applied (a) first, as specifically required hereby; (b) second, to Obligations then due
and owing in the same order of priority as set forth in Section 2.13(b); (b) third, so long as no Default or Event of Default
then exists or would result therefrom, to other Obligations specified by the Borrower; and (c) fourth, as determined by the Lender
in its discretion.

 

    	21

    	 

    

 

(b)          Notwithstanding
anything in any Credit Document to the contrary, during an Event of Default, monies to be applied to the Obligations, whether arising
from payments by the Borrower, realization on collateral under the Security Documents, setoff or otherwise, shall be allocated
as follows:

 

(i)         first, to all costs
and expenses owing to the Lender;

 

(ii)        second, to all Obligations
constituting fees;

 

(iii)       third, to all
Obligations constituting interest;

 

(iv)       fourth, to all Loans;
and

 

(v)        last, to all remaining
Obligations.

 

Amounts shall be applied to payment of each
category of Obligations only after payment in full of all preceding categories.

 

2.14         Warrants.
On the Closing Date, the Borrower shall issue the Warrants to the Lender pursuant to the Investment Agreement. The Borrower and
the Lender hereby acknowledge and agree that (i) the Loans and the Warrants are part of an investment unit within the meaning of
Section 1273(c)(2) of the Code, (ii) for United States federal income tax purposes, (A) the issue price of the Warrants referred
to in clause (i) of Section 3.2(a)(vii) within the meaning of Section 1273(b) of the Code, which issue price was determined
pursuant to Section 1.1273-2(h)(1) of the Treasury Regulations, is equal to $10,000 and (B) the issue price of the Warrants referred
to in clause (ii) of Section 3.2(a)(vii) within the meaning of Section 1273(b) of the Code, which issue price was determined
pursuant to Section 1.1273-2(h)(1) of the Treasury Regulations, is equal to $100, and (iii) each of the Borrower and the Lender
shall use such issue prices for all income tax purposes with respect to the making of the Loans and the issuance of the Warrants.

 

ARTICLE
III

 

CLOSING;
CONDITIONS OF CLOSING AND BORROWING

 

3.1           Conditions
of Initial Loans. The obligation of the Lender to make Loans in connection with the initial Borrowing hereunder is subject
to the satisfaction of the following conditions precedent:

 

(a)          Credit
Documents. The Lender shall have received the following, each dated as of the Closing Date (unless otherwise specified) and
in such number of copies as the Lender shall have requested:

 

    	22

    	 

    

 

(i)          from
each of the parties hereto, a duly executed counterpart of this Agreement signed by such party;

 

(ii)         the
Guaranty, duly completed and executed by Subsidiaries (other than Immaterial Subsidiaries), in form and substance satisfactory
to the Lender;

 

(iii)        the
Pledge and Security Agreement, duly completed and executed by the Borrower and Subsidiaries (other than Immaterial Subsidiaries),
in form and substance satisfactory to the Lender; together with any certificates evidencing the Capital Stock being pledged thereunder
as of the Closing Date and undated assignments separate from certificate for any such certificate, duly executed in blank, each
in form and substance satisfactory to the Lender;

 

(iv)         Intercompany
Notes, duly completed and executed by the Borrower and each Subsidiary of the Borrower intending to incur Indebtedness pursuant
to clauses (iii) or (v) of Section 7.2, together with allonges attached thereto, each in form and substance satisfactory
to the Lender;

 

(v)          Intercompany
Loan Agreements, duly completed and executed by the Borrower or applicable Subsidiary of the Borrower, as lender, and the applicable
Affiliated Physician Practice Entity, as borrower, together with allonges attached thereto, each in form and substance satisfactory
to the Lender;

 

(vi)         warrants,
substantially in the form of Exhibit B to the Investment Agreement, duly completed and executed by the Borrower (i) for
1,000,000 shares of common equity of the Borrower with an exercise of $1 per warrant share and (ii) for 2,000,000 shares of common
equity of the Borrower with an exercise price of $2 per warrant share (such warrants, together with all warrants issued upon transfer,
division or combination of, or in substitution for, such warrants or any other such warrants (the “Warrants”));

 

(vii)        the
Shareholders Agreement (as supplemented, amended, restated, extended, renewed, replaced or otherwise modified from time to time
in accordance with the terms hereof and thereof, the “Shareholders Agreement”), duly completed and executed
by certain shareholders of the Borrower, the Borrower and the Lender, in form and substance satisfactory to the Lender; and

 

(viii)      the
Registration Rights Agreement (as supplemented, amended, restated, extended, renewed, replaced or otherwise modified from time
to time in accordance with the terms hereof and thereof, the “Registration Rights Agreement”), duly completed
and executed by the Borrower, in form and substance satisfactory to the Lender.

 

(b)          Investment
Documents. All conditions precedent to the consummation of the issuance by the Borrower to the Purchaser of the Convertible
Note and the Borrower’s Capital Stock and warrants as set forth in the Investment Documents, shall have been satisfied to
the reasonable satisfaction of the Lender.

 

    	23

    	 

    

 

(c)          Closing
Certificate. The Lender shall have received a certificate, signed by the president, the chief executive officer or the chief
financial officer of the Borrower, dated as of the Closing Date and in form and substance reasonably satisfactory to the Lender,
certifying that (i) all representations and warranties of the Borrower and its Subsidiaries contained in this Agreement and the
other Credit Documents are true, correct and complete as of the Closing Date, both immediately before and after giving effect to
the making of the initial Loans and the application of the proceeds thereof (except to the extent any such representation or warranty
is expressly stated to have been made as of a specific date, in which case such representation or warranty shall be true and correct
as of such date), (ii) no Default or Event of Default has occurred and is continuing, both immediately before and after giving
effect to the making of the initial Loans and the application of the proceeds thereof, (iii) both immediately before and after
giving effect to the making of the initial Loans and the application of the proceeds thereof, no Material Adverse Effect has occurred
since January 31, 2013, and there exists no event, condition or state of facts that could reasonably be expected to result in a
Material Adverse Effect, and (iv) all conditions to the initial extensions of credit hereunder set forth in this Section 3.1
and in Section 3.2 have been satisfied or waived as required hereunder.

 

(d)          Secretary’s
Certificate. The Lender shall have received a certificate of the secretary or an assistant secretary of the Borrower and each
Subsidiary Guarantor as of the Closing Date, dated as of the Closing Date and in form and substance reasonably satisfactory to
the Lender, certifying (i) that attached thereto is a true and complete copy of the articles or certificate of incorporation, certificate
of formation or other organizational document and all amendments thereto of such party, certified as of a recent date by the Secretary
of State (or comparable Governmental Authority) of its jurisdiction of organization, and that the same has not been amended since
the date of such certification, (ii) that attached thereto is a true and complete copy of the bylaws, operating agreement or similar
governing document of such party, as then in effect and as in effect at all times from the date on which the resolutions referred
to in clause (iii) below were adopted to and including the date of such certificate, (iii) that attached thereto is a true and
complete copy of resolutions adopted by the board of directors (or similar governing body) of such party, authorizing the execution,
delivery and performance of this Agreement and the other Credit Documents to which it is a party, and (iv) as to the incumbency
and genuineness of the signature of each officer of such party executing this Agreement or any of such other Credit Documents,
and attaching all such copies of the documents described above.

 

(e)          Good
Standings. The Lender shall have received a certificate as of a recent date of the good standing of the Borrower and each of
its Subsidiaries as of the Closing Date, under the laws of its jurisdiction of organization, from the Secretary of State (or comparable
Governmental Authority) of such jurisdiction.

 

(f)          Solvency
Certificate. The Lender shall have received a certificate of the president or chief financial officer of the Borrower, dated
as of the Closing Date and in form and substance reasonably satisfactory to the Lender, certifying that the Borrower and each Subsidiary
Guarantor is Solvent.

 

    	24

    	 

    

 

(g)          Consents;
Approvals. All approvals, permits and consents of any Governmental Authorities or other Persons required in connection with
the execution and delivery of this Agreement or the other Credit Documents shall have been obtained, without the imposition of
conditions that are not satisfactory to the Lender, and all related filings, if any, shall have been made, and all such approvals,
permits, consents and filings shall be in full force and effect and the Lender shall have received such copies thereof as it shall
have reasonably requested.

 

(h)          Lien
Searches. The Lender shall have received certified reports from an independent search service satisfactory to it listing any
judgment or tax lien filing or Uniform Commercial Code financing statement that names the Borrower, or any of the Borrower’s
Subsidiaries as debtor in any of the jurisdictions listed beneath its name on Schedule I to the Pledge and Security Agreement,
and the results thereof shall be reasonably satisfactory to the Lender.

 

(i)          Recording
and Filing. The Lender shall have received evidence that UCC financing statements naming the Borrower as debtor and the Lender
as secured party and describing the collateral encumbered by the Security Documents have been duly filed in each jurisdiction necessary
to perfect the Liens created by the Security Documents and that all other filings and action needed to provide the Lender with
a perfected, first priority security interest in the collateral described in the Security Documents have occurred.

 

(j)          Insurance.
The Lender shall have received certificates of insurance evidencing the insurance coverages described on Schedule 4.18 and
all other or additional coverages required under the Security Documents.

 

(k)         No
Litigation. No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or proposed
before any court or other governmental authority to enjoin, restrain or prohibit, or to obtain substantial damages in respect of,
or that is related to or arises from, the making of the Loans.

 

(l)          Fees.
The Borrower shall have paid to the Lender the fees required to be paid to it on the Closing Date.

 

(m)        No
Material Adverse Change. Since January 31, 2013, both immediately before and after giving effect to the consummation of this
Agreement, there shall not have occurred (i) a Material Adverse Effect or (ii) any event, condition or state of facts that could
reasonably be expected to have a Material Adverse Effect.

 

(n)         Legal
Opinions. The Borrower shall have delivered to the Lender opinions of counsel to the Borrower dated as of the Closing Date,
addressed to the Lender, in form and substance satisfactory to the Lender.

 

(o)         Certain
Agreements. (i) Each Affiliated Physician Practice Entity shall have entered into amendments to the Physician Practice Management
Agreement and the Intercompany Loan Agreement, in each case, on terms and conditions satisfactory to Lender; (ii) owners of
the Capital Stock issued by the Affiliated Physician Practice Entities shall have entered into a Physician Shareholder Agreement
on terms and conditions satisfactory to the Lender; and (iii) each of Warren Hosseinion, M.D. and Adrian Vazquez, M.D. shall have
entered into employment agreements on terms and conditions satisfactory to the Lender (as such agreements in this clause (iii)
are in effect on the Closing Date, the “Executive Employment Agreements”), and each of the Physician Practice
Management Agreements and the Physician Shareholder Agreements referred to in clauses (i) and (ii) of this paragraph (o) shall
have been assigned to the Lender as part of the collateral pursuant to the Security Documents.

 

    	25

    	 

    

 

(p)          Other
Documents. The Lender shall have received such other documents, certificates, opinions, instruments and other evidence as the
Lender may reasonably request, all in form and substance satisfactory to the Lender and its counsel.

 

Notwithstanding the foregoing, the Closing
Date shall not occur unless all of the foregoing conditions are satisfied by March 31, 2014.

 

3.2           Conditions
to all Loans. The obligation of the Lender to make any Loan hereunder (including any Loans made on or after the Closing Date),
is subject to the continued validity of all Credit Documents and the satisfaction of the following conditions:

 

(a)          The
Lender shall have received a notice of borrowing (each a “Notice of Borrowing”), in the form of Exhibit B,
specifying (i) the aggregate principal amount of the requested Loan to be made pursuant to such Borrowing, which amount shall not
be less than $50,000, and (ii) the requested date of such Borrowing, which shall be a Business Day and which shall be at least
three Business Days after the Lender receives such Notice of Borrowing (other than any Borrowing on the Closing Date). Each such
Notice of Borrowing shall be irrevocable.

 

(b)          Each
of the representations and warranties made by the Borrower in Article IV shall be true and correct in all material respects
(except to the extent any such representation or warranty is qualified as to materiality or by Material Adverse Effect, in which
case such representation or warranty shall be true in all respects) on and as of such date
with the same effect as if made on and as of such date (except to the extent any such representation or warranty related to a specific
date, in which case such representation or warranty shall be true and correct in all material respects as of such date (except
to the extent any such representation or warranty is qualified as to materiality or Material Adverse Effect, in which case such
representation or warranty shall be true in all respects as of such date)).

 

(c)          No
Default or Event of Default shall have occurred and be continuing on such date or after giving effect to the portion of the Loan
to be made on such date.

 

Each Borrowing hereunder shall be deemed to
be a representation and warranty by the Borrower on the date of such Borrowing as to the truth and accuracy of the facts specified
in paragraphs (a) and (b) of this Section.

 

3.3           Post-Closing.
The Borrower and the Subsidiary Guarantors shall use reasonable best efforts to comply with Section 4.10 of the Pledge and
Security Agreement within 90 days after the Closing Date.

 

    	26

    	 

    

 

ARTICLE
IV

 

REPRESENTATIONS
AND WARRANTIES

 

To induce the Lender to enter into this
Agreement and make the Loans contemplated hereby, the Borrower represents and warrants to the Lender as of the Closing Date and
each date of Borrowing as follows:

 

4.1           Corporate
Organization and Power. Each Credit Party (i) is a corporation or a limited liability company duly organized or formed,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation, as the case may be
(which jurisdictions, as of the Closing Date, are set forth on Schedule 4.1), (ii) has the full corporate or limited
liability company power and authority to execute, deliver and perform the Credit Documents to which it is or will be a party, to
own and hold its property and to engage in its business as presently conducted, and (iii) is duly qualified to do business
as a foreign corporation or limited liability company and is in good standing in each jurisdiction where the nature of its business
or the ownership of its properties requires it to be so qualified, except where the failure to be so qualified, individually or
in the aggregate, could not reasonably be expected to have a Material Adverse Effect.

 

4.2           Authorization;
Enforceability. Each Credit Party has taken, or on the Closing Date will have taken, all necessary corporate or limited liability
company action, as applicable, to execute, deliver and perform each of the Credit Documents to which it is or will be a party,
and has, or on the Closing Date (or any later date of execution and delivery) will have, validly executed and delivered each of
the Credit Documents to which it is or will be a party. This Agreement constitutes, and each of the other Credit Documents upon
execution and delivery will constitute, the legal, valid and binding obligation of each Credit Party that is a party hereto or
thereto, enforceable against it in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium or other similar laws affecting creditors’ rights generally, by general equitable principles or
by principles of good faith and fair dealing (regardless of whether enforcement is sought in equity or at law).

 

4.3           No
Violation. The execution, delivery and performance by each Credit Party of each of the Credit Documents to which it is or will
be a party, and compliance by it with the terms hereof and thereof, do not and will not (i) violate any provision of its articles
or certificate of incorporation or formation, its bylaws or operating agreement, or other applicable formation or organizational
documents, (ii) contravene any other Requirement of Law applicable to it, (iii) conflict with, result in a breach of
or constitute (with notice, lapse of time or both) a default under any indenture, mortgage, lease, agreement, contract or other
instrument to which it is a party, by which it or any of its properties is bound or to which it is subject, or (iv) except
for the Liens granted in favor of the Lender pursuant to the Security Documents, result in or require the creation or imposition
of any Lien upon any of its properties, revenues or assets; except, in the case of clauses (ii) and (iii) above, where such
violations, conflicts, breaches or defaults, individually or in the aggregate, could not reasonably be expected to have a Material
Adverse Effect.

 

    	27

    	 

    

 

4.4           Governmental
and Third-Party Authorization; Permits. No consent, approval, authorization or other action by, notice to, or registration
or filing with, any Governmental Authority or other Person is or will be required as a condition to or otherwise in connection
with the due execution, delivery and performance by each Credit Party of this Agreement or any of the other Credit Documents to
which it is or will be a party or the legality, validity or enforceability hereof or thereof, other than (i) filings of Uniform
Commercial Code financing statements and other instruments and actions necessary to perfect the Liens created by the Security Documents,
(ii) consents, authorizations and filings that have been (or on or prior to the Closing Date will have been) made or obtained
and that are (or on the Closing Date will be) in full force and effect, which consents, authorizations and filings are listed on
Schedule 4.4, (iii)  consents, authorization and filings required under the Securities Act, the Exchange Act and
applicable state securities laws, and (iv) consents and filings the failure to obtain or make which, individually or in the aggregate,
could not reasonably be expected to have a Material Adverse Effect. Each Credit Party has, and is in good standing with respect
to, all governmental approvals, licenses, permits and authorizations necessary to conduct its business as presently conducted and
to own or lease and operate its properties, except for those the failure to obtain which, individually or in the aggregate, could
not reasonably be expected to have a Material Adverse Effect.

 

4.5           Litigation.
There are no actions, investigations, suits or proceedings pending or, to the knowledge of the Borrower, threatened, at law, in
equity or in arbitration, before any court, other Governmental Authority, arbitrator or other Person, (i) against or affecting
any of the Credit Parties or any of their respective properties that, if adversely determined, could reasonably be expected to
have a Material Adverse Effect, or (ii) with respect to this Agreement, any of the other Credit Documents or any of the transactions
contemplated hereby or thereby.

 

4.6           Taxes.
Each Credit Party has timely filed all federal, state, local and foreign tax returns and reports required to be filed by it and
has paid, prior to the date on which penalties would attach thereto or a Lien would attach to any of the properties of a Credit
Party if unpaid, all taxes, assessments, fees and other charges levied upon it or upon its properties that are shown thereon as
due and payable, other than those that are not yet delinquent or that are being contested in good faith and by proper proceedings
and for which adequate reserves have been established in accordance with GAAP. Such returns accurately reflect in all material
respects all liability for taxes of the Credit Parties for the periods covered thereby. As of the Closing Date, there is no ongoing
audit or examination or, to the knowledge of the Borrower, other investigation by any Governmental Authority of the tax liability
of any of the Credit Parties, and there is no material unresolved claim by any Governmental Authority concerning the tax liability
of any Credit Party for any period for which tax returns have been or were required to have been filed, other than unsecured claims
for which adequate reserves have been established in accordance with GAAP. As of the Closing Date, no Credit Party has waived or
extended or has been requested to waive or extend the statute of limitations relating to the payment of any taxes.

 

    	28

    	 

    

 

 

4.7           Capitalization.

 

(a)          As
of the Closing Date, the authorized Capital Stock of the Borrower consists of (i) 100,000,000 shares of Common Stock, par
value $.001 per share, _____ shares of which, as of the close of business on February 28, 2014, were issued and outstanding and
no more of which additional shares (excluding any shares issued upon exercise of outstanding options) have been issued between
February 28, 2014 and the Closing Date; and (ii) 5,000,000 shares of Preferred Stock, par value $.001 per share, no shares of which
as of the Closing Date are issued and outstanding. All of the issued and outstanding shares of Common Stock have been duly authorized
and are validly issued, fully paid and non-assessable.

 

(b)          As
of the Closing Date, except as contemplated by this Agreement and as disclosed on Schedule 4.7(b), there are (i) no
authorized or outstanding securities, rights (preemptive or other), subscriptions, calls, commitments, warrants, options, or other
agreements that give any Person the right to purchase, subscribe for, or otherwise receive or be issued Capital Stock of the Borrower
or any security convertible into or exchangeable or exercisable for Capital Stock of the Borrower, (ii) no outstanding debt
or equity securities of the Borrower that upon the conversion, exchange, or exercise thereof would require the issuance, sale,
or transfer by the Borrower of any new or additional Capital Stock of the Borrower (or any other securities of the Borrower which,
whether after notice, lapse of time, or payment of monies, are or would be convertible into or exchangeable or exercisable for
Capital Stock of the Borrower), (iii) no agreements or commitments obligating the Borrower to repurchase, redeem, or otherwise
acquire Capital Stock or other securities of the Borrower or its Subsidiaries, (iv) no agreements or commitments to which
the Borrower is a party or is otherwise bound or that otherwise exists to the knowledge of the Borrower with respect to the voting
(including, without limitation, any voting trusts or proxies), registration under the Securities Act, or sale or transfer (including,
without limitation, agreements relating to preemptive rights, rights of first refusal, rights of first offer, buy-sell rights,
co-sale rights or “drag along” rights) of any Capital Stock of the Borrower and (v) no outstanding or authorized stock
appreciation rights, phantom stock, stock rights, or other equity-based interests in respect of the Borrower. Except as disclosed
on Schedule 4.7(b), as of the Closing Date, the Borrower does not have outstanding any indebtedness that is exercisable
or exchangeable for or convertible into Capital Stock of the Borrower.

 

(c)          The
Borrower has registered its Common Stock pursuant to Section 12(g) of the Exchange Act. The Common Stock is currently quoted on
the OTCQB Marketplace (the “OTCQB”) maintained by the OTC Markets Group, Inc. under the symbol “AMEH.”
The Borrower has not received any oral or written notice from OTC Markets Group that is pending as of the Closing Date that its
Common Stock is not eligible or will become ineligible for quotation on the OTCQB nor that its Common Stock does not meet all the
requirements for the continuation of such quotation.

 

(d)          Schedule
4.7(d) sets forth, as of the Closing Date, as to each Subsidiary Guarantor and, to the knowledge of the Borrower, each other
Subsidiary (x) the number of shares, units or other interests of each class of Capital Stock outstanding in each such Subsidiary,
and the number and effect, if exercised, of all outstanding options, warrants, rights of conversion or purchase and similar rights
and (y) the registered holders of all such Capital Stock of the Subsidiaries and the number of shares, units, interests, options,
warrants or other purchase rights held by each. All outstanding shares of Capital Stock of the Subsidiary Guarantors and, to the
knowledge of the Borrower, each other Subsidiary are duly and validly issued, fully paid and nonassessable. Except for the shares
of Capital Stock and the other equity arrangements expressly indicated on Schedule 4.7(d), as of the Closing Date, there
are no shares of Capital Stock, warrants, rights, options or other equity securities, or other Capital Stock of any Subsidiary
Guarantor and, to the knowledge of the Borrower, each other Subsidiary outstanding or reserved for any purpose.

 

    	29

    	 

    

 

4.8           Full
Disclosure. All factual information heretofore, contemporaneously or hereafter furnished in writing to the Lender by or on
behalf of any Credit Party for purposes of or in connection with this Agreement and the other Credit Documents is or will be true
and accurate in all material respects on the date as of which such information is dated or certified (or, if such information has
been updated, amended or supplemented, on the date as of which any such update, amendment or supplement is dated or certified)
and not made incomplete by omitting to state a material fact necessary to make the statements contained herein and therein, in
light of the circumstances under which such information was provided, not misleading; provided that, with respect to projections,
budgets and other estimates, except as specifically represented in Section 4.11(b), the Borrower represents only that
such information was prepared in good faith based upon assumptions believed to be reasonable at the time. As of the Closing Date,
there is no fact known to any Credit Party that has, or could reasonably be expected to have, a Material Adverse Effect, which
fact has not been set forth herein, in the financial statements of the Borrower and its Subsidiaries furnished to the Lender, or
in any certificate, opinion or other written statement made or furnished by the Borrower to the Lender.

 

4.9           Margin
Regulations. No Credit Party is engaged principally, or as one of its important activities, in the business of extending credit
for the purpose of purchasing or carrying Margin Stock. No proceeds of the Loans will be used, directly or indirectly, to purchase
or carry any Margin Stock, to extend credit for such purpose or for any other purpose, in each case that would violate or be inconsistent
with Regulations T, U or X or any provision of the Exchange Act.

 

4.10         No
Material Adverse Effect. There has been no Material Adverse Effect since January 31, 2013, and there exists no event, condition
or state of facts that could reasonably be expected to result in a Material Adverse Effect.

 

4.11         Financial
Matters.

 

(a)          The
Borrower has heretofore furnished to the Lender copies of (i) the audited consolidated balance sheets of the Borrower and
its Subsidiaries as of January 31, 2013, 2012 and 2011, in each case with the related statements of income, cash flows and stockholders’
equity for the fiscal years then ended, together with the opinion of Kabani & Company, Inc. thereon, and (ii) the unaudited
consolidated balance sheet of the Borrower and its Subsidiaries as of October 31, 2013, and the related statements of income, cash
flows and stockholders’ equity for the nine-month period then ended. Such financial statements have been prepared in accordance
with GAAP (subject, with respect to the unaudited financial statements, to the absence of notes required by GAAP and to normal
year-end adjustments) and present fairly in all material respects the financial condition of the Borrower and its Subsidiaries
on a consolidated basis as of the respective dates thereof and the results of operations of the Borrower and its Subsidiaries on
a consolidated basis for the respective periods then ended. Except as fully reflected in the most recent financial statements referred
to above and the notes thereto, there are no material liabilities or obligations with respect to the Borrower and its Subsidiaries
of any nature whatsoever (whether absolute, contingent or otherwise and whether or not due) that are required in accordance with
GAAP to be reflected in such financial statements and that are not so reflected.

 

    	30

    	 

    

 

(b)          The
Borrower has prepared, and has heretofore furnished to the Lender a copy of the Projections. In the good faith opinion of management
of the Borrower, the assumptions used in the preparation of the Projections were fair, complete and reasonable when made and continue
to be fair, complete and reasonable as of the date hereof. The Projections have been prepared in good faith by the executive and
financial personnel of the Borrower, are complete and represent a reasonable estimate of the future performance and financial condition
of the Borrower and its Subsidiaries, subject to the uncertainties and approximations inherent in any projections.

 

(c)          Each
Credit Party (i) has capital sufficient to carry on its businesses as conducted and as proposed to be conducted, (ii) has
assets with a fair saleable value, determined on a going concern basis, which are (y) not less than the amount required to
pay the probable liability on its existing debts as they become absolute and matured and (z) greater than the total amount
of its liabilities (including identified contingent liabilities, valued at the amount that can reasonably be expected to become
absolute and matured in their ordinary course), and (iii) does not intend to, and does not believe that it will, incur debts
or liabilities beyond its ability to pay such debts and liabilities as they mature in their ordinary course.

 

(d)          Since
January 31, 2013, there has not been an occurrence of a fraud that involves management or other employees who have a significant
role in, the Borrower’s internal controls over financial reporting, as described in Section 404 of the Sarbanes-Oxley Act
of 2002 and all rules and regulations promulgated thereunder and the accounting and auditing principles, rules, standards and practices
promulgated or approved with respect thereto.

 

(e)          Neither
(i) the board of directors of any Credit Party, a committee thereof or an authorized officer of any Credit Party has concluded
that any financial statement previously furnished to the Lender should no longer be relied upon because of an error, nor (ii) has
any Credit Party been advised by its auditors that a previously issued audit report or interim review cannot be relied on.

 

4.12         Ownership
of Properties. Each Credit Party (i) has good and marketable title to all real property owned by it, (ii) holds interests
as lessee under valid leases in full force and effect with respect to all material leased real and personal property used in connection
with its business, and (iii) has good title to all of its other material properties and assets reflected in the most recent
financial statements referred to in Section 4.11(a)(ii) (except as sold or otherwise disposed of since the date thereof
in the ordinary course of business), in each case free and clear of all Liens other than Permitted Liens. Schedule 4.12
lists, as of the Closing Date, all Realty of the Credit Parties, indicating in each case the identity of the owner, the address
of the property, the nature of use of the premises, and whether such interest is a leasehold or fee ownership interest.

 

    	31

    	 

    

 

4.13         ERISA.

 

(a)          Each
Credit Party and its ERISA Affiliates is in compliance with the applicable provisions of ERISA, and each Plan is and has been administered
in compliance with all applicable Requirements of Law, including, without limitation, the applicable provisions of ERISA and the
Code, in each case except where the failure so to comply, individually or in the aggregate, could not reasonably be expected to
have a Material Adverse Effect. No ERISA Event that could reasonably be expected to have a Material Adverse Effect (i) has
occurred within the five-year period prior to the Closing Date, (ii) has occurred and is continuing, or (iii) to the
knowledge of the Borrower, is reasonably expected to occur with respect to any Plan. Except as could not reasonably be expected
to have a Material Adverse Effect, no Plan has any Unfunded Pension Liability as of the most recent annual valuation date applicable
thereto, and no Credit Party or any of its ERISA Affiliates has engaged in a transaction that could be subject to Section 4069
or 4212(c) of ERISA.

 

(b)          No
Credit Party or any of its ERISA Affiliates has any outstanding liability on account of a complete or partial withdrawal from any
Multiemployer Plan, and no Credit Party or any of its ERISA Affiliates would become subject to any liability under ERISA if any
such Credit Party or ERISA Affiliate were to withdraw completely from all Multiemployer Plans as of the most recent valuation date.
No Multiemployer Plan is in “reorganization” or is “insolvent” within the meaning of such terms under ERISA.

 

4.14         Environmental
Matters. Except as set forth on Schedule 4.14:

 

(a)          No
Hazardous Substances are or have been generated, used, located, released, treated, transported, disposed of or stored, currently
or in the past, (i) by any Credit Party or (ii) to the knowledge of the Borrower, by any other Person (including any
predecessor in interest) or otherwise, in either case in, on, about or to or from any portion of any real property, leased, owned
or operated by any Credit Party, except in compliance with all applicable Environmental Laws; no portion of any such real property
or, to the knowledge of the Borrower, any other real property at any time leased, owned or operated by any Credit Party is contaminated
by any Hazardous Substance; and no portion of any real property leased, owned or operated by any Credit Party is presently or,
to the knowledge of the Borrower, has ever been, the subject of an environmental audit, assessment or remedial action.

 

(b)          No
portion of any real property leased, owned or operated by any Credit Party has been used by any Credit Party or, to the knowledge
of the Borrower, by any other Person, as or for a mine, landfill, dump or other disposal facility, gasoline service station or
bulk petroleum products storage facility; and no portion of such real property or any other real property currently or at any time
in the past leased, owned or operated by any Credit Party has, pursuant to any Environmental Law, been placed on the “National
Priorities List” or “CERCLIS List” (or any similar federal, state or local list) of sites subject to possible
environmental problems.

 

(c)          All
activities and operations of the Credit Parties are in compliance with the requirements of all applicable Environmental Laws; each
Credit Party has obtained all licenses and permits under Environmental Laws necessary to its respective operations, all such licenses
and permits are being maintained in good standing, and each Credit Party is in compliance with all terms and conditions of such
licenses and permits; and no Credit Party is involved in any suit, action or proceeding, or has received any notice, complaint
or other request for information from any Governmental Authority or other Person, with respect to any actual or alleged Environmental
Claims, and to the knowledge of the Borrower, there are no threatened Environmental Claims, nor any basis therefor.

 

    	32

    	 

    

 

4.15         Compliance
with Laws. Each Credit Party has timely filed all material reports, documents and other materials required to be filed by it
under all applicable Requirements of Law with any Governmental Authority, has retained all material records and documents required
to be retained by it under all applicable Requirements of Law, and is otherwise in compliance with all applicable Requirements
of Law in respect of the conduct of its business and the ownership and operation of its properties, except in each case to the
extent that the failure to comply therewith, individually or in the aggregate, could not reasonably be expected to have a Material
Adverse Effect.

 

4.16         Intellectual
Property. Each Credit Party owns, or has the legal right to use, all Intellectual Property necessary for it to conduct its
business as currently conducted. Schedule 4.16 lists, as of the Closing Date, all registered Intellectual Property
owned by any Credit Party. No claim has been asserted or is pending by any Person challenging or questioning the use of any such
Intellectual Property or the validity or effectiveness of any such Intellectual Property, nor does the Borrower know of any such
claim, and to the knowledge of the Borrower, the use of such Intellectual Property by any Credit Party does not infringe on the
known rights of any Person, except for such claims and infringements that, individually or in the aggregate, could not reasonably
be expected to have a Material Adverse Effect.

 

4.17         Investment
Company Act. No Credit Party is an “investment company,” a company “controlled” by an “investment
company,” or an “investment advisor,” within the meaning of the Investment Company Act of 1940, as amended.

 

4.18         Insurance.
Schedule 4.18 sets forth, as of the Closing Date, an accurate and complete list and a brief description (including
the insurer, policy number, type of insurance, coverage limits, deductibles, expiration dates and any special cancellation conditions)
of all policies of property and casualty, liability (including, but not limited to, product liability), business interruption,
workers’ compensation, and other forms of insurance owned or held by the Credit Parties or pursuant to which any of their
respective assets are insured. The assets, properties and business of the Credit Parties are insured against such hazards and liabilities,
under such coverages and in such amounts, as are customarily maintained by prudent companies similarly situated and under policies
issued by insurers of recognized responsibility.

 

4.19         Material
Contracts. Schedule 4.19 lists, as of the Closing Date, each “material contract” (within the meaning
of Item 601(b)(10) of Regulation S-K under the Securities Act) to which any Credit Party is a party, by which any Credit Party
or its properties is bound or to which any Credit Party is subject (collectively, “Material Contracts”), and
also indicates the parties thereto. As of the Closing Date, (i) each Material Contract is in full force and effect and is
enforceable by each Credit Party that is a party thereto in accordance with its terms, except as enforceability may be limited
by bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally, by general
or equitable principles or by principles of good faith and fair dealing, and (ii) no Credit Party or, to the knowledge of
the Borrower, any other party thereto is in breach of or default under any Material Contract in any material respect or has given
notice of termination or cancellation of any Material Contract.

 

    	33

    	 

    

 

4.20         Security
Documents. The provisions of each of the Security Documents (whether executed and delivered prior to or on the Closing Date
or thereafter) are and will be effective to create in favor of the Lender a valid and enforceable, first priority security interest
in and Lien upon all right, title and interest of each Credit Party that is a party thereto in and to the collateral purported
to be pledged by it thereunder and described therein, and upon (i) the initial extension of credit hereunder, (ii) the
filing of appropriately completed Uniform Commercial Code financing statements and continuations thereof in the jurisdictions specified
therein, (iii) the filing of appropriately completed short-form assignments in the U.S. Patent and Trademark Office and the
U.S. Copyright Office, as applicable, and (iv) the possession by the Lender of any certificates evidencing the securities
pledged thereby, duly endorsed or accompanied by duly executed stock powers, such security interest and Lien shall constitute from
the Closing Date a fully perfected and first priority security interest in and Lien upon such right, title and interest of the
applicable Credit Party in and to such collateral, to the extent that such security interest and Lien can be perfected by such
filings, actions and possession, subject only to Permitted Liens.

 

4.21         Labor
Relations. No Credit Party is engaged in any unfair labor practice within the meaning of the National Labor Relations Act of
1947, as amended. As of the Closing Date, there is (i) no unfair labor practice complaint before the National Labor Relations
Board, or grievance or arbitration proceeding arising out of or under any collective bargaining agreement, pending or, to the knowledge
of the Borrower, threatened, against any Credit Party, (ii) no strike, lock-out, slowdown, stoppage, walkout or other labor
dispute pending or, to the knowledge of the Borrower, threatened, against any Credit Party, and (iii) to the knowledge of
the Borrower, no petition for certification or union election or union organizing activities taking place with respect to any Credit
Party. As of the Closing Date, there are no collective bargaining agreements or Multiemployer Plans covering the employees of the
Credit Parties.

 

4.22         No
Burdensome Restrictions. No Credit Party is a party to any written agreement or instrument or subject to any other obligations
or any charter or corporate restriction or any provision of any applicable Requirement of Law that, individually or in the aggregate,
would reasonably be expected to have a Material Adverse Effect.

 

4.23         OFAC;
Anti-Terrorism Laws.

 

(a)          No
Credit Party is a Sanctioned Person or does business in a Sanctioned Country or with a Sanctioned Person in violation of the economic
sanctions of the United States administered by OFAC.

 

(b)          Neither
the making of the Loans hereunder nor the use of the proceeds thereof will violate the PATRIOT Act, the Trading with the Enemy
Act, as amended, the Foreign Corrupt Practices Act or any of the foreign assets control regulations of the United States Treasury
Department (31 CFR, Subtitle B, Chapter V, as amended) or any enabling legislation or executive order relating thereto. The Credit
Parties are in compliance in all material respects with the PATRIOT Act.

 

    	34

    	 

    

 

4.24         Investment
Documents. Each of the representations and warranties contained in the Investment Documents made by each Credit Party is true
and correct as of the Closing Date. Each of the Credit Parties agrees that, by this reference, such representations and warranties
contained in the other Investment Documents by a Credit Party, without limiting any of the representations and warranties otherwise
contained herein or in any other Credit Document, hereby are incorporated herein, mutatis mutandis, for the benefit of the Lender.

 

ARTICLE
V

 

AFFIRMATIVE
COVENANTS

 

Until the termination of the Revolving Credit
Commitment and the payment in full in cash of all principal and interest with respect to the Loans, together with all fees, expenses
and other amounts then due and owing hereunder:

 

5.1           Financial
Statements. The Borrower will deliver to the Lender:

 

(a)          As
soon as available and in any event within 50 days (or, if earlier or up to five Business Days later, if applicable to the Borrower
at the time of delivery, the quarterly report deadline as extended by Rule 12b-25 under the Exchange Act rules and regulations
and, if such day is not a Business Day, then on the next succeeding Business Day) after the end of each fiscal quarter of each
fiscal year (excluding the fourth fiscal quarter of each fiscal year), beginning with the first fiscal quarter for which such financial
statements were not delivered as of the Closing Date, unaudited consolidated and consolidating balance sheets of the Borrower and
its Subsidiaries as of the end of such fiscal quarter and unaudited consolidated and consolidating statements of income, cash flows
and stockholders’ equity for the Borrower and its Subsidiaries for the fiscal quarter then ended and for that portion of
the fiscal year then ended, in each case setting forth comparative consolidated figures as of the end of and for the corresponding
period in the preceding fiscal year together with comparative budgeted figures for the fiscal period then ended, all in reasonable
detail and prepared in accordance with GAAP (subject to the absence of notes required by GAAP and subject to normal year-end adjustments)
applied on a basis consistent with that of the preceding quarter or containing disclosure of the effect on the financial condition
or results of operations of any change in the application of accounting principles and practices during such quarter;

 

(b)          As
soon as available and in any event within 105 days (or, if earlier or up to 15 Business Days later, if applicable to the Borrower
at the time of delivery, the annual report deadline as extended by Rule 12b-25 under the Exchange Act rules and regulations and,
if such day is not a Business Day, then on the next succeeding Business Day) after the end of each fiscal year, beginning with
fiscal year 2014, an audited consolidated and unaudited consolidating balance sheet of the Borrower and its Subsidiaries as of
the end of such fiscal year and the related audited consolidated and unaudited consolidating statements of income, cash flows and
stockholders’ equity for the Borrower and its Subsidiaries for the fiscal year then ended, including the notes thereto, in
each case setting forth comparative consolidated figures as of the end of and for the preceding fiscal year together with comparative
budgeted figures for the fiscal year then ended, all in reasonable detail and (with respect to the audited statements) certified
by the independent certified public accounting firm regularly retained by the Borrower or another independent certified public
accounting firm of recognized national standing reasonably satisfactory to the Lender, together with (y) a report thereon
by such accountants that is not qualified as to scope of audit and to the effect that such financial statements present fairly
in all material respects the consolidated financial condition and results of operations of the Borrower and its Subsidiaries as
of the dates and for the periods indicated in accordance with GAAP applied on a basis consistent with that of the preceding year
or containing disclosure of the effect on the financial condition or results of operations of any change in the application of
accounting principles and practices during such year, and (z) a letter from such accountants to the effect that, based on
and in connection with their examination of the financial statements of the Borrower and its Subsidiaries, they obtained no knowledge
of the occurrence or existence of any Default or Event of Default relating to accounting or financial reporting matters (which
certificate may be limited to the extent required by accounting rules or guidelines), or a statement specifying the nature and
period of existence of any such Default or Event of Default disclosed by their audit; and

 

    	35

    	 

    

 

(c)          Concurrently
with each delivery of the financial statements described in Sections 5.1(a) and 5.1(b), a report in form and
method of analysis similar to the Management’s Discussion and Analysis found in an annual report, Form 10-K or Form 10-Q
of a publicly registered company, or in such other form as may be satisfactory to the Lender, regarding such topics as the Borrower’s
financial condition and results of operations, the Borrower’s business and corresponding industry and the Borrower’s
management.

 

Documents required to be delivered pursuant
to Sections 5.1 or 5.2(c) (to the extent such documents are included in materials otherwise filed with the U.S. Securities
Exchange Commission) may be delivered electronically and if so delivered, will be deemed to have been delivered on the date on
which such documents are posted to EDGAR.

 

5.2           Other
Business and Financial Information. The Borrower will deliver to the Lender:

 

(a)          Concurrently
with each delivery of the financial statements described in Sections 5.1(a) (including with respect to financial statements
as of the end of and for the fourth fiscal quarter of each fiscal year) and 5.1(b), a Compliance Certificate with respect
to the period covered by the financial statements being delivered thereunder, executed by a Financial Officer of the Borrower,
together with a Covenant Compliance Worksheet reflecting the computation of the financial covenants set forth in Article VI
as of the last day of the period covered by such financial statements;

 

(b)          Promptly
upon receipt thereof, copies of any “management letter” submitted to any Credit Party by its certified public accountants
in connection with each annual, interim or special audit, and promptly upon completion thereof, any response reports from such
Credit Party in respect thereof;

 

(c)          Promptly
upon the sending, filing or receipt thereof, copies of (i) all financial statements, reports, notices and proxy statements
that any Credit Party shall send or make available generally to its shareholders, (ii) all regular, periodic and special reports,
registration statements and prospectuses (other than on Form S-8) that any Credit Party shall render to or file with the Securities
and Exchange Commission, the National Association of Securities Dealers, Inc. or any national securities exchange, and (iii) all
press releases and other statements made available generally by any Credit Party to the public concerning material developments
in the business of the Credit Parties;

 

    	36

    	 

    

 

(d)          Promptly
upon (and in any event within five Business Days after) any Responsible Officer of any Credit Party obtaining knowledge thereof,
written notice of any of the following:

 

(i)          the
occurrence of any Default or Event of Default, together with a written statement of a Responsible Officer of the Borrower specifying
the nature of such Default or Event of Default, the period of existence thereof and the action that the Borrower has taken and
proposes to take with respect thereto;

 

(ii)         the
institution or threatened institution of any action, suit, investigation or proceeding against or affecting any Credit Party, including
any such investigation or proceeding by any Governmental Authority (other than routine periodic inquiries, investigations or reviews),
that, if adversely determined, could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect,
and any material development in any litigation or other proceeding previously reported pursuant to this Section;

 

(iii)        the
receipt by any Credit Party from any Governmental Authority of (A) any notice asserting any failure by any Credit Party to
be in compliance with applicable Requirements of Law or that threatens the taking of any action against any Credit Party or sets
forth circumstances that, if taken or adversely determined, could reasonably be expected to have a Material Adverse Effect, or
(B) any notice of any actual or threatened suspension, limitation or revocation of, failure to renew, or imposition of any
restraining order, escrow or impoundment of funds in connection with, any license, permit, accreditation or authorization of any
Credit Party, where such action could reasonably be expected to have a Material Adverse Effect;

 

(iv)         the
occurrence of any ERISA Event, together with (x) a written statement of a Responsible Officer of the Borrower specifying the
details of such ERISA Event and the action that the applicable Credit Party has taken and proposes to take with respect thereto,
(y) a copy of any notice with respect to such ERISA Event that may be required to be filed with the PBGC and (z) a copy
of any notice delivered by the PBGC to any Credit Party or an ERISA Affiliate with respect to such ERISA Event;

 

(v)          the
occurrence of any material default under, or any proposed or threatened termination or cancellation of, any Material Contract or
other material contract or agreement to which any Credit Party is a party, in any such case the default under or termination or
cancellation of which could reasonably be expected to have a Material Adverse Effect;

 

    	37

    	 

    

 

(vi)         the
occurrence of any of the following: (x) the assertion of any Environmental Claim against or affecting any Credit Party or
any real property leased, operated or owned by any Credit Party, or any Credit Party’s discovery of a basis for any such
Environmental Claim; (y) the receipt by any Credit Party of notice of any alleged violation of or noncompliance with any Environmental
Laws or release of any Hazardous Substance; or (z) the taking of any investigation, remediation or other responsive action
by any Credit Party or any other Person in response to the actual or alleged violation of any Environmental Law by any Credit Party
or generation, storage, transport, release, disposal or discharge of any Hazardous Substances on, to, upon or from any real property
leased, operated or owned by any Credit Party; but in each case under clauses (x), (y) and (z) above, only to the extent the
same could reasonably be expected to have a Material Adverse Effect;

 

(vii)        if
the Borrower has not already provided notice to the Lender pursuant to Section 5.8, the occurrence of a Permitted Acquisition
together with a reasonably detailed description of the material terms of such Permitted Acquisition (including, without limitation,
the Acquisition Amount and method and structure of payment) and of each Target that is the subject of such Permitted Acquisition
and

 

(viii)      any
other matter or event that has, or could reasonably be expected to have, a Material Adverse Effect, together with a written statement
of a Responsible Officer of the Borrower setting forth the nature and period of existence thereof and the action that the affected
Credit Parties have taken and propose to take with respect thereto;

 

(e)          Concurrently
with each delivery of the financial statements described in Section 5.1(b), commencing with respect to the financial
statements for fiscal year ended 2015, calculations reflecting the computation of Consolidated EBITDA for the Immaterial Subsidiaries
as of the last day of the period covered by such financial statements; and

 

(f)          As
promptly as reasonably possible, such other information about the business, condition (financial or otherwise), operations or properties
of any Credit Party as the Lender may from time to time reasonably request.

 

5.3           Existence;
Franchises; Maintenance of Properties. The Borrower will, and will cause each of its Subsidiary Guarantors to, (i) maintain
and preserve in full force and effect its existence, except as expressly permitted otherwise by Section 7.1, (ii) obtain,
maintain and preserve in full force and effect all other rights, franchises, licenses, permits, certifications, approvals and authorizations
required by Governmental Authorities and necessary to the ownership, occupation or use of its properties or the conduct of its
business, except to the extent the failure to do so could not reasonably be expected to have a Material Adverse Effect, and (iii) keep
all material properties in good working order and condition (normal wear and tear and damage by casualty excepted) and from time
to time make all necessary repairs to and renewals and replacements of such properties, except to the extent that any of such properties
are obsolete or are being replaced or, in the good faith judgment of the Borrower, are no longer useful or desirable in the conduct
of the business of the Credit Parties.

 

5.4           Compliance
with Laws. The Borrower will, and will cause each of its Subsidiary Guarantors to, comply in all respects with all Requirements
of Law applicable in respect of the conduct of its business and the ownership and operation of its properties, except to the extent
the failure so to comply could not reasonably be expected to have a Material Adverse Effect.

 

    	38

    	 

    

 

5.5           Payment
of Obligations. The Borrower will, and will cause each of its Subsidiary Guarantors to, (i) pay, discharge or otherwise
satisfy at or before maturity all liabilities and obligations as and when due (subject to any applicable subordination, grace and
notice provisions), except to the extent failure to do so would not cause an Event of Default pursuant to Section 8.1(e),
and (ii) pay and discharge all taxes, assessments and governmental charges or levies imposed upon it, upon its income or profits
or upon any of its properties, prior to the date on which penalties would attach thereto, and all lawful claims that, if unpaid,
would become a Lien (other than a Permitted Lien) upon any of the properties of any Credit Party; provided, however,
that no Credit Party shall be required to pay any such obligation, tax, assessment, charge, levy or claim that is being contested
in good faith and, if applicable, by proper proceedings and, if applicable, as to which such Credit Party is maintaining adequate
reserves with respect thereto in accordance with GAAP.

 

5.6           Insurance.

 

(a)          The
Borrower will, and will cause each of its Subsidiary Guarantors to, maintain with financially sound and reputable insurance companies
insurance with respect to its assets, properties and business, against such hazards and liabilities, of such types and in such
amounts, as is customarily maintained by companies in the same or similar businesses similarly situated. Each such policy of insurance
shall contain a clause requiring the insurer to give not less than 30 days’ prior written notice to the Lender before any
cancellation of the policies for any reason whatsoever and shall provide that any loss shall be payable in accordance with the
terms thereof notwithstanding any act of any Credit Party that might result in the forfeiture of such insurance.

 

(b)          The
Borrower will, and will cause each of its Subsidiary Guarantors to, direct all insurers under policies of property and casualty
insurance on the collateral purported to be covered by the Security Documents to pay all proceeds payable thereunder directly to
the Lender as loss payee and additional insured, as applicable. The Lender shall hold all such proceeds for the account of the
Credit Parties. So long as no Event of Default has occurred and is continuing, and subject Section 2.2, the Lender shall,
at the Borrower’s request, disburse such proceeds as payment for the purpose of replacing or repairing destroyed or damaged
assets, as and when required to be paid and upon presentation of evidence satisfactory to the Lender of such required payments
and such other documents as the Lender may reasonably request. As and to the extent required by Section 2.2, and in
any event upon and during the continuance of an Event of Default, the Lender shall apply such proceeds as a prepayment of the Loans
in the manner provided in Section 2.2.

 

5.7           Maintenance
of Books and Records; Inspection. The Borrower will, and will cause each of its Subsidiary Guarantors to, (i) maintain
adequate books, accounts and records, in which full, true and correct entries shall be made of all financial transactions in relation
to its business and properties, and prepare all financial statements required under this Agreement, in each case in accordance
with GAAP and in compliance with the requirements of any Governmental Authority having jurisdiction over it, and (ii) permit
employees or agents of the Lender to visit and inspect its properties and examine or audit its books, records, working papers and
accounts and make copies and memoranda of them, and to discuss its affairs, finances and accounts with its officers and employees
and, upon notice to the Borrower, the independent public accountants of the Borrower and its Subsidiary Guarantors (and by this
provision the Borrower authorizes such accountants to discuss the finances and affairs of the Borrower and its Subsidiary Guarantors),
all at such times and from time to time, upon reasonable notice and during business hours, as may be reasonably requested.

 

    	39

    	 

    

 

5.8           Permitted
Acquisitions. In addition to the requirements contained in the definition of Permitted Acquisition and in the other applicable
terms and conditions of this Agreement, the Borrower shall, with respect to any Permitted Acquisition in which the corresponding
Acquisition Amount exceeds $500,000, comply with, and cause each other applicable Credit Party to comply with, the following covenants:

 

(a)          Not
less than ten Business Days prior to the consummation of any Permitted Acquisition, the Borrower shall have delivered to the Lender
the following:

 

(i)          a
reasonably detailed description of the material terms of such Permitted Acquisition (including, without limitation, the Acquisition
Amount and method and structure of payment) and of each Person or business that is the subject of such Permitted Acquisition (each,
a “Target”);

 

(ii)         audited
historical financial statements of the Target (or, if there are two or more Targets that are the subject of such Permitted Acquisition
and that are part of the same consolidated group, consolidated historical financial statements for all such Targets) for the two
most recent fiscal years available, prepared by a firm of independent certified public accountants reasonably satisfactory to the
Lender (or, if audited financial statements are not available, unaudited financial statements for such periods), and (if available)
unaudited financial statements for any interim periods since the most recent fiscal year-end;

 

(iii)        consolidated
projected income statements of the Borrower and its Subsidiaries (giving effect to such Permitted Acquisition and the consolidation
with the Borrower of each relevant Target) for the three-year period following the consummation of such Permitted Acquisition,
in reasonable detail, together with any appropriate statement of assumptions and pro forma adjustments;

 

(iv)         with
respect to any such Permitted Acquisition in which any Contingent Purchase Price Obligations shall be incurred by the Borrower
or any other Credit Party, a copy of the most recent draft of the acquisition agreement (including schedules and exhibits thereto,
to the extent available) and other material documents (including the documentation evidencing such Contingent Purchase Price Obligations);

 

(v)          a
certificate, in form and substance reasonably satisfactory to the Lender, executed by a Financial Officer of the Borrower setting
forth the Acquisition Amount (including a good faith calculation of any Contingent Purchase Price Obligations) and further to the
effect that, to the best of such Financial Officer’s knowledge, (w) the consummation of such Permitted Acquisition will
not result in a violation of any provision of this Section 5.8 or any other provision of this Agreement, (x) the Borrower
shall show pro forma compliance with the financial covenants set forth in Article VI (with such covenant calculations to
be attached to the certificate using the Covenant Compliance Worksheet), (y) the Borrower believes in good faith that it will
continue to comply with such financial covenants for a period of one year following the date of the consummation of such Permitted
Acquisition, and (z) after giving effect to such Permitted Acquisition and any Borrowings in connection therewith, the Borrower
believes in good faith that it will have sufficient availability hereunder to meet its ongoing working capital requirements; and

 

    	40

    	 

    

 

(vi)         true
and correct copies of the final execution copy of the acquisition agreement (including schedules and exhibits thereto) and other
material documents and closing papers delivered in connection therewith.

 

(b)          The
consummation of each Permitted Acquisition shall be deemed to be a representation and warranty by the Borrower that (except as
shall have been approved in writing by the Lender) all conditions thereto set forth in this Section 5.8 and in the description
furnished under Section 5.8(a)(i) have been satisfied, that the same is permitted in accordance with the terms of this Agreement,
and that the matters certified to by the Financial Officer of the Borrower in the certificate referred to in Section 5.8(a)(v)
are, to the best of such Financial Officer’s knowledge, true and correct in all material respects as of the date such certificate
is given, which representation and warranty shall be deemed to be a representation and warranty as of the date thereof for all
purposes hereunder.

 

5.9           Creation
or Acquisition of Subsidiaries. Subject to the provisions of Section 5.8, the Borrower may from time to time create
or acquire new physician practices that will be Subsidiaries hereunder and other new Subsidiaries in connection with Permitted
Acquisitions or otherwise, and Subsidiary Guarantors of the Borrower may create or acquire new Subsidiaries; provided that:

 

(a)          Concurrently
with (and in any event within ten Business Days after) the creation or direct or indirect acquisition by the Borrower thereof,
(i) each such new Subsidiary, other than if such new Subsidiary constitutes an Immaterial Subsidiary, will execute and deliver
to the Lender (A) a joinder to the Guaranty, pursuant to which such new Subsidiary shall become a guarantor thereunder and
shall guarantee the payment in full of the Obligations of the Borrower under this Agreement and the other Credit Documents and
(B) a joinder to the Pledge and Security Agreement, pursuant to which such new Subsidiary shall become a party thereto and
shall grant to the Lender a first priority Lien upon and security interest in its accounts receivable, inventory, equipment, general
intangibles and other property as collateral for its obligations under the Guaranty, subject only to Permitted Liens, and (ii)
other than if such Subsidiary is a physician practice, the Borrower will, or will cause the parent Subsidiary that owns the Capital
Stock of such new Subsidiary to, execute and deliver to the Lender an amendment or supplement to the Pledge and Security Agreement
pursuant to which all of the Capital Stock so owned by the Borrower or such other Subsidiary shall be pledged to the Lender, together
with the certificates evidencing such Capital Stock and undated stock powers duly executed in blank and, in each case, any such
other documents and certificates , in form and substance reasonably satisfactory to the Lender, as the Lender may reasonably request
in connection therewith;

 

(b)          Concurrently
with (and in any event within 10 Business Days after) the creation or acquisition of any new Subsidiary, the Borrower will deliver
to the Lender:

 

    	41

    	 

    

 

(i)          (A) a
copy of the certificate of incorporation (or other charter documents) of such Subsidiary, certified as of a date that is satisfactory
to the Lender by the applicable Governmental Authority of the jurisdiction of incorporation or organization of such Subsidiary,
(B) a copy of the bylaws or similar organizational document of such Subsidiary, certified on behalf of such Subsidiary as
of a date that is satisfactory to the Lender by the corporate secretary or assistant secretary of such Subsidiary, (C) an
original certificate of good standing for such Subsidiary issued by the applicable Governmental Authority of the jurisdiction of
incorporation or organization of such Subsidiary and, (D)  other than if such new Subsidiary constitutes an Immaterial Subsidiary,
copies of the resolutions of the board of directors and, if required, stockholders or other equity owners of such Subsidiary authorizing
the execution, delivery and performance of the agreements, documents and instruments executed pursuant to Section 5.9(a),
certified on behalf of such Subsidiary by an Authorized Officer of such Subsidiary, all in form and substance reasonably satisfactory
to the Lender;

 

(ii)         other
than if such new Subsidiary constitutes an Immaterial Subsidiary, a report of Uniform Commercial Code financing statement, tax
and judgment lien searches performed against such Subsidiary in each jurisdiction in which such Subsidiary is incorporated or organized,
has a place of business or maintains any assets, which report shall show no Liens on its assets (other than Permitted Liens);

 

(iii)        other
than if such new Subsidiary constitutes an Immaterial Subsidiary, a certificate of the secretary or an assistant secretary of such
Subsidiary as to the incumbency and signature of the officers executing agreements, documents and instruments executed pursuant
to Section 5.9(a);

 

(iv)         other
than if such new Subsidiary constitutes an Immaterial Subsidiary, a certificate as to the solvency of such Subsidiary, addressed
to the Lender, dated as of the date of creation or acquisition of such Subsidiary and in form and substance reasonably satisfactory
to the Lender;

 

(v)          other
than if such new Subsidiary constitutes an Immaterial Subsidiary, evidence satisfactory to the Lender that no Default or Event
of Default shall exist immediately before or after the creation or acquisition of such Subsidiary or be caused thereby; and

 

(vi)         a
certificate executed by an Authorized Officer of the Borrower and, if such Subsidiary does not constitute an Immaterial Subsidiary,
such Subsidiary, which shall constitute a representation and warranty by the Borrower and such Subsidiary as of the date of the
creation or acquisition of such Subsidiary that all conditions contained in this Agreement to such creation or acquisition have
been satisfied, in form and substance reasonably satisfactory to the Lender; and

 

    	42

    	 

    

 

(c)          If
the Acquisition involves a physician practice that will be a Subsidiary of the Borrower, other than if such Subsidiary constitutes
an Immaterial Subsidiary, concurrently with the creation or direct or indirect acquisition by the Borrower thereof, each such physician
practice and the owner of all the Capital Stock issued by such physician practice (or, if there is more than one owner, owners
of at least seventy five percent (75%) of the Capital Stock issued by such physician practice) within ten (10) Business Days after
the Acquisition shall enter into a Physician Shareholder Agreement, a Physician Practice Management Agreement and collateral assignments
thereof to the Lender, in each case on terms and conditions satisfactory to the Lender.

 

(d)          If
for any reason and at any time a Subsidiary previously qualifying as an Immaterial Subsidiary no longer qualifies as an Immaterial
Subsidiary and such Subsidiary involves a physician practice, such Subsidiary and the owner of all the Capital Stock issued by
such Subsidiary (or, if there is more than one owner, owners of at least seventy five percent (75%) of the Capital Stock issued
by such Subsidiary) within ten (10) Business Days after the first date such Subsidiary no longer qualifies as an Immaterial Subsidiary
shall enter into a Physician Shareholder Agreement, a Physician Practice Management Agreement and collateral assignments thereof
to the Lender, in each case on terms and conditions satisfactory to the Lender.

 

(e)          Other
than with respect to a new Subsidiary that constitutes an Immaterial Subsidiary, as promptly as reasonably possible, the Borrower
and the Subsidiary Guarantors will deliver any such other documents, certificates and opinions, in form and substance reasonably
satisfactory to the Lender, as the Lender may reasonably request in connection therewith and will take such other action as the
Lender may reasonably request to create in favor of the Lender a perfected security interest in the collateral being pledged pursuant
to the documents described above.

 

5.10         Additional
Security.

 

(a)          The
Borrower will, and will cause each of the Subsidiary Guarantors to, grant to the Lender from time to time security interests, mortgages
and other Liens in and upon such of its assets and properties as are not covered by the Security Documents executed and delivered
on the Closing Date or pursuant to Section 5.9, and as may be reasonably requested from time to time by the Lender. Such
security interests and Liens shall be granted pursuant to documentation in form and substance reasonably satisfactory to the Lender
and shall constitute valid and perfected security interests and Liens, subject to no Liens other than Permitted Liens.

 

(b)          If
for any reason and at any time a Subsidiary previously qualifying as an Immaterial Subsidiary no longer qualifies as an Immaterial
Subsidiary, such Subsidiary will execute and deliver to the Lender within ten (10) Business Days after the first date such Subsidiary
no longer qualifies as an Immaterial Subsidiary (A) a joinder to the Guaranty, pursuant to which such Subsidiary shall become
a guarantor thereunder and shall guarantee the payment in full of the Obligations of the Borrower under this Agreement and the
other Credit Documents, (B) a joinder to the Pledge and Security Agreement, pursuant to which such Subsidiary shall become
a party thereto and shall grant to the Lender a first priority Lien upon and security interest in its accounts receivable, inventory,
equipment, general intangibles and other property as collateral for its obligations under the Guaranty, subject only to Permitted
Liens, and (C) any such other documents, certificates and opinions, in form and substance reasonably satisfactory to the Lender,
as the Lender may reasonably request in connection therewith and will take such other action as the Lender may reasonably request
to create in favor of the Lender a perfected security interest in the collateral being pledged pursuant to the documents described
above.

 

    	43

    	 

    

 

5.11         Environmental
Laws. The Borrower will, and will cause each of the Subsidiary Guarantors to, (i) comply in all material respects with,
and use commercially reasonable efforts to ensure compliance in all material respects by all tenants and subtenants, if any, with,
all applicable Environmental Laws and obtain and comply in all material respects with and maintain, and use commercially reasonable
efforts to ensure that all tenants and subtenants obtain and comply in all material respects with and maintain, any and all licenses,
approvals, notifications, registrations or permits required by applicable Environmental Laws, except to the extent that the failure
to do so could not reasonably be expected to have a Material Adverse Effect, and (ii) conduct and complete all investigations,
studies, sampling and testing, and all remedial, removal and other actions, required under Environmental Laws and promptly comply
in all material respects with all lawful orders and directives of all Governmental Authorities regarding Environmental Laws, except
to the extent that the same are being contested in good faith by appropriate proceedings or to the extent the failure to conduct
or complete any of the foregoing could not reasonably be expected to have a Material Adverse Effect.

 

5.12         PATRIOT
Act Compliance. The Borrower will, and will cause each of the Subsidiary Guarantors to,  provide, to the extent commercially
reasonable, such information and take such actions as are reasonably requested by the Lender in order to assist the Lender in maintaining
compliance with the PATRIOT Act.

 

5.13         Securities
Filings. Each regular, periodic and special report, registration statement and prospectus that any Credit Party shall render
to or file with the Securities and Exchange Commission, the National Association of Securities Dealers, Inc. or any national securities
exchange shall satisfy all Requirements of Law when such report, registration statement and prospectus is so rendered or filed.

 

5.14         Further
Assurances. The Borrower will, and will cause each of the Subsidiary Guarantors to, make, execute, endorse, acknowledge and
deliver any amendments, modifications or supplements hereto and restatements hereof and any other agreements, instruments or documents,
and take any and all such other actions, as may from time to time be reasonably requested by the Lender to perfect and maintain
the validity and priority of the Liens granted pursuant to the Security Documents and to effect, confirm or further assure or protect
and preserve the interests, rights and remedies of the Lender under this Agreement and the other Credit Documents.

 

5.15         Board
Rights. The Lender shall have the rights of the Purchaser set forth in Sections 6.1 and 6.2 of the Investment
Agreement and such rights hereby are incorporated herein, mutatis mutandis, for the benefit of the Lender as if the Lender is the
Purchaser under the Investment Agreement. The Lender shall retain such rights under this Agreement after the Investment Agreement
is terminated as long as the Term Loan remains outstanding

 

    	44

    	 

    

 

5.16         Immaterial
Subsidiaries. Concurrently with the delivery of the calculations required by Section 5.2(e), and if necessary in order
to avoid Immaterial Subsidiaries designated pursuant to clause (ii)(B) of the definition thereof from exceeding an aggregate of
5% of Consolidated EBITDA for the fiscal year of the Borrower most recently ended prior to such date of determination, the Borrower
shall remove one or more Subsidiaries from such designation and cause any such Subsidiary to comply with Sections 5.9(d)
and 5.10(b), as applicable.

 

ARTICLE
VI

 

FINANCIAL
COVENANTS

 

Until the termination
of the Revolving Credit Commitment and the payment in full in cash of all principal and interest with respect to the Loans, together
with all fees, expenses and other amounts then due and owing hereunder, the Borrower will not:

 

6.1           Consolidated
EBITDA. Permit Consolidated EBITDA as of the last day of each fiscal quarter shown below, calculated on a year-to-date basis
for the fiscal year ended March 2016, to be less than the amount corresponding to such fiscal quarter:

 

	Period	 	Minimum Consolidated 
 EBITDA	 
	2nd fiscal quarter ended September 2015	 	$	1,000,000	 
	3rd fiscal quarter ended December 2015	 	$	1,500,000	 
	4th fiscal quarter ended March 2016	 	$	2,000,000	 

 

6.2           Leverage
Ratio. Commencing with the Borrower’s fiscal quarter ended March 2016 and for each fiscal quarter thereafter, permit
Leverage Ratio as of the last day of the fiscal quarter then ended, to be greater than 4.0 to 1.0.

 

6.3           Fixed
Charge Coverage Ratio. Commencing with the Borrower’s fiscal quarter ended September 2015 and for each fiscal quarter
thereafter, permit the Fixed Charge Coverage Ratio as of the last day of the fiscal quarter then ended, to be less than 1.25 to
1.0.

 

6.4           Consolidated
Tangible Net Worth. Permit Consolidated Tangible Net Worth as of the last day of each fiscal quarter shown below to be less
than the amount corresponding to such fiscal quarter:

 

    	45

    	 

    

 

	Period	 	Consolidated Tangible 
 Net Worth	 
	1st fiscal quarter ended June 2014	 	$	(3,700,000	)
	2nd fiscal quarter ended September 2014	 	$	(3,700,000	)
	3rd fiscal quarter ended December 2014	 	$	(3,700,000	)
	4th fiscal quarter ended March 2015	 	$	(3,700,000	)
	1st fiscal quarter ended June 2015	 	$	(3,700,000	)
	2nd fiscal quarter ended September 2015	 	$	(3,700,000	)
	3rd fiscal quarter ended December 2015	 	$	0	 
	4th fiscal quarter ended March 2016 and for each fiscal quarter thereafter	 	$	2,000,000	 

 

ARTICLE
VII

 

NEGATIVE
COVENANTS

 

Until the termination
of the Revolving Credit Commitment and the payment in full in cash of all principal and interest with respect to the Loans, together
with all fees, expenses and other amounts then due and owing hereunder:

 

7.1           Merger;
Consolidation. The Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to liquidate, wind up or dissolve,
or enter into any consolidation, merger or other combination, or agree to do any of the foregoing; provided, however,
that:

 

(i)          any
Wholly Owned Subsidiary of the Borrower may merge or consolidate with, or be liquidated into, (x) the Borrower (so long as
the Borrower is the surviving or continuing entity) or (y) any other Wholly Owned Subsidiary (so long as, if either constituent
entity is a Subsidiary Guarantor, the surviving or continuing entity is a Subsidiary Guarantor), and in each case so long as no
Default or Event of Default has occurred and is continuing or would result therefrom;

 

(ii)         any
Wholly Owned Subsidiary of the Borrower may merge or consolidate with another Person (other than another Credit Party), so long
as (x) the surviving entity is a Subsidiary Guarantor, (y) such merger or consolidation constitutes a Permitted Acquisition
and the applicable conditions and requirements of Sections 5.8 and 5.9 are satisfied, and (z) no Default
or Event of Default has occurred and is continuing or would result therefrom; and

 

(iii)        the
Borrower may merge or consolidate with another Person (other than another Credit Party), so long as (x) the Borrower is the
surviving entity, (y) such merger or consolidation constitutes a Permitted Acquisition and the applicable conditions and requirements
of Sections 5.8 and 5.9 are satisfied, and (z) no Default or Event of Default has occurred and is continuing
or would result therefrom.

 

    	46

    	 

    

 

7.2           Indebtedness.
The Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to, create, incur, assume or suffer to exist
any Indebtedness other than (without duplication):

 

(i)          Indebtedness
of the Credit Parties in favor of the Lender incurred under this Agreement and the other Credit Documents;

 

(ii)         purchase
money Indebtedness of the Borrower and the Subsidiary Guarantors incurred solely to finance the acquisition, construction or improvement
of any equipment, real property or other fixed assets in the ordinary course of business (or assumed or acquired by the Borrower
and the Subsidiary Guarantors in connection with a Permitted Acquisition or other transaction permitted under this Agreement),
including Capitalized Lease Obligations, and any renewals, replacements, refinancings or extensions thereof; provided that
all such Indebtedness shall not exceed $50,000 in aggregate principal amount outstanding at any one time;

 

(iii)        unsecured
loans and advances (A) by the Borrower or any Subsidiary Guarantor to any Subsidiary Guarantor or (B) by any Subsidiary
Guarantor to the Borrower, provided, in each case that any such loan or advance is subordinated in right and time of payment
to the Obligations and is evidenced by an Intercompany Note, in form and substance reasonably satisfactory to the Lender and pledged
to the Lender pursuant to the Security Documents;

 

(iv)         loans
and advances by the Borrower or any Subsidiary Guarantor to an Affiliated Physician Practice Entity that is also a Subsidiary Guarantor
so long as (A) such Affiliated Physician Practice Entity is consolidated with the Borrower in accordance with GAAP, (B) such Affiliated
Physician Practice Entity is party to a Physician Practice Management Agreement with the Borrower or any Subsidiary and (C) the
owner(s) of at least seventy five percent (75%) of the Capital Stock of such Affiliated Physician Practice Entity have entered
into a Physician Shareholder Agreement, in each case referred to in clauses (B) and (C) on terms and conditions satisfactory to
the Lender, provided that, any such loan or advance is (I) not subordinated in right and time of payment to any other
obligations of such Affiliated Physician Practice Entity and (II) made in the ordinary course of business and pursuant to the terms
of the Intercompany Loan Agreements and in conjunction with the applicable Physician Practice Management Agreement as then in effect,
and such Intercompany Loan Agreement is assigned by way of security to the Lender pursuant to the Security Documents;

 

(v)          loans
and advances by the Borrower or any Subsidiary Guarantor to any Immaterial Subsidiary in an aggregate amount not exceeding $50,000
at any one time outstanding; provided, that any such loan or advance is evidenced by an Intercompany Note, in form and substance
reasonably satisfactory to the Lender and pledged to the Lender pursuant to the Security Documents;

 

    	47

    	 

    

 

(vi)         Hedge
Agreements entered into in the ordinary course of business to manage existing or anticipated interest rate, foreign currency or
commodity risks and not for speculative purposes;

 

(vii)        Indebtedness
existing on the Closing Date and described in Schedule 7.2 as in effect as of the Closing Date, which Indebtedness,
for the avoidance of doubt hereunder, may not be refinanced, amended, modified or extended;

 

(viii)      Indebtedness
consisting of Guaranty Obligations of the Borrower or any of the Subsidiary Guarantors incurred in the ordinary course of business
for the benefit of another Credit Party;

 

(ix)         unsecured
Indebtedness consisting of (x) Contingent Purchase Price Obligations of the Borrower and the Subsidiary Guarantors or (y) existing
Indebtedness of any Person that becomes a Subsidiary of the Borrower, in each case incurred after the Closing Date in connection
with a Permitted Acquisition;

 

(x)          Indebtedness
arising from any judgment, order, decree or award not constituting an Event of Default under Section 8.1(j);

 

(xi)         Indebtedness
that may be deemed to exist pursuant to any performance bond, surety, statutory appeal or similar obligation entered into or incurred
by the Borrower or any of the Subsidiary Guarantors in the ordinary course of business;

 

(xii)        Indebtedness
of the Borrower and the Subsidiary Guarantors arising from the honoring by a bank or other financial institution of a check, draft
or similar instrument inadvertently (except in the case of daylight overdrafts) drawn against insufficient funds in the ordinary
course of business; provided that such Indebtedness is extinguished within five Business Days of its incurrence;

 

(xiii)      Indebtedness
in respect of the Convertible Note in a principal amount not to exceed $2,000,000, and renewals, refinancings, restatements, replacements
or extensions of the foregoing in a principal amount not in excess of that outstanding as of the date of such renewal, refinancing
or extension (plus the amount of reasonable fees and expenses relating thereto, including, without limitation, contractual or market
rate call or tender premiums) and on terms substantially similar to the Convertible Note or no less favorable in any material respect,
or with respect to any subordination terms, in any respect, to the Borrower or the Lender; and

 

(xiv)        Indebtedness
not otherwise permitted under this Section 7.2, provided that such additional Indebtedness is (a) unsecured, (b)
taken together with all other Indebtedness permitted under this clause (xii), does not exceed, in the aggregate principal amount
outstanding at any time, $50,000, and (c) ranks pari passu or junior in right of payment to the Obligations under this Agreement
and the other Credit Documents.

 

    	48

    	 

    

 

7.3           Liens.
The Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to, directly or indirectly, make, create,
incur, assume or suffer to exist, any Lien upon or with respect to any part of its property or assets, whether now owned or hereafter
acquired, or file or permit the filing of, or permit to remain in effect, any financing statement or other similar notice of any
Lien with respect to any such property, asset, income or profits under the Uniform Commercial Code of any state or under any similar
recording or notice statute, or agree to do any of the foregoing, other than the following (collectively, “Permitted Liens”):

 

(i)          Liens
in favor of the Lender created by or otherwise existing under or in connection with this Agreement and the other Credit Documents;

 

(ii)         Liens
in existence on the Closing Date and set forth on Schedule 7.3;

 

(iii)        Liens
imposed by law, such as Liens of carriers, warehousemen, mechanics, materialmen and landlords, incurred in the ordinary course
of business for sums not constituting borrowed money that are not overdue for a period of more than 30 days or that are being contested
in good faith by appropriate proceedings and for which adequate reserves have been established in accordance with GAAP (if so required);

 

(iv)         Liens
(other than any Lien imposed by ERISA, the creation or incurrence of which would result in an Event of Default under Section
8.1(m)) incurred in the ordinary course of business in connection with worker’s compensation, unemployment insurance
or other forms of governmental insurance or benefits, or to secure the performance of letters of credit, bids, tenders, statutory
obligations, surety and appeal bonds, leases, public or statutory obligations, government contracts and other similar obligations
(other than obligations for borrowed money) entered into in the ordinary course of business;

 

(v)          Liens
for taxes, assessments or other governmental charges or statutory obligations that are not delinquent or remain payable without
any penalty or that are being contested in good faith by appropriate proceedings and for which adequate reserves have been established
in accordance with GAAP (if so required);

 

(vi)         any
attachment, judgment or other Lien not constituting an Event of Default under clause (j), (k) or (l) of Section 8.1;

 

(vii)        Liens
securing the Indebtedness permitted under Section 7.2(ii); provided that (x) any such Lien shall attach
to the property or Person being acquired, constructed or improved with such Indebtedness concurrently with or within 90 days after
the acquisition (or completion of construction or improvement) or the refinancing thereof by the Borrower or such Subsidiary, (y) the
amount of the Indebtedness secured by such Lien shall not exceed 100% of the cost to the Borrower or such Subsidiary of acquiring,
constructing or improving the property and any other assets then being financed solely by the same financing source, and (z) any
such Lien shall not encumber any other property of the Borrower or any of the Subsidiary Guarantors except assets then being financed
solely by the same financing source;

 

(viii)      customary
rights of set-off, revocation, refund or chargeback under deposit agreements or under the Uniform Commercial Code of banks or other
financial institutions where the Borrower or any of the Subsidiary Guarantors maintains deposits (other than deposits intended
as cash collateral) in the ordinary course of business;

 

    	49

    	 

    

 

(ix)         Liens
that arise in favor of banks under Article 4 of the Uniform Commercial Code on items in collection and the documents relating thereto
and proceeds thereof;

 

(x)          Liens
arising from the filing (for notice purposes only) of UCC-1 financing statements (or equivalent filings, registrations or agreements
in foreign jurisdictions) in respect of true leases otherwise permitted hereunder;

 

(xi)         with
respect to any Realty occupied by the Borrower or any of the Subsidiary Guarantors, (a) all easements, rights of way, reservations,
licenses, encroachments, variations and similar restrictions, charges and encumbrances on title that do not secure monetary obligations
and do not materially impair the use of such property for its intended purposes or the value thereof, and (b) any other Lien
or exception to coverage described in mortgagee policies of title insurance issued in favor of and accepted by the Lender;

 

(xii)        any
leases, subleases, licenses or sublicenses granted by the Borrower or any of the Subsidiary Guarantors to third parties in the
ordinary course of business and not interfering in any material respect with the business of the Borrower and the Subsidiary Guarantors,
and any interest or title of a lessor, sublessor, licensor or sublicensor under any lease or license permitted under this Agreement;

 

(xiii)      Liens
arising out of conditional sale, title retention, consignment or similar arrangements for sale of goods entered into by any Credit
Party in the ordinary course of business not materially interfering with the conduct of the business of the Credit Parties taken
as a whole;

 

(xiv)        real
estate security deposits with respect to leaseholds in the ordinary course of business;

 

(xv)         interests
of any collection agency in accounts receivable assigned to it by any Credit Party in the ordinary course of business for the purpose
of facilitating the collection of such accounts receivable; and

 

(xvi)        Liens
not otherwise permitted under this Section 7.3, provided that the obligations secured by such other Liens
will not exceed $50,000 in the aggregate at any time outstanding.

 

7.4           Asset
Dispositions. The Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to, directly or indirectly,
make or agree to make any Asset Disposition except for:

 

(i)          the
sale or other disposition of inventory and Cash Equivalents in the ordinary course of business, non-exclusive licenses of intellectual
property in the ordinary course of business and the sale, discount or write-off of past due or impaired accounts receivable for
collection purposes (but not for factoring, securitization or other financing purposes), and the termination or unwinding of Hedge
Agreements permitted hereunder;

 

    	50

    	 

    

 

(ii)         the
sale or other disposition of assets pursuant to any Casualty Event; provided any Net Cash Proceeds therefrom are reinvested
or applied to the prepayment of the Loans in accordance with the provisions of Section 2.2(d);

 

(iii)        the
sale, lease or other disposition of assets by the Borrower or any Subsidiary Guarantor to the Borrower or to a Subsidiary Guarantor,
in each case so long as no Event of Default shall have occurred and be continuing or would result therefrom;

 

(iv)         the
sale, exchange or other disposition in the ordinary course of business of equipment or other assets that are obsolete or no longer
used in or necessary for the operations of the Borrower and the Subsidiary Guarantors;

 

(v)          the
sale, exchange or disposition of assets incidental to any transactions permitted under Section 7.1;

 

(vi)         the
sale, exchange or other disposition of assets (other than the Capital Stock of Subsidiaries) outside the ordinary course of business
for fair value and for cash; provided that (x) the aggregate amount of proceeds from all such sales or dispositions
that are consummated during any fiscal year shall not exceed $250,000, (y) any Net Cash Proceeds shall, to the extent required
hereunder, be reinvested or applied to the prepayment of the Loans in accordance with the provisions of Section 2.2(e),
and (z) no Default or Event of Default shall have occurred and be continuing or would result therefrom; and

 

(vii)        the
sale, exchange or other disposition of Capital Stock as permitted by Schedule 7.4(vii).

 

7.5           Investments.
The Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to, directly or indirectly, purchase, own,
invest in or otherwise acquire any Capital Stock, evidence of indebtedness or other obligation or security or any interest whatsoever
in any other Person, or make or permit to exist any loans, advances or extensions of credit to, or any investment in cash or by
delivery of property in, any other Person, or purchase or otherwise acquire (whether in one or a series of related transactions)
any portion of the assets, business or properties of another Person (including pursuant to an Acquisition), or create or acquire
any Subsidiary, or become a partner or joint venturer in any partnership or joint venture (collectively, “Investments”),
or make a commitment or otherwise agree to do any of the foregoing, other than:

 

(i)          Investments
consisting of Cash Equivalents;

 

(ii)         Investments
consisting of the extension of trade credit, the creation of prepaid expenses, the purchase of inventory, supplies, equipment and
other assets, and advances to employees, in each case by the Borrower and the Subsidiary Guarantors in the ordinary course of business;

 

(iii)        Investments
consisting of loans and advances to employees, officers or directors of the Borrower and the Subsidiary Guarantors in the ordinary
course of business not exceeding $25,000 at any time outstanding;

 

    	51

    	 

    

 

(iv)         Investments
(including equity securities and debt obligations) of the Borrower and the Subsidiary Guarantors received in connection with the
bankruptcy or reorganization of suppliers and customers and in good faith settlement of delinquent obligations of, and other disputes
with, customers and suppliers arising in the ordinary course of business;

 

(v)          Investments
consisting of intercompany Indebtedness permitted under clauses (iii), (iv) and (v) of Section 7.2;

 

(vi)         Investments
existing as of the Closing Date and described in Schedule 7.5;

 

(vii)        Investments
consisting of the making of capital contributions or the purchase of Capital Stock (x) by the Borrower or any Subsidiary Guarantor
in any Affiliate or other Subsidiary that either is a Subsidiary Guarantor immediately prior to, or will be a Subsidiary Guarantor
immediately after giving effect to, such Investment; provided that in the case of an Acquisition of any newly created or
acquired Subsidiary, the Borrower complies with the provisions of Sections 5.8 and 5.9 and all requirements of this
Agreement applicable to Permitted Acquisitions, and (z) by any Subsidiary Guarantor in the Borrower;

 

(viii)      Permitted
Acquisitions;

 

(ix)         Guaranty
Obligations constituting Indebtedness to the extent permitted by Section 7.2(viii);

 

(x)          Hedge
Agreements to the extent permitted by Section 7.2(vi);

 

(xi)         Investments
constituting capital expenditures to the extent otherwise permitted in this Agreement;

 

(xii)        Investments
constituting prepaid expenses, negotiable instruments held for collection and lease, utility and workers’ compensation, performance
and other similar deposits provided to third parties, in each case, in the ordinary course of business; and

 

(xiii)      Investments
made pursuant to Physician Practice Management Agreements.

 

7.6           Restricted
Payments.

 

(a)          The
Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to, directly or indirectly, declare or make any
dividend payment, or make any other distribution of cash, property or assets, in respect of any of its Capital Stock or any warrants,
rights or options to acquire its Capital Stock, or purchase, redeem, retire or otherwise acquire for value any shares of its Capital
Stock or any warrants, rights or options to acquire its Capital Stock, or set aside funds for any of the foregoing, except that:

 

    	52

    	 

    

 

(i)          the
Borrower and any of the Subsidiary Guarantors may declare and make dividend payments or other distributions payable solely in its
common stock;

 

(ii)         each
Wholly Owned Subsidiary of the Borrower may declare and make dividend payments or other distributions to the Borrower or to another
Wholly Owned Subsidiary of the Borrower, in each case to the extent not prohibited under applicable Requirements of Law;

 

(iii)        each
non-Wholly Owned Subsidiary may declare and make dividend payments to the Borrower and the other equity holders thereof so long
as (i) such dividend payments are not prohibited under applicable Requirements of Law and (ii) Apollo Medical Management, Inc.
(or another Subsidiary Guarantor of the Borrower that directly owns such non-Wholly Owned Subsidiary) receives at least its proportionate
share of each such dividend payments based upon its relative holding of the Capital Stock in such non-Wholly Owned Subsidiary;
and

 

(iv)         the
Borrower and its Subsidiaries may purchase shares of their Capital Stock as permitted by Schedule 7.6(a)(iv) if (A) no Default
or Event of Default then exists and (B)(I) in an aggregate amount that shall not exceed $50,000 from the Closing Date until such
time as the Borrower delivers its financial statements pursuant to Section 5.1(a) for its fiscal quarter ended in December
2015 and, thereafter, (II) in any amount as long as the Borrower shall be in compliance with the financial covenants set forth
in Article VI, before and after giving effect to any such payment, calculated on a pro forma basis as if any such payment
was made at the beginning of the calculation period for each such applicable financial covenant.

 

(b)          The
Borrower will not, and will not permit any of the Subsidiary Guarantors to, make any payment in respect of any Contingent Purchase
Price Obligations (whether or not such Contingent Purchase Price Obligations constitute Indebtedness) unless (i) no Default
or Event of Default has occurred and is continuing or would result therefrom and (ii) immediately after giving effect to such
payment, the Borrower is in compliance with the financial covenants contained in Article VI, such compliance determined
with regard to calculations made on a pro forma basis for the Reference Period most recently ended, calculated in accordance with
GAAP as if such payment had been made on the last day of such Reference Period, and the Lender has received a certificate of a
Financial Officer of the Borrower to such effect.

 

7.7           Transactions
with Affiliates. The Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to, enter into any transaction
(including, without limitation, any purchase, sale, lease or exchange of property or the rendering of any service) with any officer,
director, stockholder or other Affiliate of the Borrower or any of the Subsidiary Guarantors, except in the ordinary course of
its business and upon fair and reasonable terms that are no less favorable to it than it would be obtained in a comparable arm’s
length transaction with a Person other than an Affiliate of the Borrower or any of the Subsidiary Guarantors; provided,
however, that nothing contained in this Section 7.7 shall prohibit:

 

    	53

    	 

    

 

(i)          transactions
described on Schedule 7.7 (and any renewals or replacements thereof on terms not materially more disadvantageous to
the applicable Credit Party) or otherwise expressly permitted under this Agreement;

 

(ii)         transactions
among the Borrower and/or the Subsidiary Guarantors not prohibited or contemplated under this Agreement (provided that such
transactions shall remain subject to any other applicable limitations and restrictions set forth in this Agreement);

 

(iii)        (A)
Equity Issuances with respect to the Borrower’s Capital Stock to directors, officers and employees of the Credit Parties
pursuant to equity incentive plans, employment, consulting or director agreements or other employment, consulting or director arrangements
approved by the Board of Directors (or the compensation committee thereof) of the Borrower; (B) Equity Issuances by Apollomed Accountable
Care Organization, Inc. to directors, officers and employees that do not cause an Event of Default pursuant to Section 8.1(o);
and (C) Equity Issuances by Maverick Medical Group, Inc. to directors, officers and employees that do not cause a Default
or Event of Default;

 

(iv)         the
payment by the Borrower of reasonable compensation and benefits to its directors, officers and employees consistent with past practice
as of the date hereof; and

 

(v)          the
Borrower and the Subsidiary Guarantors entering into, and performing under, Physician Practice Management Agreements, Physician
Shareholder Agreements and Intercompany Loan Agreements, each on terms and conditions satisfactory to the Lender.

 

7.8           Lines
of Business. The Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to, engage in any material
respect in any lines of business other than the lines of businesses engaged in by it on the Closing Date and businesses and activities
reasonably related thereto.

 

7.9           Sale-Leaseback
Transactions. The Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to, directly or indirectly,
become or remain liable as lessee or as guarantor or other surety with respect to any lease, whether an operating lease or a Capitalized
Lease, of any property (whether real, personal or mixed, and whether now owned or hereafter acquired) (i) that any Credit
Party has sold or transferred (or is to sell or transfer) to a Person that is not a Credit Party or (ii) that any Credit Party
intends to use for substantially the same purpose as any other property that, in connection with such lease, has been sold or transferred
(or is to be sold or transferred) by a Credit Party to another Person that is not a Credit Party.

 

    	54

    	 

    

 

7.10         Certain
Amendments. The Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to, amend, modify or waive
(i) any provision of any Existing Note or the Convertible Note or any private placement memorandum relating thereto, the effect
of which would be (A) to increase the principal amount due thereunder or provide for any mandatory prepayments not already
provided for by the terms thereof, (B) to increase the applicable interest rate or amount of any fees or costs due thereunder,
(C) to amend any of the subordination provisions thereunder (including any of the definitions relating thereto), (D) to
make any covenant or event of default therein more restrictive or add any new covenant or event of default, (E) to grant any
security or collateral to secure payment thereof or (F) to effect any change in the rights or obligations of the Credit Parties
thereunder or of the holders thereof that, in the reasonable determination of the Lender, would be adverse in any material respect
to the rights or interests of the Lender, (ii) any provision of its articles or certificate of incorporation or formation,
bylaws, operating agreement or other applicable formation or organizational documents, as applicable, the terms of any class or
series of its Capital Stock, or any agreement among the holders of its Capital Stock or any of them, in each case other than in
a manner that could not reasonably be expected to adversely affect the Lender in any material respect (provided that the
Borrower shall give the Lender notice of any such amendment, modification or change, together with certified copies thereof), or
(iii) any provision or term of, or the amount of the fees or compensation with respect to, any Physician Practice Management Agreement,
Intercompany Loan Agreement, Physician Shareholder Agreement or Executive Employment Agreement without the Lender’s written
consent.

 

7.11         Limitation
on Certain Restrictions. The Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to, directly
or indirectly, create or otherwise cause or suffer to exist or become effective any restriction or encumbrance on (a) the
ability of the Credit Parties to perform and comply with their respective obligations under the Credit Documents or (b) the
ability of any Subsidiary of the Borrower to make any dividend payment or other distribution in respect of its Capital Stock, to
repay Indebtedness owed to the Borrower or any other Subsidiary, to make loans or advances to the Borrower or any other Subsidiary,
or to transfer any of its assets or properties to the Borrower or any other Subsidiary, except (in the case of clause (b)
above only) for such restrictions or encumbrances existing under or by reason of (i) this Agreement and the other Credit Documents,
(ii) applicable Requirements of Law, (iii) customary non-assignment provisions in leases and licenses of real or personal
property entered into by the Borrower or any Subsidiary as lessee or licensee in the ordinary course of business, restricting the
assignment or transfer thereof or of property that is the subject thereof, and (iv) customary restrictions and conditions
contained in any agreement relating to the sale of assets (including Capital Stock of a Subsidiary) pending such sale; provided
that such restrictions and conditions apply only to the assets being sold and such sale is permitted under this Agreement.

 

7.12         No
Other Negative Pledges. The Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to, enter into
or suffer to exist any agreement or restriction that, directly or indirectly, prohibits or conditions the creation, incurrence
or assumption of any Lien upon or with respect to any part of its property or assets, whether now owned or hereafter acquired,
or agree to do any of the foregoing, except for such agreements or restrictions existing under or by reason of (i) this Agreement
and the other Credit Documents, (ii) applicable Requirements of Law, (iii) any agreement or instrument creating a Permitted
Lien (but only to the extent such agreement or restriction applies to the assets subject to such Permitted Lien), (iv) customary
provisions in leases and licenses of real or personal property entered into by the Borrower or any Subsidiary as lessee or licensee
in the ordinary course of business, restricting the granting of Liens therein or in property that is the subject thereof, and (v) customary
restrictions and conditions contained in any agreement relating to the sale of assets (including Capital Stock of a Subsidiary)
pending such sale; provided that such restrictions and conditions apply only to the assets being sold and such sale is permitted
under this Agreement.

 

    	55

    	 

    

 

7.13         Fiscal
Year. The Borrower and the Subsidiary Guarantors shall change their fiscal year so that it ends in March, but otherwise the
Borrower will not, and will not permit or cause any of the Subsidiary Guarantors to, change its fiscal year or its method of determining
fiscal quarters.

 

7.14         Accounting
Changes. Other than as permitted pursuant to Section 1.2, the Borrower will not, and will not permit or cause any of
the Subsidiary Guarantors to, make or permit any material change in its accounting policies or reporting practices, except as may
be required by GAAP.

 

ARTICLE
VIII

 

EVENTS
OF DEFAULT; REMEDIES

 

8.1           Events
of Default. The occurrence of any one or more of the following events shall constitute an Event of Default hereunder:

 

(a)          The
Borrower shall fail to (i) pay when due any principal amount payable under this Agreement or under any other Credit Document
or (ii) pay any interest, fees or other charges payable under this Agreement or under any other Credit Document within three
(3) Business Days after the same becomes due;

 

(b)          The
Borrower shall fail to observe or perform any covenant, restriction or agreement contained in Sections 2.8, 5.1, 5.2(a), 5.2(d)(i),
5.3(i), 5.8 or 5.9 or Articles VI or VII of this Agreement;

 

(c)          The
Borrower or any Subsidiary shall fail to observe or perform any covenant, restriction or agreement contained in this Agreement
or any Credit Document and not described in Sections 8.1(a) or (b) above for fifteen (15) days after the earlier
of the Borrower (i) obtaining knowledge of such failure, or (ii) receiving written notice of such failure from the Lender;

 

(d)          Any
representation, warranty, certification or statement made or deemed made by the Borrower or any Subsidiary Guarantor in Article
IV of this Agreement, in any other Credit Document or in any certificate, financial statement or other document delivered pursuant
to this Agreement or any other Credit Document shall prove to have been incorrect in any material respect when made or deemed made;

 

(e)          The
occurrence and continuance of any default or event of default on the part of the Borrower or any Subsidiary Guarantor (including
specifically, but without limitation, defaults due to non-payment) under the terms of any agreement, document or instrument pursuant
to which the Borrower or a Subsidiary has incurred any Indebtedness in excess of $50,000, which default would permit acceleration
of such indebtedness;

 

    	56

    	 

    

 

(f)          Any
Credit Document to which the Borrower or any Subsidiary Guarantor is now or hereafter a party shall for any reason cease to be
in full force and effect or any Security Document shall cease to be effective to give the Lender a valid and perfected first priority
security interest in and Lien upon the collateral purported to be covered thereby, subject to no Liens other than Permitted Liens,
in each case unless any such cessation occurs in accordance with the terms thereof or is due to any act or failure to act on the
part of the Lender; or the Borrower or any Subsidiary Guarantor shall assert any of the foregoing; or any Subsidiary Guarantor
or any Person acting on behalf of any Subsidiary Guarantor shall deny or disaffirm such Subsidiary’s obligations under the
Guaranty or such;

 

(g)          The
Borrower or any Subsidiary Guarantor (i) other than as permitted under Section 7.1, files a petition for relief under the
Bankruptcy Code or any other insolvency law or seeking to adjudicate it bankrupt or insolvent, or seeking dissolution, winding
up, liquidation, reorganization, arrangement, adjustment or composition of it or its debts under any law relating to bankruptcy,
insolvency or reorganization or relief of debtors or fails to file an answer or other pleading denying the material allegations
of any such proceeding filed against it, (ii) other than as permitted under Section 7.1, takes any corporate action to authorize
or effect any of the foregoing actions, (iii) generally fails to pay, or admits in writing its inability to pay, its debts as such
debts become due; (iv) shall apply for, seek or consent to, or acquiesce in, the appointment of a custodian, receiver, trustee,
examiner, liquidator or similar official for it or for any material portion of its assets; (v) benefits from or is subject to the
entry of an order for relief under any bankruptcy or insolvency law; or (vi) makes an assignment for the benefit of creditors;

 

(h)          Failure
of the Borrower or any Subsidiary Guarantor within thirty (30) days after the commencement of any proceeding against it seeking
any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future
statute, law or regulation, to have such proceeding dismissed, or to have all orders or proceedings thereunder affecting the operations
or the business of the Borrower or such Subsidiary Guarantor stayed, or failure of the Borrower or such Subsidiary Guarantor within
thirty (30) days after the appointment, without its consent or acquiescence, of any custodian, receiver trustee, examiner, liquidator
or similar official for it or for any material portion of its assets, to have such appointment vacated;

 

(i)          The
Borrower or any Subsidiary Guarantor ceases to be Solvent, or ceases to conduct its business substantially as now conducted or
is enjoined, restrained or in any way prevented by court order from conducting all or any material part of its business affairs;

 

(j)          The
entry of one or more judgments or orders for the payment of money in excess of $50,000 in the aggregate against the Borrower or
any Subsidiary Guarantor and such judgment(s) or order(s) shall continue unsatisfied and unstayed for a period of thirty (30) days;

 

(k)          The
issuance of a writ of execution, attachment or similar process against the Borrower or any Subsidiary Guarantor which shall not
be dismissed, stayed, discharged or bonded within thirty (30) days after the Borrower acquires knowledge thereof;

 

    	57

    	 

    

 

(l)          A
notice of Lien, levy or assessment in excess of $50,000 is filed of record with respect to all or any portion of the assets of
the Borrower or any Subsidiary Guarantor by the United States, or any department, agency or instrumentality thereof, or by any
other Governmental Authority, including, without limitation, the PBGC, or if any taxes or debts in excess of $50,000 owing at any
time or times hereafter to any one of them becomes a lien or encumbrance upon any assets of the Borrower or any Subsidiary Guarantor
in each case and the same is not satisfied, released, discharged or bonded within thirty (30) days after the same becomes a lien
or encumbrance or, in the case of ad valorem taxes, prior to the last day when payment may be made without material penalty;

 

(m)          Any
ERISA Event or any other event or condition shall occur or exist with respect to any Plan or Multiemployer Plan and, as a result
thereof, together with all other ERISA Events and other events or conditions then existing, the Borrower and its ERISA Affiliates
have incurred or would be reasonably likely to incur liability to any one or more Plans or Multiemployer Plans or to the PBGC (or
to any combination thereof) in excess of $50,000;

 

(n)          Any
one or more licenses, permits, accreditations or authorizations of the Borrower or any Subsidiary Guarantor shall be suspended,
limited or terminated or shall not be renewed, or any other action shall be taken, by any Governmental Authority in response to
any alleged failure by the Borrower or any of its Subsidiaries to be in compliance with applicable Requirements of Law, and such
action, individually or in the aggregate, if the event giving rise to such action is not remediated within thirty (30) days of
notice of any of the foregoing events, would be reasonably likely to have a Material Adverse Effect;

 

(o)          Any
of the following shall occur: (i) the Borrower, itself or through 100% ownership and control of any of the Subsidiary Guarantors,
ceases to own, beneficially and of record, and control 100% of the total Capital Stock of any Subsidiary Guarantor hereunder, other
than Apollomed Accountable Care Organization, Inc. or any physician practice that is a Subsidiary, (ii) the Borrower, itself or
through 100% ownership and control of any of its Subsidiaries, ceases to own, beneficially and of record, and control 51% of the
total Capital Stock of Apollomed Accountable Care Organization, Inc., (iii) any Person, or group of Persons acting in concert
shall become the “beneficial owner” of Capital Stock of the Borrower representing 35% or more of (x) the combined
voting power of the then outstanding Capital Stock of the Borrower ordinarily having the right to vote in the election of directors
or (y) all Capital Stock of the Borrower, (iv) Warren Hosseinion, M.D. shall cease to serve as a senior executive pursuant to his
Executive Employment Agreement unless (A) because of his death or disability or (B) the Borrower hires a new senior executive within
thirty (30) days after Warren Hosseinion, M.D. ceases to serve as senior executive and who is reasonably satisfactory to Lender,
(v) any Physician Practice Management Agreement or Physician Shareholder Agreement is terminated, for any reason, unless any such
agreement is replaced concurrently with its termination by another agreement in form and substance satisfactory to the Lender in
its sole discretion and the Lender has provided its written confirmation of such satisfaction prior to the termination of such
agreement, or (vi) during any period of up to twelve (12) consecutive months, commencing after the Closing Date, individuals who
at the beginning of such twelve (12) month period were directors of the Borrower (together with any new director whose election
by the Borrower’s board of directors or whose nomination for election by Borrower’s stockholders was approved by a
vote of at least two-thirds of the directors then still in office who either were directors at the beginning of such period or
whose election or nomination for election was previously so approved) cease for any reason to constitute a majority of the directors
of the Borrower then in office; or

 

    	58

    	 

    

 

(p)          The
occurrence of an Event of Default under, and as defined in, the Convertible Note.

 

8.2           Remedies.
Upon the occurrence and during the continuance of any Event of Default:

 

(a)          Termination
of Revolving Credit Commitment; Acceleration of Indebtedness. The Lender may, in its sole discretion, (i) terminate the Revolving
Credit Commitment, which shall thereupon terminate; (ii) declare all or any part of the Loans immediately due and payable, whereupon
such Loans shall become immediately due and payable without presentment, demand, protest, notice or legal process of any kind,
all of which are hereby expressly waived by the Borrower; provided, however, that all Loans shall automatically become
due and payable upon the occurrence of an Event of Default under Sections 8.1(f) or (h); and (iii) pursue all other
remedies available to it by contract, at law or in equity, including but not limited to its rights under the Security Documents.

 

(b)          Rights
and Remedies Cumulative; Non-Waiver; etc. The enumeration of the Lender’s rights and remedies set forth in this Agreement
is not intended to be exhaustive and the exercise by the Lender of any right or remedy shall not preclude the exercise of any other
rights or remedies, all of which shall be cumulative, and shall be in addition to any other right or remedy given hereunder, under
the other Credit Documents or under any other agreement between the Borrower and the Lender or that may now or hereafter exist
in law or in equity or by suit or otherwise. No delay or failure to take action on the part of the Lender in exercising any right,
power or privilege shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or privilege
preclude other or further exercise thereof or the exercise of any other right, power or privilege or shall be construed to be a
waiver of any Event of Default. No course of dealing between the Borrower and the Lender or their agents or employees shall be
effective to change, modify or discharge any provision of this Agreement or any of the other Credit Documents or to constitute
a waiver of any Event of Default.

 

ARTICLE
IX

 

MISCELLANEOUS

 

9.1           Costs,
Expenses and Taxes. The Borrower agrees to pay on demand all reasonable out-of-pocket expenses of the Lender, including reasonable
fees and disbursements of counsel, in connection with: (i) any amendments, supplements, consents or waivers hereto or to the Credit
Documents because of actual or prospective Defaults or Events of Default, and (ii) the enforcement of this Agreement and the other
Credit Documents. In addition, the Borrower shall pay any and all stamp and other taxes and fees payable or determined to be payable
in connection with the execution, delivery, filing and recording of this Agreement and the other Credit Documents and agrees to
save the Lender harmless from and against any and all liabilities with respect to or resulting from any delay in paying or omission
to pay such taxes and fees. It is the intention of the parties hereto that the Borrower shall pay amounts referred to in this Section
directly. In the event the Lender pays any of the amounts referred to in this Section directly, the Borrower will reimburse the
Lender for such advances and interest on such advance shall accrue until reimbursed at the Default Rate applicable for the Term
Loan.

 

    	59

    	 

    

 

9.2           Indemnification.
From and at all times after the date of this Agreement, and in addition to all of the Lender’s other rights and remedies
against the Borrower, the Borrower agrees to indemnify, defend and hold harmless the Lender and its directors, officers, employees,
agents, successors, assigns and affiliates from and against the following (collectively “Costs”): any and all
claims (whether valid or not), losses, damages, actions, suits, inquiries, investigations, administrative proceedings, judgments,
liens, liabilities, penalties, fines, amounts paid in settlement, requirements of Governmental Authorities, punitive damages, interest,
damages to natural resources and other costs and expenses of any kind or nature whatsoever (including without limitation reasonable
attorneys’ fees and expenses, court costs and fees, and consultant and expert witness fees and expenses) arising in any manner,
directly or indirectly, out of or by reason of (a) the negotiation, preparation, execution, performance of this Agreement or the
other Credit Documents, or any transaction contemplated herein or therein, whether or not the Lender or any other party protected
under this Section is a party to any action, proceeding or suit in question, or the target of any inquiry or investigation in question;
provided, however, that no indemnified party shall have the right to be indemnified hereunder for any liability resulting from
such indemnified party’s willful misconduct, gross negligence, willful misconduct or breach of any of its covenants hereunder
or under any other Credit Document (as finally determined by a court of competent jurisdiction); and, provided, further, that no
indemnified party shall have the right to be reimbursed hereunder for typical “closing” costs incurred in connection
with the negotiation, preparation and execution of this Agreement or the other Credit Documents, (b) any breach of any of the covenants,
warranties or representations of the Borrower hereunder or under any other Credit Document, (c) any lien or charge upon amounts
payable hereunder by the Borrower to the Lender or any taxes, assessments, impositions and other charges in respect of the collateral
described in the Security Documents, (d) damage to property or any injury to or death of any person that may be occasioned by any
cause whatsoever pertaining to any such collateral or the use thereof, (e) any violation or alleged violation of any Environmental
Law, federal or state securities law, common law, equitable requirement or other legal requirement by the Borrower or with respect
to any property owned, leased or operated by the Borrower (in the past, currently or in the future), or (f) any presence,
generation, treatment, storage, disposal, transport, movement, release, suspected release or threatened release of any Hazardous
Substance on, in, to or from any property (or any part thereof including without limitation the soil and groundwater thereon and
thereunder) owned, leased or operated by the Borrower (in the past, currently or in the future).

 

All Costs shall be additional Obligations
of the Borrower under this Agreement, shall be payable on demand to the party to be indemnified, and shall be secured by the lien
of the Security Documents.

 

Without limiting the foregoing, the Borrower
shall be obligated to pay, on demand, the costs of any investigation, monitoring, assessment, enforcement, removal, remediation,
restoration or other response or corrective action undertaken by the Lender or any other indemnified party, or their respective
agents, with respect to any property owned, leased or operated by the Borrower.

 

    	60

    	 

    

 

It is expressly understood and agreed that
the obligations of the Borrower under this Section shall not be limited to any extent by payment of the Obligations and termination
of this Agreement and shall remain in full force and effect until expressly terminated by the Lender in writing.

 

9.3           Consent
to Jurisdiction; Waiver of Jury Trial. AS PART OF THE CONSIDERATION FOR NEW VALUE THIS DAY RECEIVED, EACH OF THE BORROWER AND
THE LENDER HEREBY CONSENTS TO THE EXCLUSIVE JURISDICTION OF FEDERAL COURT SITTING IN THE SOUTHERN DISTRICT OF THE STATE OF NEW
YORK AND THE COURTS OF NEW YORK SITTING IN THE BOROUGH OF MANHATTAN FOR ANY ACTION TO WHICH THE BORROWER AND THE LENDER ARE PARTIES.
TO THE EXTENT PERMITTED BY LAW, EACH OF THE BORROWER AND THE LENDER WAIVES TRIAL BY JURY AND WAIVES ANY OBJECTION WHICH IT MAY
HAVE BASED ON LACK OF JURISDICTION OR IMPROPER VENUE OR FORUM NON CONVENIENS TO THE CONDUCT OF ANY ACTION INSTITUTED HEREUNDER
OR UNDER ANY OF THE OTHER CREDIT DOCUMENTS, OR ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ANY OF THE OTHER CREDIT DOCUMENTS,
OR ANY OTHER PROCEEDING TO WHICH THE BORROWER OR THE LENDER IS A PARTY, INCLUDING ANY ACTIONS BASED UPON, ARISING OUT OF OR IN
CONNECTION WITH ANY COURSE OF CONDUCT, COURSE OF DEALING OR STATEMENT (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE LENDER OR THE
BORROWER. THE BORROWER ALSO CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED APPROPRIATE BY THE COURT.

 

9.4           Notices.
All demands, notices, approvals, consents, requests, and other communications hereunder shall be in writing and shall be deemed
to have been given when the writing is delivered, if given or delivered by hand, overnight delivery service or facsimile transmitter
(with confirmed receipt), or five (5) days after being mailed, if mailed, by first class, registered or certified mail, postage
prepaid, to the address or telecopy number set forth below. If any time period for giving notice or taking action hereunder expires
on a day that is not a Business Day, the time period shall automatically be extended to the Business Day immediately following
such day. Such notices, demands, requests, consents and other communications shall be sent to the following Persons at the following
addresses:

 

	Party	Address
	 	 
	Borrower	Apollo Medical Holdings, Inc.
	 	700 N. Brand Blvd., Suite 220
	 	Glendale, California  91203
	 	Attention:  Chief Financial Officer
	 	Telephone:  (818) 396-8050
	 	Fax:  (818) 844-3888

 

    	61

    	 

    

 

	Lender	NNA of Nevada, Inc.
	 	920 Winter Street
	 	Waltham, Massachusetts  02451
	 	Attention:  Mark Fawcett/Christine Smith
	 	Telephone:  (781) 699-2668/(781) 699-9165
	 	Fax:(781) 699-9756

 

The Borrower or the Lender may, by notice given hereunder, designate
any further or different addresses or telecopy numbers to which subsequent demands, notices, approvals, consents, requests or other
communications shall be sent or persons to whose attention the same shall be directed.

 

9.5           Continuing
Obligations. All agreements, representations and warranties contained herein or made in writing by or on behalf of the Borrower
in connection with the transactions contemplated hereby shall survive the execution and delivery of this Agreement and the other
Credit Documents. The Borrower further agrees that to the extent the Borrower makes a payment to the Lender, which payment or any
part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required to be repaid to a trustee,
receiver or any other party under any bankruptcy, insolvency or other similar state or federal statute, or principle of equity,
then, to the extent of such repayment by the Lender, the Obligation or part thereof intended to be satisfied by such payment shall
be revived and continued in full force and effect as if such payment had not been received by the Lender.

 

9.6           Confidential
Information. In the event the Receiving Party (including its officers, employees, counsel, accountants, partners and other
authorized representatives) obtains or has obtained from the Disclosing Party any Confidential Information, the Receiving Party
(i) shall treat all such Confidential Information as confidential, (ii) shall use such Confidential Information only for the purposes
contemplated in the Credit Documents and the Investment Agreement (and related documents), (iii) shall protect such Confidential
Information with the same degree of care as the Receiving Party uses to protect its own confidential and proprietary information
against public disclosure, but in no case with less than reasonable care, and (iv) shall not disclose such Confidential Information
to any third party except to such officers, employees, counsel, accountants, partners and other authorized representatives of the
Receiving Party, its Affiliates or potential permitted transferees of the Receiving Party’s rights under this Agreement and
the other Credit Documents who need to know such Confidential Information for any proper purpose related to the Credit Documents
or any transaction contemplated thereby and who have been informed of and have agreed in writing to protect the confidential nature
of such Confidential Information and not to use such Confidential Information for any unlawful purpose (and the Receiving Party
shall be responsible for compliance with this Section 9.6 by its and its Affiliates’ officers, employees, counsel,
accountants, partners and other authorized representatives) or to the extent required by applicable Requirements of Law, provided
that, if not prohibited by applicable Requirements of Law, the Receiving Party will (i) provide reasonable advance notice to the
Disclosing Party of such disclosure so that the Disclosing Party may seek an appropriate protective order and (ii) to cooperate
with the Disclosing Party, at the Disclosing Party’s expense, to obtain such protective order. Each party agrees that, due
to the unique nature of the Confidential Information, the unauthorized disclosure or use of any Confidential Information of the
Disclosing Party may cause irreparable harm and significant injury to the Disclosing Party, the extent of which may be difficult
to ascertain and for which there may be no adequate remedy at law. Accordingly, each party agrees that the Disclosing Party, in
addition to any other available remedies, shall have the right to seek an immediate injunction and other equitable relief enjoining
any breach or threatened breach of this Section 9.6 without the necessity of posting any bond or other security. The
Receiving Party shall notify the Disclosing Party in writing immediately upon the Receiving Party’s becoming aware of any
such breach or threatened breach. Notwithstanding anything to the contrary set forth in this Agreement, any other Credit Document
or any Investment Document, this Section 9.6 shall survive the termination of this Agreement.

 

    	62

    	 

    

 

9.7           Controlling
Law. This Agreement and, unless otherwise provided in any other Credit Document, the other Credit Documents shall be governed
by and interpreted in accordance with the laws of the State of New York (including Sections 5-1401 and 5-1402 of the New York General
Obligations Law, but excluding all other choice of law and conflicts of law rules).

 

9.8           Successors
and Assigns. This Agreement shall be binding upon the Borrower and its successors and assigns and all rights against the Borrower
arising under this Agreement shall be for the sole benefit of the Lender.

 

9.9           Assignment
and Sale. The Borrower may not sell, assign or transfer this Agreement or any of the other Credit Documents or any portion
hereof or thereof, including without limitation the Borrower’s rights, title, interests, remedies, powers, and duties hereunder
or thereunder. The Lender may not sell, assign or transfer this Agreement or any of the other Credit Documents or any portion hereof
or thereof, including without limitation the Lender’s rights, title, interests, remedies, powers, and duties hereunder or
thereunder, to any Person whose principal business is providing integrated healthcare services or who otherwise is a competitor
of the Borrower as determined reasonably and in good faith by the Board of Directors of the Borrower. Subject to the foregoing,
nothing in this Agreement or any other Credit Document shall prohibit the Lender from pledging or assigning this Agreement and
the Lender’s rights under any of the other Credit Documents, including collateral therefor, so long as any such pledgee or
assignee is a “United States Person” for purposes of Section 7701(a)(30) of the Code. Any attempted assignment, delegation
or transfer in violation of this Section 9.9 shall be void and of no force and effect.

 

9.10         Entire
Agreement. THIS AGREEMENT AND THE OTHER INVESTMENT DOCUMENTS AND INSTRUMENTS EXECUTED AND DELIVERED CONTEMPORANEOUSLY HEREWITH
EMBODY THE ENTIRE AGREEMENT AND UNDERSTANDING BETWEEN THE PARTIES HERETO AND SUPERSEDE ALL PRIOR AGREEMENTS AND UNDERSTANDINGS
OF SUCH PERSONS, VERBAL OR WRITTEN, RELATING TO THE SUBJECT MATTER HEREOF. THIS AGREEMENT AND THE DOCUMENTS AND INSTRUMENTS EXECUTED
IN CONNECTION HEREWITH REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY PRIOR, CONTEMPORANEOUS
OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.

 

    	63

    	 

    

 

9.11         Amendment.
Any provision of this Agreement or any other Credit Document to which the Borrower is a party may be amended if such amendment
is in writing and is signed by the Borrower and the Lender. In connection with any amendment entered into in accordance with this
Section, the Borrower shall pay to the Lender a fee to be negotiated between the Borrower and the Lender. Payment of such fee by
the Borrower to the Lender shall be a condition precedent to the effectiveness of such amendment and shall be due on the date such
amendment is signed by the Lender.

 

9.12         Severability.
In the event that any provision of this Agreement shall be determined to be invalid or unenforceable by any court of competent
jurisdiction, such determination shall not invalidate or render unenforceable any other provision hereof.

 

9.13         Counterparts.
This Agreement may be executed in several counterparts, each of which shall be an original and all of which, together shall constitute
but one and the same instrument.

 

9.14         Captions.
The captions to the various sections and subsections of this Agreement have been inserted for convenience only and shall not limit
or affect any of the terms hereof.

 

9.15         Termination
of Existing Credit Agreement. Upon the Closing Date and except with respect to any provisions which by their terms survive
termination, the Existing Credit Agreement and the other Credit Documents (as defined in the Existing Credit Agreement) shall be
deemed to be terminated without any further action by the parties thereto.

 

9.16         Public
Announcements. The Borrower and the Lender shall consult with each other before issuing any press release or other public disclosure
with respect to this Agreement or the transactions contemplated hereby and neither shall issue any such press release or make any
such public statement with respect thereto without the prior consent of the other, which consent shall not be unreasonably withheld,
delayed or conditioned; provided, however, that a party may, without the prior consent of the other party, issue such press
release or make such public disclosure as may upon the advice of counsel be required by Law or by the rules of the OTCQB, provided
that, to the extent time permits, such party has used all commercially reasonable efforts to consult with the other party prior
thereto. The Borrower and the Lender agree that the initial press release or other public disclosure relating to this Agreement
and the transactions contemplated herein shall state, among other things, that the Lender is an Affiliate of Fresenius Medical
Care Holdings, Inc.

 

[The remainder of this page is left blank
intentionally.]

 

    	64

    	 

    

 

IN WITNESS WHEREOF, the parties hereto
have caused this Agreement to be duly executed and delivered by their respective duly authorized officers as of the date first
above written.

 

	 	BORROWER:
	 	 
	 	APOLLO MEDICAL HOLDINGS, INC.
	 	 	 
	 	By:	/s/ Kyle Francis
	 	 	 
	 	Name:	Kyle Francis
	 	 	 
	 	Title:	CFO

 

Signature Page to Credit Agreement (1
of 2)

 

    	 

    	 

    

 

	 	LENDER:
	 	 
	 	NNA OF NEVADA, INC.
	 	 	 
	 	By:	/s/ Mark Fawcett
	 	 	 
	 	Name:	Mark Fawcett
	 	 	 
	 	Title:	Vice President and Treasurer

 

Signature Page to Credit Agreement (2
of 2)Exhibit 10.2	EXECUTION COPY

 

 

 

INVESTMENT
AGREEMENT

 

between

 

APOLLO
MEDICAL HOLDINGS, INC.

 

and

 

NNA
OF NEVADA, INC.

 

March
28, 2014

 

 

 

    	 

    	 

    

 

Table
of Contents

 

	 	 	Page
	 	 	 
	 	ARTICLE I	 
	 	 	 
	 	DEFINITIONS	 
	 	 	 
	1.1	Defined Terms	1
	1.2	Additional Definitions	8
	1.3	Singular/Plural	8
	 	 	 
	 	ARTICLE II	 
	 	 	 
	 	PURCHASE AND SALE OF THE SECURITIES	 
	 	 	 
	2.1	Purchase and Sale	8
	2.2	Closing	9
	2.3	Closing Deliveries	9
	2.4	Calculation of Conversion Price	9
	2.5	Warrants	9
	2.6	Acceptability of Proceedings at Closing	10
	 	 	 
	 	ARTICLE III	 
	 	 	 
	 	REPRESENTATIONS AND WARRANTIES OF COMPANY	 
	 	 	 
	3.1	Corporate Organization and Power	10
	3.2	Authorization	10
	3.3	Reservation; Valid Issuance	11
	3.4	No Conflicts; Consents and Approvals; No Violation	11
	3.5	Brokers Fees	11
	3.6	Capitalization	12
	3.7	Offering; Investment Company Act	13
	3.8	SEC Documents; Financial Statements; Internal Controls and Procedures	13
	3.9	Absence of Undisclosed Liabilities	14
	3.10	Absence of Certain Changes	14
	3.11	Litigation	14
	3.12	Credit Documents	15
	 	 	 
	 	ARTICLE IV	 
	 	 	 
	 	REPRESENTATIONS AND WARRANTIES OF PURCHASER	 
	 	 	 
	4.1	Organization	15
	4.2	Authorization	15
	4.3	No Conflicts; Consents and Approvals; No Violation	16
	4.4	Brokers or Finders	16

 

    	-i-

    	 

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	4.5	Securities Law Matters	16
	4.6	Availability of Funds	17
	4.7	No Reliance	17
	4.8	Restricted Securities	17
	4.9	Legends	18
	 	 	 
	 	ARTICLE V	 
	 	 	 
	 	COVENANTS	 
	 	 	 
	5.1	Public Announcements	18
	5.2	Consents, Approvals and Filings	18
	5.3	Further Assurances	19
	5.4	Quotation and Listing	19
	5.5	Reservation of Common Stock	19
	5.6	Integration	19
	5.7	Rule 144 and 144A Information	19
	5.8	CUSIP	20
	5.9	Confidential Information	20
	5.10	Notification of Certain Matters	21
	5.11	Funding Fee	21
	5.12	Market Stand-off Agreement	21
	 	 	 
	 	ARTICLE VI	 
	 	 	 
	 	bOARD AND OTHER RIGHTS	 
	 	 	 
	6.1	Board Rights	22
	6.2	Vacancies	23
	6.3	Subscription Rights	23
	6.4	Certain Other Covenants	26
	 	 	 
	 	ARTICLE VII	 
	 	 	 
	 	CONDITIONS TO CLOSING	 
	 	 	 
	7.1	Conditions to Obligations of Purchaser and Company at Closing	26
	7.2	Additional Conditions to Obligations of Purchaser at Closing	26
	7.3	Additional Conditions to Obligations of Company at Closing	28

 

    	-ii-

    	 

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	 	ARTICLE VIII	 
	 	 	 
	 	SURVIVAL; INDEMNIFICATION	 
	 	 	 
	8.1	Survival of Representations and Warranties	28
	8.2	Indemnification	29
	8.3	Method of Asserting Indemnification for Third Party Claims	29
	8.4	Method of Asserting Indemnification for Other Claims	30
	8.5	Limitations on Indemnification	30
	 	 	 
	 	ARTICLE IX	 
	 	 	 
	 	MISCELLANEOUS	 
	 	 	 
	9.1	Fees and Expenses	30
	9.2	Independent Contractors	31
	9.3	Specific Enforcement	31
	9.4	Successors and Assigns	31
	9.5	Entire Agreement	31
	9.6	Notices	32
	9.7	Time Periods; Business Days	32
	9.8	Amendments	33
	9.9	Waiver	33
	9.10	Descriptive Headings; No Strict Construction	33
	9.11	Governing Law	33
	9.12	Consent to Jurisdiction; Waiver of Jury Trial	33
	9.13	Severability	34
	9.14	Counterparts	34
	9.15	Captions	34
	 	 	 
	EXHIBITS	 
	 	 
	A.	Form of Convertible Note	 
	B.	Form of Warrant	 
	C.	Form of Registration Rights Agreement	 

 

    	-iii-

    	 

    

 

INVESTMENT AGREEMENT

 

THIS INVESTMENT AGREEMENT, dated
as of March 28, 2014 (the “Effective Date”), is entered into
by and between Apollo Medical Holdings, Inc., a Delaware corporation (“Company”), and NNA of Nevada, Inc., a
Nevada corporation (“Purchaser”).

 

BACKGROUND STATEMENT

 

A.              In connection with the consummation
of the transactions contemplated by this Agreement, Company and Purchaser are entering into a credit agreement, dated as of March
28, 2014, pursuant to which Purchaser, as lender, will provide to Company, as borrower,
(i) a revolving credit facility of up to $1,000,000 and (ii) a term loan of $7,000,000 (such credit agreement, as amended,
restated, refinanced, extended, renewed, supplemented or otherwise modified from time to time, the “Credit Agreement”).

 

B.              Upon the terms and subject to the
conditions set forth in this Agreement, Company wishes to sell to Purchaser and Purchaser wishes to purchase from Company the following:
(i) a convertible note of Company providing an option for Company to borrow $2,000,000 pursuant to the terms thereof, (ii) 2,000,000
shares of Common Stock of Company, $.001 par value, at a price of $1.00 per share, (iii) warrants to purchase 1,000,000 shares
of Common Stock at an exercise price of $1.00 per share if Company borrows under the convertible note as described in clause (i)
above, (iv) warrants to purchase 1,000,000 shares of Common Stock at an exercise price of $1.00 per share in connection with Purchaser’s
purchase of Common Stock referenced in clause (ii) above, and (v) (a) warrants to purchase 1,000,000 shares of Company’s
Common Stock at an exercise price of $1.00 per share and (b) warrants to purchase 2,000,000 shares of Company’s Common Stock
at an exercise price of $2.00 per share, each in connection with the loans extended by Purchaser pursuant to the Credit Agreement.

 

AGREEMENT

 

NOW, THEREFORE, in consideration
of the premises, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto agree as follows:

 

ARTICLE
I

 

DEFINITIONS

 

1.1              Defined Terms. In addition
to the words and terms defined elsewhere in this Agreement, the following terms when used herein shall have the following respective
meanings:

 

“Acquisition”
means any transaction or series of related transactions, consummated on or after the Effective Date, by which Company or any of
its Subsidiaries, (i) acquires all or substantially all of the assets of any Person or any going business, division thereof
or line of business, whether through purchase of assets, merger or otherwise, (ii) acquires Capital Stock of any Person having
at least a majority of combined voting power of the then outstanding Capital Stock of such Person or (iii) enters into a Physician
Practice Management Agreement (as defined in the Convertible Note), some other physician practice management agreement or such
other agreement with another Person and the effect of which is to cause such Person to be consolidated with Company in accordance
with GAAP.

 

    	 

    	 

    

 

“Affiliate”
means, as to any Person, (i) any other Person which directly, or indirectly through one or more intermediaries, controls such Person
or is consolidated with such Person in accordance with GAAP, (ii) any other Person which directly, or indirectly through one or
more intermediaries, is controlled by or is under common control with such Person, or (iii) any other Person of which such Person
owns, directly or indirectly, ten percent (10%) or more of the common stock or equivalent equity interests. As used herein, the
term “control” means possession, directly or indirectly, of the power to direct or cause the direction of the
management or policies of a Person, whether through the ownership of voting securities or otherwise.

 

“Agreement”
means this Investment Agreement and all schedules and exhibits hereto, together with any amendments, modifications, replacements
and supplements hereto, any substitutes herefor, and any replacements, renewals or extensions hereof, in whole or in part, and
shall refer to this Agreement as the same may be in effect at the time such reference becomes operative.

 

“Business Day”
means any day of the year on which banks are open for business in Waltham, Massachusetts.

 

“Capital Stock”
means (i) with respect to any Person that is a corporation, any and all shares, interests or equivalents in capital stock (whether
voting or nonvoting, and whether common or preferred) of such corporation, and (ii) with respect to any Person that is not a corporation,
any and all partnership, membership, limited liability company or other equity interests of such Person; and in each case, any
and all warrants, rights or options to purchase any of the foregoing.

 

“Capital Stock
Equivalents” means any evidences of indebtedness, shares of capital stock or other securities (including without limitation
the Warrants and Convertible Note) that are convertible into or exchangeable for, with or without payment of additional consideration
in cash or property, shares of Capital Stock, and any and all options, warrants or other securities or rights to subscribe for,
purchase or otherwise acquire shares of Capital Stock or any of the foregoing and any other security or instrument representing,
convertible into or exchangeable for Capital Stock or any of the foregoing, in each case whether or not immediately exercisable.

 

“Common Stock”
means common stock of Company.

 

“Common Stock
Equivalents” means any evidences of indebtedness, Capital Stock, shares of stock or other securities (including without
limitation the Warrants and Convertible Note) that are convertible into or exchangeable for, with or without payment of additional
consideration in cash or property, shares of Common Stock, and any options, warrants or other securities or rights to subscribe
for, purchase or otherwise acquire shares of Common Stock or any of the foregoing, in each case whether or not immediately exercisable.

 

    	2

    	 

    

 

“Company Board”
means the Board of Directors of Company and each board of directors of the Subsidiaries of which Company owns, directly or indirectly,
more than fifty percent (50%) of the voting securities thereof.

 

“Company Parties”
means Company and the Subsidiary Guarantors.

 

“Confidential
Information” means, with respect to a party hereto or any of its Affiliates (the “Disclosing Party”),
any and all confidential or proprietary information and material disclosed by the Disclosing Party to the other party hereto or
any of its Affiliates (the “Receiving Party”) or obtained by the Receiving Party through inspection or observation
of the Disclosing Party’s property or facilities (whether in writing, or in oral, graphic, electronic or any other form),
whether disclosed or obtained before, on or after the Effective Date, including any (a) trade secret, know-how, idea, invention,
process, technique, algorithm, program (whether in source code or object code form), hardware, device, design, schematic, drawing,
formula, data, plan, strategy and forecast of, and (b) technical, engineering, manufacturing, product, marketing, servicing, financial,
personnel, log-in or identification passwords and other information and materials of, the Disclosing Party and its employees, consultants,
investors, Affiliates, licensors, suppliers, vendors, customers, clients and other Persons, provided, that Confidential
Information shall not include any such information which (a) was in the public domain on the Closing Date or comes into the public
domain other than through the fault or negligence of the other party hereto (the “Receiving Party”) or any of
its Affiliates, (b) was lawfully obtained by the Receiving Party from a third party, but only to the extent that such source is
not known by the Receiving Party to be bound by a confidentiality agreement with, or other contractual, legal or fiduciary obligation
of confidentiality to, the Disclosing Party or any other party with respect to such information, (c) was known to the Receiving
Party or any of its Affiliates at the time of disclosure of such Confidential Information to the Receiving Party by the Disclosing
Party, provided that the Receiving Party was not, at such time, subject to any confidentiality obligation to the Disclosing
Party with respect thereto, or (d) was independently developed by the Receiving Party without making use of any Confidential Information.
For the avoidance of doubt, it is expressly agreed and understood that (i) financial projections of Company were disclosed by Company
to Purchaser (or any person on behalf of the Purchaser) on March 4, 2014 and on March 11, 2014 (collectively, the "Projections")
as required by Purchaser and the Projections were prior to the date hereof subject to the confidentiality provisions of Section
9.6 of the Credit Agreement, dated as of October 15, 2013, as amended by the First Amendment To Credit Agreement, dated as of December
20, 2013 (as so amended, the “Existing Credit Agreement”), (ii) information that was subject to the confidentiality
provisions of Section 9.6 of the Existing Credit Agreement, including the Projections, shall be deemed Confidential Information
and subject to the confidentiality provisions of Section 5.9, and (iii) Purchaser acknowledges that the Projections have
only been used to determine the financial covenants in the Convertible Note and the Credit Agreement and shall not be used for
any other purpose

 

“Convertible
Note” means the Convertible Note of Company providing an option for Company to borrow $2,000,000 pursuant to the terms
thereof and substantially in the form of Exhibit A to be issued in accordance with ARTICLE II.

 

“Credit Documents”
has the meaning set forth in the Credit Agreement.

 

    	3

    	 

    

 

“Equity-Based
Payments” means any payments arising out of or in connection with any phantom equity rights, equity appreciation rights,
profits interests, bonuses or other payments calculated in reference to the valuation or changes in valuation of Company’s
equity, including without limitation, any phantom equity, profits interests and/or similar rights granted by Company pursuant to
any employment or consulting agreement or any employee benefit plan.

 

“Exempt Issuance”
means the issuance of (a) shares of Common Stock, options or other Common Stock Equivalents, in each case at or above Fair Market
Value of Common Stock at the time of issuance, to employees, consultants, officers or directors of Company pursuant to the 2013
Equity Incentive Plan, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder, (c) Common
Stock Equivalents listed on Schedule 3.6(b), provided that such securities have not been amended since the date of this
Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such
securities, (d) shares of Common Stock pursuant to the conversion or exercise of Common Stock Equivalents previously treated as
a Subsequent Issuance for the anti-dilution protection in the Warrants and the Convertible Note and a New Security for the subscription
rights in Section 6.3, (e) shares of Common Stock and Common Stock Equivalents issued pursuant to acquisitions or strategic transactions
approved by a majority of the disinterested directors of the Company Board, provided that any such issuance shall only be to a
Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of
an asset in a business synergistic with the business of Company and shall provide to Company additional benefits in addition to
the investment of funds, but shall not include a transaction in which Company is issuing securities primarily for the purpose of
raising capital or to an entity whose primary business is investing in securities, and (f) shares of Common Stock in a bona fide,
firmly underwritten public offering pursuant to a registration statement under the Securities Act, and with a purchase price per
share of at least $2.00 (such offering pursuant to this clause (f), a “Qualified IPO”).

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended, as in effect from time to time (except as provided herein).

 

“Fair Market
Value” means, with respect to a share of Common Stock, an option or other Common Stock Equivalent issued by Company,
for any date, the price determined by the first of the following clauses that applies: (a) the average of the daily volume weighted
average trading price of the Common Stock for the five Trading Days immediately prior to such date on the Principal Trading Market,
or (b) if the Common Stock is not so listed or quoted, as reasonably determined by the Company Board in good faith; provided, that
in connection with an Acquisition, the Fair Market Value shall be determined based upon the cash and fair market value of any securities
and other consideration as would be received for such Common Stock.

 

“Fully Diluted Basis”
means, with respect to the Common Stock, as of any date of determination, the number of shares of outstanding Common Stock as of
such date plus, without duplication, the maximum number of shares of Common Stock issuable as of such date upon exercise of the
purchase, conversion or exchange rights associated with all issued and outstanding Common Stock Equivalents.

 

    	4

    	 

    

 

“GAAP”
means generally accepted accounting principles, as recognized by the American Institute of Certified Public Accountants, consistently
applied and maintained on a consistent basis for Company and its Subsidiaries on a consolidated basis throughout the period indicated
and consistent with the financial practice of Company and its Subsidiaries prior to the Effective Date.

 

“Governmental
Authority” means any nation or government, any state, department, agency or other political subdivision thereof, and
any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to any government,
and any corporation or other entity owned or controlled (through stock or capital ownership or otherwise) by any of the foregoing.

 

“Guaranty”
means a guaranty agreement, dated as of the Effective Date, made by the Subsidiary Guarantors in favor of Purchaser, as amended,
modified, restated and supplemented from time to time.

 

“Laws”
mean all United States and foreign national, federal, state, and local laws, statutes, ordinances, rules or regulations.

 

“Liabilities”
means, in respect of a Person, all indebtedness, obligations, and other liabilities of such Person, whether absolute, accrued,
contingent, known or unknown, fixed or otherwise, or whether due or to become due.

 

“Lien”
means any interest in property securing an obligation owed to, or claim by, a Person other than the owner of such property, whether
such interest arises by virtue of contract, statute or common law, including but not limited to the lien or security interest arising
from a mortgage, security agreement, pledge, lease, conditional sale, consignment or bailment for security purposes or from attachment,
judgment or execution. The term “Lien” shall include any easements, covenants, restrictions, conditions, encroachments,
reservations, rights-of-way, leases and other title exceptions and encumbrances affecting real property. For the purpose of this
Agreement, Company Parties shall be deemed to own, subject to a Lien, any proceeds of a sale with recourse of accounts receivable,
any asset leased under any “sale and lease back” or similar arrangement and any asset which it has acquired
or holds subject to the interest of a vendor or lessor under any conditional sale agreement, financing lease or other title retention
agreement relating to such asset.

 

“Material Adverse
Effect” means a material adverse effect upon, or a material adverse change in, any of (i) the financial condition, operations,
business or properties of Company Parties, taken as a whole, (ii) the ability of Company Parties to perform under this Agreement
or any other Transaction Document in any material respect or any other material contract in any material respect to which any one
or more of them is a party; (iii) the legality, validity or enforceability of this Agreement or any other Transaction Document;
or (iv) the rights and remedies of Purchaser under this Agreement or any other Transaction Document (other than a change resulting
from any act or omission by Purchaser), except with respect to clauses (ii) and (iv), the failure of Company to perform its obligations
under Section 2(c) of the Registration Rights Agreement related to or resulting from (A) a change in the financial, banking or
securities markets generally (including any disruption thereof and any decline in the price of any security or any market index),
(B) changes in Laws or other binding directives issued by any Governmental Authority or (C) the failure for any reason whatsoever
(other than because of any failure of Company to perform the covenants and obligations within its control under the Registration
Rights Agreement) of the SEC to declare effective any registration statement of Company as required under the Registration Rights
Agreement.

 

    	5

    	 

    

 

“NASDAQ”
means the NASDAQ Stock Market or, when used with reference to a particular market tier of the NASDAQ Stock Market, including without
limitation the NASDAQ Global Select Market or NASDAQ Global Market, means and includes that particular market tier and its related
listing criteria and rules.

 

”Order”
means any order, judgment, injunction, edict, decree, ruling, pronouncement, determination, decision, opinion, sentence, subpoena,
writ or award issued, made, entered or rendered by (i) any court, administrative agency or other Governmental Authority or (ii)
any arbitrator that is legally binding.

 

“Person”
means an individual, a corporation, a partnership, a limited liability company, an association, a trust or any other entity or
organization, including a government or political subdivision or an agency or instrumentality thereof.

 

“Principal
Trading Market” means the OTC Markets Group, Inc.’s OTCQB Marketplace, NASDAQ, or, if the Common Stock is
not listed or traded on a marketplace maintained by either the OTC Markets Group, Inc. or NASDAQ, the national securities exchange,
automated quotation system or other securities trading market on which the Common Stock is then primarily listed or quoted.

 

“Purchase Shares”
means the 2,000,000 shares of Common Stock to be purchased and sold in accordance with ARTICLE II.

 

“Registration
Rights Agreement” means the registration rights agreement in the form of Exhibit C to be entered into by Purchaser
and Company on the Closing Date.

 

“Sarbanes-Oxley
Act” means the Sarbanes-Oxley Act of 2002, as amended, as in effect from time to time.

 

“Securities”
means, collectively, the Convertible Note, the Conversion Shares, the Purchase Shares, the Warrants and the Warrant Shares.

 

“Securities Act”
means the Securities Act of 1933, as amended, as in effect from time to time.

 

“Shareholders
Agreement” means the Shareholders Agreement, dated as of the Effective Date, by and between certain shareholders of Company
and Purchaser.

 

“Subsequent Issuance”
means any issue, sale, grant by Company of Common Stock or Common Stock Equivalents or rights to acquire any of the foregoing after
the initial issuance of the Warrants and the Convertible Note.

 

    	6

    	 

    

 

“Subsidiary”
means any corporation, partnership, limited liability company, association or other business entity (i) of which Company owns,
directly or indirectly, more than fifty percent (50%) of the voting securities thereof or (ii) the management of which is otherwise
controlled, directly or indirectly through one or more intermediaries, by Company and is consolidated with Company in accordance
with GAAP.

 

“Subsidiary Guarantor”
means any Subsidiary of Company that is a guarantor of the obligations under the Guaranty (or under another guaranty agreement
in form and substance satisfactory to Purchaser as holder of the Convertible Note).

 

“Trading Day”
means any day on which the Common Stock is traded on the Principal Trading Market; provided that “Trading Day”
shall not include any day on which the Common Stock is scheduled to trade on the Principal Trading Market for less than 4.5 hours
or any day that the Common Stock is suspended from trading during the final hour of trading on the Principal Trading Market (or
if the Principal Trading Market does not designate in advance the closing time of trading thereon, then during the hour ending
at 4:00 p.m., New York City time).

 

“Transaction
Documents” means each and all of this Agreement, the Registration Rights Agreement, the Convertible Note, the Warrants,
the Guaranty, the Credit Documents, the Shareholders Agreement and any and all other agreements, instruments and documents
now or hereafter executed by or behalf of Company Parties or delivered to Purchaser with respect to this Agreement or with respect
to the transactions contemplated by this Agreement, and in each case, together with any amendments, modifications and supplements
thereto, any replacements, renewals, extensions and restatements thereof, and any substitutes therefor, in whole or in part.

 

“2013 Equity
Incentive Plan” means the 2013 equity incentive plan of Company as in effect on the Closing Date.

 

“Warrants”
mean the Common Stock Purchase Warrants in substantially the form of Exhibit B to be issued in accordance with ARTICLE
II, which Warrants shall mean and include each of the following: (a) warrants to purchase 1,000,000 shares of Common Stock
at an initial exercise price of $1.00 per share in connection with Purchaser’s purchase of the Purchase Shares, (b) warrants
to purchase 1,000,000 shares of Company’s Common Stock at an initial exercise price of $1.00 per share, in connection with
Purchaser’s purchase of the Convertible Note, and (c) (i) warrants to purchase 1,000,000 shares of Company’s Common
Stock at an initial exercise price of $1.00 per share and (ii) warrants to purchase 2,000,000 shares of Company’s Common
Stock at an exercise price of $2.00 per share, each of such warrants described in (c)(i) and (ii) in connection with the loans
extended by Purchaser pursuant to the Credit Agreement.

 

“Warrant Shares
or Warrant Number” means, with respect to any Warrant, the number of shares of Common Stock issuable upon cash exercise
in full of such Warrant and, with respect to all Warrants, the aggregate total number of shares of Common Stock issuable upon cash
exercise in full of all such Warrants.

 

    	7

    	 

    

 

1.2              Additional Definitions.

 

The following terms
have the meanings set forth in the corresponding Sections of this Agreement:

 

	 	Term	 	Section
	 	Board Observer	 	6.1
	 	Closing	 	2.2
	 	Closing Date	 	2.2
	 	Common Stock	 	Background Statement
	 	Company	 	Preamble
	 	Consents, Approvals and Filings	 	3.4
	 	Conversion Shares	 	3.2
	 	Credit Agreement	 	Background Statement
	 	Disclosing Party	 	Definition of Confidential Information
	 	Effective Date	 	Preamble
	 	Express Company Representations	 	4.7
	 	Indemnity Notice	 	8.4
	 	Losses	 	8.2(a)
	 	New Security	 	6.3(a)
	 	OTCQB	 	3.6(c)
	 	Principal Officer Certifications	 	3.8(c)
	 	Purchaser	 	Preamble
	 	Purchaser Director	 	6.1
	 	Qualified IPO	 	Clause (e) of Exempt Issuances
	 	Receiving Party	 	Definition of Confidential Information
	 	Requisite Holder Condition	 	6.1
	 	Response Period	 	6.3(b)
	 	SEC	 	3.8(a)
	 	SEC Documents	 	3.8(a)
	 	Subscription Proposals	 	6.3(c)
	 	Superior Trading Market	 	5.4

 

1.3              Singular/Plural. Unless the
context otherwise requires, words in the singular include the plural and words in the plural include the singular.

 

ARTICLE
II

 

PURCHASE
AND SALE OF THE SECURITIES

 

2.1              Purchase and Sale. Upon the
terms and subject to the conditions set forth herein, at Closing, Company shall issue and sell to Purchaser, and Purchaser shall
purchase from Company, as specified below, the Securities:

 

(a)         the Convertible Note, for a purchase
price equal to the principal amount of the loan to be funded thereunder at Closing;

 

(b)         the Purchase Shares, for a purchase
price of $1.00 per share;

 

    	8

    	 

    

 

(c)         the Warrants, to purchase an aggregate
of 5,000,000 shares of Common Stock, in such amounts and at such initial exercise prices as specified in Section 1.1 in
the definition of “Warrants.”

 

2.2              Closing. The closing of the
purchase and sale of the Convertible Note, the Purchase Shares and the Warrants pursuant to Section 2.1 (the “Closing”)
shall take place remotely via exchange of documents on the first Business Day following the satisfaction or waiver of the applicable
conditions set forth in ARTICLE VII (other than those conditions that by their nature are to be satisfied at such Closing,
but subject to the satisfaction or waiver of those conditions), provided, that the Closing may take place at such other
place, time or date as shall be mutually agreed upon by Company and Purchaser (the date of the Closing, the “Closing Date”).

 

2.3              Closing Deliveries. At the
Closing, Company shall deliver to Purchaser (a) the Convertible Note, (b) the Purchase Shares, (c) the Warrants
and (d) such other deliveries as are specified in Section 7.2(f). Delivery of the Convertible Note, the Purchase Shares
and the Warrants and such other deliveries shall be made against receipt by Company of (i) the purchase price payable for
such Securities as specified in Section 2.1, which shall be paid by Purchaser by wire transfer of immediately available
funds to Company’s account designated in writing to Purchaser not later than the second Business Day before the Closing Date,
and (ii) such other deliveries as are specified in Section 7.3(c).

 

2.4              Calculation of Conversion Price.
The Convertible Note shall, subject to adjustment as provided in the Convertible Note, initially be convertible into a number of
shares of Common Stock derived by dividing the aggregate outstanding principal amount of the Convertible Note to be converted by
$1.00. The Conversion Price and other terms of the Convertible Note will be subject to adjustment as provided in the Convertible
Note.

 

2.5              Warrants. Company and Purchaser
hereby acknowledge and agree that (i) the Warrants are part of an investment unit within the meaning of Section 1273(c)(2) of the
Code, (ii) for United States federal income tax purposes, (A) the issue price of the Warrants referred to in clause (a) of the
definition thereof within the meaning of Section 1273(b) of the Code, which issue price was determined pursuant to Section 1.1273-2(h)(1)
of the Treasury Regulations, is equal to $10,000 (or $0.01 per warrant as of the Effective Date), (B) the issue price of the Warrants
referred to in clause (b) of the definition thereof within the meaning of Section 1273(b) of the Code, which issue price was determined
pursuant to Section 1.1273-2(h)(1) of the Treasury Regulations, is equal to $0.01 per warrant as of the date of its issuance, (C)
the issue price of the Warrants referred to in clause (c) of the definition thereof within the meaning of Section 1273(b) of the
Code, which issue price was determined pursuant to Section 1.1273-2(h)(1) of the Treasury Regulations, is as set forth in Section
2.14 of the Credit Agreement, and (iii) each of Company and Purchaser shall use such issue price for all income tax purposes with
respect to the issuance of the Warrants.

 

    	9

    	 

    

 

2.6              Acceptability of Proceedings at
Closing. All actions to be taken and all documents to be executed and delivered by the Company Parties and other related Persons
in connection with the consummation of the transactions contemplated at the Closing shall be reasonably satisfactory in form and
substance to Purchaser and its counsel, and all actions to be taken and all documents to be executed and delivered by Purchaser
in connection with the consummation of the transactions contemplated at the Closing shall be reasonably satisfactory in form and
substance to Company and its counsel. All actions to be taken and all documents to be executed and delivered by all parties hereto
at the Closing shall be deemed to have been taken and executed and delivered simultaneously, and no action shall be deemed taken
nor any document executed or delivered until all have been taken, executed, and delivered.

 

ARTICLE
III

 

REPRESENTATIONS
AND WARRANTIES OF COMPANY

 

To induce Purchaser to enter into this Agreement
and the transactions contemplated hereby, Company represents and warrants to Purchaser as of the Closing Date as follows:

 

3.1              Corporate Organization and Power.
Each Company Party (i) is a corporation or a limited liability company duly organized or formed, validly existing and in good
standing under the Laws of the jurisdiction of its incorporation or formation, as the case may be (which jurisdictions, as of the
Closing Date, are set forth on Schedule 3.1) and (ii) is duly qualified to do business as a foreign corporation
or limited liability company and is in good standing in each jurisdiction where the nature of its business or the ownership of
its properties requires it to be so qualified, except where the failure to be so qualified, individually or in the aggregate, could
not reasonably be expected to have a Material Adverse Effect.

 

3.2              Authorization. Each Company
Party has the requisite corporate power and authority to enter into this Agreement and each of the other Transaction Documents
to which it is a party and to consummate the transactions contemplated hereby and thereby. The execution and delivery by each Company
Party of this Agreement and each of the other Transaction Documents to which it is a party, the issuance, sale and delivery of
the Securities by Company, the compliance by each Company Party with each of the provisions of this Agreement and each of the other
Transaction Documents to which it is a party (including the reservation and issuance of the Common Stock issuable upon conversion
of the Convertible Note if the term loan is made thereunder (the “Conversion Shares”) and the reservation, issuance
and sale of the Warrant Shares), and the consummation by each Company Party of the transactions contemplated hereby and thereby
(a) are within the corporate power and authority of Company (including such approval and authorization by the Company Board required
under the Laws of the State of Delaware and Company’s certificate of incorporation and bylaws) and each of its Subsidiaries
and (b) have been duly authorized by all necessary corporate action of Company and each of its Subsidiaries. This Agreement has
been, and each of the other Transaction Documents to which each Company Party is a party, when executed and delivered by such Company
Party shall be, duly and validly executed and delivered by such Company Party. Assuming due authorization, execution and delivery
by Purchaser of the Transaction Documents to which it is a party, this Agreement constitutes, and each of such other Transaction
Documents when executed and delivered by each Company Party that is intended to be a party thereto shall constitute a valid and
binding agreement of each such Company Party enforceable against it in accordance with its terms, except (i) as such enforcement
is limited by bankruptcy, insolvency and other similar Laws affecting the enforcement of creditors’ rights generally and
(ii) for limitations imposed by general principles of equity.

 

    	10

    	 

    

 

3.3              Reservation; Valid Issuance.
The Purchase Shares, when issued and delivered in accordance with this Agreement, shall be duly and validly issued and outstanding,
fully paid and non-assessable, and not subject to the preemptive or other similar rights of the stockholders of Company or any
other Person. As of the Closing Date, the Conversion Shares and the Warrant Shares have been reserved for issuance upon conversion
of the Convertible Note and exercise of the Warrants and, when issued and delivered in accordance with the terms of the Convertible
Note and the Warrants, respectively, shall be duly and validly issued and outstanding, fully paid and non-assessable, and not subject
to the preemptive or other similar rights of the stockholders of Company, any other Company Party or any other Person.

 

3.4              No Conflicts; Consents and Approvals;
No Violation. Neither the execution, delivery or performance by each Company Party of this Agreement or any of the other Transaction
Documents to which it is a party nor the consummation by each Company Party of the transactions contemplated hereby or thereby
shall (a) result in a breach or a violation of, any provision of its certificate of incorporation or bylaws; (b) constitute,
with or without notice or the passage of time or both, a breach, violation or default, create a Lien, or give rise to any right
of termination, modification, cancellation, prepayment, suspension, limitation, revocation or acceleration, under (i) any Law or
(ii) any provision of any agreement or other instrument to which it is a party or pursuant to which any of it or any of its assets
or properties is subject, except for, in the case of each clause (i) and (ii), (A) the Liens granted in favor of Purchaser pursuant
to the Credit Documents and (B) violations, breaches or defaults, which, individually or in the aggregate, would not constitute
a Material Adverse Effect; or (c) require any consent, Order, approval or authorization of, notification or submission to, filing
with, license or permit from, or exemption or waiver by, any Governmental Authority or any other Person (collectively, the “Consents,
Approvals and Filings”) on its part, except for (w) the Consents, Approvals and Filings required under the Securities
Act, the Exchange Act and applicable state securities Laws and the Principal Trading Market, (x) filings of Uniform Commercial
Code financing statements and other instruments and actions necessary to perfect the Liens created by the Credit Documents, (y)
consents, authorizations and filings that have been (or on or prior to the Closing Date will have been) made or obtained and that
are (or on the Closing Date will be) in full force and effect, which consents, authorizations and filings are listed on Schedule 3.4,
and (z) such other Consents, Approvals and Filings which the failure of a Company Party to make or obtain would not, individually
or in the aggregate, constitute a Material Adverse Effect. No Company Party is in violation or breach of any term or provision
of its certificate of incorporation or bylaws, and, other than any violation or breach that would not, individually or in the aggregate,
constitute a Material Adverse Effect, no Company Party is in violation or breach of any provision of any other agreement, indebtedness,
mortgage, indenture, contract, Law or Order applicable to any Company Party.

 

3.5              Brokers Fees. No agent, broker,
investment banker or other Person is or shall be entitled to any broker’s or finder’s fee or any other commission or
similar fee from any of the Company Parties in connection with any of the transactions contemplated by this Agreement to occur
on the Closing Date.

 

    	11

    	 

    

 

3.6              Capitalization.

 

(a)         As of the Effective Date, the authorized
Capital Stock of Company consists of (i) 100,000,000 shares of Common Stock, par value $.001 per share, 47,134,549 shares
of which, as of the close of business on February 28, 2014, were issued and outstanding and no more of which additional shares
(excluding any shares issued upon exercise of outstanding options) have been issued between February 28, 2014 and the Effective
Date; and (ii) 5,000,000 shares of Preferred Stock, par value $.001 per share, no shares of which as of the Effective Date are
issued and outstanding. All of the issued and outstanding shares of Common Stock have been duly authorized and are validly issued,
fully paid and non-assessable.

 

(b)         As of the Effective Date, except
as contemplated by this Agreement and as disclosed on Schedule 3.6(b), there are (i) no authorized or outstanding securities,
rights (preemptive or other), subscriptions, calls, commitments, warrants, options, or other agreements that give any Person the
right to purchase, subscribe for, or otherwise receive or be issued Capital Stock of Company or any security convertible into or
exchangeable or exercisable for Capital Stock of Company, (ii) no outstanding debt or equity securities of Company that upon
the conversion, exchange, or exercise thereof would require the issuance, sale, or transfer by Company of any new or additional
Capital Stock of Company (or any other securities of Company which, whether after notice, lapse of time, or payment of monies,
are or would be convertible into or exchangeable or exercisable for Capital Stock of Company), (iii) no agreements or commitments
obligating Company to repurchase, redeem, or otherwise acquire Capital Stock or other securities of Company or its Subsidiaries,
(iv) no agreements or commitments to which Company is a party or is otherwise bound or that otherwise exists to the knowledge
of Company with respect to the voting (including, without limitation, any voting trusts or proxies), registration under the Securities
Act, or sale or transfer (including, without limitation, agreements relating to preemptive rights, rights of first refusal, rights
of first offer, buy-sell rights, co-sale rights or “drag along” rights) of any Capital Stock of Company and (v) no
outstanding or authorized stock appreciation rights, phantom stock, stock rights, or other equity-based interests in respect of
Company. Except as disclosed on Schedule 3.6(b), Company has not issued any indebtedness that is exercisable or exchangeable
for or convertible into Capital Stock of Company. As of the Effective Date, the Purchase Shares, the Conversion Shares (assuming
the Convertible Note is funded) and the Warrant Shares, assuming the amount of the Convertible Note is fully borrowed, constitute
12.9987% of Company’s issued and outstanding Capital Stock and Capital Stock Equivalents, in each case, calculated on a Fully
Diluted Basis.

 

(c)         Company has registered its Common
Stock pursuant to Section 12(g) of the Exchange Act. The Common Stock is currently quoted on the OTCQB Marketplace (the “OTCQB”)
maintained by the OTC Markets Group Inc. under the symbol “AMEH.” Company has not received any oral or written notice
that its Common Stock is not eligible or will become ineligible for quotation on the OTCQB nor that its Common Stock does not meet
all the requirements for the continuation of such quotation.

 

    	12

    	 

    

 

(d)         Schedule 3.6(d) sets forth,
as of the Effective Date, as to each Subsidiary Guarantor and, to the knowledge of Company, each other Subsidiary (x) the
number of shares, units or other interests of each class of Capital Stock outstanding in each such Subsidiary, and the number and
effect, if exercised, of all outstanding options, warrants, rights of conversion or purchase and similar rights and (y) the
registered holders of all such Capital Stock of the Subsidiaries and the number of shares, units, interests, options, warrants
or other purchase rights held by each. All outstanding shares of Capital Stock of the Subsidiary Guarantors and, to the knowledge
of Company, each other Subsidiary are duly and validly issued, fully paid and nonassessable. Except for the shares of Capital Stock
and the other equity arrangements expressly indicated on Schedule 3.6(d), as of the Effective Date there are no shares of
Capital Stock, warrants, rights, options or other equity securities, or other Capital Stock of any Subsidiary Guarantor and, to
the knowledge of Company, each other Subsidiary outstanding or reserved for any purpose.

 

3.7              Offering; Investment Company Act.

 

(a)         Assuming the accuracy of the representations
and warranties of Purchaser set forth in ARTICLE IV, the offer, sale, and issuance of the Securities, as contemplated
hereby are or will be exempt from the registration requirements of the Securities Act and are or will have been registered or qualified
(or are exempt from registration and qualification) under the registration or qualification requirements of all applicable state
securities Laws.

 

(b)         Company is not, and after giving
effect to the issuance of the Securities and the conversion and exercise, as applicable, of the Convertible Note and the Warrants
and the application of the proceeds thereof will not be, an “investment company” within the meaning of the Investment
Company Act of 1940, as amended.

 

3.8              SEC Documents; Financial Statements;
Internal Controls and Procedures.

 

(a)         Company has filed or furnished all
forms, documents and reports required to be filed or furnished by it with the Securities and Exchange Commission (the “SEC”)
on a timely basis since January 31, 2011 (together with any documents so filed or furnished during such period and the period between
the Effective Date and the Closing Date, in each case as may have been, or between the Effective Date and the Closing Date may
be, amended, the “SEC Documents”). Each of the SEC Documents, including all SEC Documents filed or furnished
after the Effective Date but prior to or on the Closing Date, complied or, if not yet filed, will comply, as to form in all material
respects with the applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act. As of the date filed
or furnished with the SEC, none of the SEC Documents, including all SEC Documents filed or furnished after the Effective Date but
prior to or on the Closing Date, contained or, if not yet filed, will contain any untrue statement of a material fact or omitted,
or if not yet filed, will omit to state any material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading. As of the Effective Date, there are no material outstanding
or unresolved comments received from the SEC with respect to any of the SEC Documents.

 

(b)         Since January 31, 2011, subject to
any applicable grace periods, Company has been and is in compliance with the applicable provisions of the Sarbanes-Oxley Act and
the applicable rules and regulations of the OTCQB, except for any such noncompliance that would not, individually or in the aggregate,
constitute a Material Adverse Effect.

 

    	13

    	 

    

 

(c)         Except as disclosed in the SEC Documents,
Company has designed and maintained disclosure controls and procedures and internal control over financial reporting (as such terms
are defined in paragraphs (e) and (f), respectively, of Rule 13a-15 under the Exchange Act) as required by Rule 13a-15 under the
Exchange Act and as necessary to permit preparation of financial statements in conformity with GAAP. Company’s disclosure
controls and procedures are reasonably designed to ensure that all material information required to be disclosed by Company in
the reports that it files or furnishes under the Exchange Act is recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the SEC, and that all such material information is accumulated and communicated to Company’s
principal executive officer and its principal financial officer by others in Company or its Subsidiaries to allow timely decisions
regarding required disclosure and to make the certifications required pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act
(the “Principal Officer Certifications”). As required by the Sarbanes-Oxley Act and in accordance with the most
recent Principal Officer Certifications, Company’s Principal Executive Officer and Principal Financial Officer have disclosed,
based on their most recent evaluation prior to the Effective Date, to Company’s auditors and the audit committee of the Company
Board (i) any material weaknesses in its internal control over financial reporting and (ii) any allegation of fraud that involves
management of Company or any other employees of Company and its Subsidiaries who have a significant role in Company’s internal
control over financial reporting or disclosure controls and procedures. Since January 31, 2011, neither Company nor any of its
Subsidiaries has received any written complaint, allegation, assertion or claim regarding the accounting or auditing practices,
procedures, methodologies or methods of Company or the Subsidiaries or their respective internal accounting controls.

 

3.9              Absence of Undisclosed Liabilities.
Except (a) as disclosed, reflected or reserved against in the consolidated balance sheet of Company and its Subsidiaries as of
January 31, 2013 (or the notes thereto), (b) for Liabilities incurred under or in accordance with the Transaction Documents
or in connection with the transactions contemplated hereby or thereby, (c) for Liabilities incurred under any contract or other
agreement or arising under any applicable Law (other than Liabilities due to breaches thereunder or violations thereof), in each
case, in the ordinary course of business since January 31, 2013, (d) for other Liabilities incurred in the ordinary course
of business since January 31, 2013 and (e) for Liabilities that have been discharged or paid in full, neither Company nor
any Subsidiary has any Liabilities that would be required by GAAP to be reflected on, or reserved against in, a consolidated balance
sheet (or the notes thereto) of Subsidiaries, other than as does not constitute, individually or in the aggregate, a Material Adverse
Effect.

 

3.10            Absence of Certain Changes.
There has been no Material Adverse Effect since January 31, 2013, and there exists no event, condition or state of facts that could
reasonably be expected to result in a Material Adverse Effect.

 

3.11            Litigation. There are no
actions, investigations, suits or proceedings pending or, to the knowledge of Company, threatened, at law, in equity or in arbitration,
before any court, other Governmental Authority, arbitrator or other Person, (i) against or affecting any of the Company Parties
or any of their respective properties that, if adversely determined, could reasonably be expected to have a Material Adverse Effect,
or (ii) with respect to this Agreement, the other Transaction Documents or any of the transactions contemplated hereby or thereby.

 

    	14

    	 

    

 

3.12            Credit Documents. Each of
the representations and warranties contained in the Credit Documents made by Company and each of its Subsidiaries is true and correct.
Company and each of the Subsidiaries agrees that, by this reference, such representations and warranties contained in the Credit
Documents by Company and each of its Subsidiaries, without limiting any of the representations and warranties otherwise contained
herein or in any other Transaction Document, hereby are incorporated herein, mutatis mutandis, for the benefit of Purchaser.

 

ARTICLE
IV

 

REPRESENTATIONS
AND WARRANTIES OF PURCHASER

 

To induce Company to
enter into this Agreement and the transactions contemplated hereby, Purchaser represents and warrants to Company as of the Closing
Date as follows:

 

4.1              Organization. Purchaser is
an entity duly organized, validly existing and in good standing under the Laws of its jurisdiction of formation and has the requisite
corporate power and authority to carry on its business as it is now being conducted.

 

4.2              Authorization. Purchaser has
the requisite corporate power and authority to enter into this Agreement and each of the other Transaction Documents to which it
is a party and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Purchaser of this
Agreement and each of the other Transaction Documents to which it is a party and the compliance by Purchaser with each of the provisions
of this Agreement and each of the Transaction Documents to which it is a party (including the consummation by Purchaser of the
transactions contemplated hereby and thereby) (a) are within the corporate power and authority of Purchaser and (b) have been duly
authorized by all necessary corporate action on the part of Purchaser (including such approvals and authorizations by the Board
of Directors of Purchaser required under the Laws of the State of Nevada and the articles of incorporation and bylaws of Purchaser).
This Agreement has been, and each of the other Transaction Documents to which it is a party when executed and delivered by Purchaser
shall be, duly and validly executed and delivered by Purchaser. Assuming due authorization, execution and delivery by Company of
the Transaction Documents to which it is a party, this Agreement constitutes, and each of such other Transaction Documents when
executed and delivered by Purchaser shall constitute, a valid and binding agreement of Purchaser enforceable against Purchaser
in accordance with its terms, except (i) as such enforcement is limited by bankruptcy, insolvency and other similar Laws affecting
the enforcement of creditors’ rights generally and (ii) for limitations imposed by general principles of equity.

 

    	15

    	 

    

 

4.3              No Conflicts; Consents and Approvals;
No Violation. Neither the execution, delivery or performance by Purchaser of this Agreement or any of the other Transaction
Documents to which it is a party nor the consummation of the transactions contemplated hereby or thereby shall (a) result in a
breach or a violation of, any provision of the articles of incorporation or bylaws of Purchaser; (b) constitute, with or without
notice or the passage of time or both, a breach, violation or default, create a Lien, or give rise to any right of termination,
modification, cancellation, prepayment, suspension, limitation, revocation or acceleration, under (i) any Law, or (ii) any provision
of any agreement or other instrument to which Purchaser is a party or pursuant to which Purchaser or its assets or properties is
subject, except for, in the case of each clause (i) and (ii), violations, breaches or defaults, which, individually or in the aggregate,
would not materially adversely affect the ability of Purchaser to perform its obligations under this Agreement or any Transaction
Document to which it is a party or to consummate the transactions contemplated hereby or thereby; or (c) require any Consents,
Approvals and Filings on the part of Purchaser, except for (x) the Consents, Approvals and Filings required under the Exchange
Act and applicable state securities Laws and (y) such other Consents, Approvals and Filings which the failure of Purchaser to make
or obtain would not materially adversely affect the ability of Purchaser to perform its obligations under this Agreement or any
Transaction Document to which it is a party or to consummate the transactions contemplated hereby or thereby.

 

4.4              Brokers or Finders. No agent,
broker, investment banker or other Person is or shall be entitled to any broker’s or finder’s fee or any other commission
or similar fee from Purchaser in connection with the transactions contemplated by this Agreement to occur on the Closing Date.

 

4.5              Securities Law Matters.

 

(a)         Purchaser is acquiring the Securities
for its own account, for investment and not with a view to, or for sale in connection with, the distribution thereof within the
meaning of the Securities Act (it being understood that except as otherwise provided in this Agreement and the other Transaction
Documents to which it is a party, Purchaser does not agree to hold the Securities for any minimum or other specific term and reserves
the right to dispose of the Securities at any time in accordance with the Securities Act and state securities Laws applicable to
such disposition).

 

(b)         Purchaser is an “accredited
investor,” as that term is as defined in Rule 501(a) of Regulation D under the Securities Act. Purchaser has sufficient knowledge
and experience in financial and business matters to be capable of evaluating the merits and risks of its investment in the Securities
and is capable of bearing the economic risks of such investment.

 

(c)         Purchaser and its advisers have been
furnished with all materials relating to the business, finances and operations of Company, its Subsidiaries and materials relating
to the offer and sale of the Securities which have been requested by Purchaser or its advisers. Purchaser and its advisers have
been afforded the opportunity to ask questions of Company’s management concerning Company and the Securities.

 

(d)         Purchaser understands that except
as provided in this Agreement or the Registration Rights Agreement, the sale or re-sale of the Securities has not been and is not
being registered under the Securities Act or any applicable state securities Laws, and the Securities may not be offered, sold
or otherwise transferred unless (i) the Securities are offered, sold or transferred pursuant to an effective registration statement
under the Securities Act, or (ii) the Securities are offered, sold or transferred pursuant to an exemption from registration under
the Securities Act and any applicable state securities Laws.

 

    	16

    	 

    

 

(e)         The principal offices of Purchaser
and the offices of Purchaser in which it made its decision to purchase the Securities are located in the State of Massachusetts.

 

4.6              Availability of Funds. Purchaser
has sufficient funds to pay the purchase price for the respective Securities it is purchasing pursuant to ARTICLE II.

 

4.7              No Reliance. Purchaser has
substantial investment experience so that Purchaser has the capacity to protect its own interests and is fully capable of evaluating
the merits and risks of its purchase of the Securities hereunder. Purchaser acknowledges that it has made its own decision to purchase
the Securities hereunder without reliance on any representation or warranty of Company or any other party (other than with respect
to the representations and warranties made by Company herein and in the other Transaction Documents (the “Express Company
Representations”)). Purchaser further acknowledges that none of Company, its Subsidiaries or any third party has any
responsibility with respect to any statements, representations or warranties that have been made or may be made regarding Company
or the value of the Securities (except with respect to the Express Company Representations), that Company has not made any representation,
warranty or covenant, express or implied and that, except with respect to the Express Company Representations, Company has not
made any representation, warranty or covenant, express or implied. Specifically, Company has not made any representation, warranty
or covenant, express or implied, with respect to Company’s business, financial condition, prospects, or value, or the value
of the Securities (except with respect to the Express Company Representations). Purchaser has access to and the opportunity to
review financial and business information concerning Company, including its public filings made with the SEC, as necessary to make
a deliberate and informed decision as to whether to purchase the Securities on the terms provided in this Agreement. Purchaser
represents that it has had a full, fair and complete opportunity to value the Securities. Purchaser acknowledges that the purchase
price of the Securities may not be indicative of the actual fair market value of the Securities. Purchaser has been given the opportunity
to (i) ask questions of and receive answers from Company and Company concerning the terms and conditions of the Securities, and
the business and financial condition of Company and (ii) obtain any additional information that Company possesses with respect
to the Securities. Purchaser has such knowledge and experience in financial or business matters and with respect to Company’s
business, financial condition, operating results and prospects that Purchaser is capable of evaluating the merits and risks of
the purchase contemplated by this Agreement.

 

4.8              Restricted Securities. Purchaser
understands that the Securities have not been registered under the Securities Act, by reason of a specific exemption from the registration
provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the
accuracy of Purchaser’s representations as expressed herein. Purchaser understands that the Securities are “restricted
securities” under applicable U.S. federal and state securities Laws and that, pursuant to these Laws, Purchaser must hold
the Securities until such time as they are registered with the SEC and qualified by state authorities, or an exemption from
such registration and qualification requirements is available. Purchaser acknowledges that if an exemption from registration or
qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of
sale, the holding period for the Securities, and on requirements relating to Company which are outside of Purchaser’s control.

 

    	17

    	 

    

 

4.9              Legends. Purchaser understands
that the Securities and any securities issued in respect of or exchange therefor, may be notated with one or all of the following
legends:

 

(a)         “THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO,
OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT
RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES
ACT OF 1933.”

 

(b)         Any legend set forth in, or required
by, the other Transaction Agreements.

 

(c)         Any legend required by the securities
laws of any state to the extent such laws are applicable to the Securities represented by the certificate, instrument, or book
entry so legended.

 

ARTICLE
V

 

COVENANTS

 

5.1              Public Announcements. Company
and Purchaser shall consult with each other before issuing any press release or other public disclosure with respect to this Agreement
or the transactions contemplated hereby and neither shall issue any such press release or make any such public statement with respect
thereto without the prior consent of the other, which consent shall not be unreasonably withheld, delayed or conditioned; provided,
however, that a party may, without the prior consent of the other party, issue such press release or make such public disclosure
as may upon the advice of counsel be required by Law or by the rules of the OTCQB, provided that, to the extent time permits,
such party has used all commercially reasonable efforts to consult with the other party prior thereto. Company and Purchaser agree
that the initial press release or other public disclosure relating to this Agreement and the transactions contemplated herein shall
state, among other things, that Purchaser is an Affiliate of Fresenius Medical Care Holdings, Inc.

 

5.2              Consents, Approvals and Filings.
Subject to the terms of this Agreement and the other Transaction Documents, Company and Purchaser each shall use their respective
commercially reasonable efforts to take, or cause to be taken, all actions, and do, or cause to be done, and to assist and cooperate
with the other party in doing, all things necessary, proper, desirable or advisable to obtain and make all Consents, Approvals
and Filings required to be obtained or made by Company and its Subsidiaries or Purchaser, as the case may be, in connection with
the authorization, execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation
of the transactions contemplated hereby and thereby.

 

    	18

    	 

    

 

5.3              Further Assurances. Except
as otherwise expressly provided in this Agreement and the other Transaction Documents, Company and Purchaser each shall use their
respective commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things
necessary, proper or advisable under applicable Laws to consummate the transactions contemplated by this Agreement or any Transaction
Document; provided that the foregoing shall not impose any obligations on Purchaser to convert the Convertible Note into Conversion
Shares or exercise any Warrant for Warrant Shares If any administrative or judicial action or proceeding, including any proceeding
by a private party, is instituted (or threatened to be instituted) challenging any transaction contemplated by this Agreement or
any Transaction Document, each party shall use commercially reasonable efforts to cooperate in all respects with the other party,
to contest and resist any such action or proceeding and to have vacated, lifted, reversed or overturned any Order, whether temporary,
preliminary or permanent, that is in effect and that prohibits, prevents or restricts the consummation of the transactions contemplated
by this Agreement or any Transaction Document; provided, however, that neither Company nor Purchaser shall be required to
expend any material funds in connection with such commercially reasonable efforts.

 

5.4              Quotation and Listing. For
so long as any Securities are outstanding, Company shall use its commercially reasonable efforts to (i) continue to have the
Common Stock quoted on the OTCQB; provided, however, that if and to the extent Company’s Common Stock meets the qualifications
for quotation and/or listing on the OTCQX or any tier of any other nationally recognized U.S. securities trading market, including
without limitation, the NASDAQ Stock Market or any other national securities exchange that imposes more stringent criteria for
listing or trading of the Common Stock (each such market or exchange, a “Superior Trading Market”) than Company’s
then Principal Trading Market, then upon the approval of the Company Board (which it may grant or withhold in its sole and absolute
discretion), Company shall use its commercially reasonable efforts to apply for, pay all applicable fees and expenses in connection
with, and obtain authorization for the listing or quotation of the Common Stock, including the Securities as and when represented
by or converted into Common Stock, on such Superior Trading Market.

 

5.5              Reservation of Common Stock.
Company at all times shall reserve and keep available, free of preemptive rights, solely for issuance and delivery upon conversion
of the Convertible Note and upon exercise of the Warrants, the number of shares of Conversion Shares and Warrants Shares, as the
case may be, from time to time issuable upon conversion of the Convertible Note or upon exercise of the Warrants, in each case
at the time outstanding.

 

5.6              Integration. Company agrees
that it will not and will cause its Affiliates not to, directly or indirectly, solicit any offer to buy, sell or make any offer
or sale of, or otherwise negotiate in respect of, securities of Company of any class if counsel to Company advises it that, as
a result of the doctrine of “integration” referred to in Rule 502 under the Securities Act, there is a substantial
likelihood that such offer or sale would render invalid (for the purpose of (i) the sale of the Securities by Company to Purchaser,
or (ii) the resale of the Securities by Purchaser to any subsequent transferee) the exemption from the registration requirements
of the Securities Act provided by Section 4(a)(2) thereof or by Rule 144, Rule 144A or by Regulation S thereunder or otherwise.

 

5.7              Rule 144 and 144A Information.
Company agrees that, in order to render the Securities eligible for resale pursuant to Rule 144 or, to the extent available, Rule
144A under the Securities Act, while any of such Securities remain outstanding, Company will make available, upon request, to Purchaser
or any prospective transferee of such Securities the information specified in Rule 144(c)(2) and/or Rule 144A(d)(4), as applicable,
unless Company furnishes information to the SEC pursuant to Section 13 or 15(d) of the Exchange Act in compliance with Rule 144(c)(1)
and/or so as to exempt it from the information requirements in Rule 144A(d)(4), as applicable.

 

    	19

    	 

    

 

5.8              [Reserved]

 

5.9              Confidential Information.
In the event the Receiving Party (including its officers, employees, counsel, accountants, partners, Board Observer and other authorized
representatives) obtains or has obtained from the Disclosing Party any Confidential Information, the Receiving Party (i) shall
treat all such Confidential Information as confidential, (ii) shall use such Confidential Information only for the purposes contemplated
in this Agreement and the other Transaction Documents (and related documents), (iii) shall protect such Confidential Information
with the same degree of care as the Receiving Party uses to protect its own confidential and proprietary information against public
disclosure, but in no case with less than reasonable care, and (iv) shall not disclose such Confidential Information to any third
party except to such officers, employees, counsel, accountants, partners and other authorized representatives of the Receiving
Party, its Affiliates or potential permitted transferees of the Receiving Party’s rights under this Agreement and the other
Transaction Documents who need to know such Confidential Information for any proper purpose related to this Agreement and the other
Transaction Documents or any transaction contemplated hereby or thereby and who have been informed of and have agreed in writing
to protect the confidential nature of such Confidential Information and not to use such Confidential Information for any unlawful
purpose (and the Receiving Party shall be responsible for compliance with this Section 5.9 by its and its Affiliates’
officers, employees, counsel, accountants, partners and other authorized representatives) or to the extent required by applicable
Requirements of Law, provided that, if not prohibited by applicable Requirements of Law, the Receiving Party will (i) provide reasonable
advance notice to the Disclosing Party of such disclosure so that the Disclosing Party may seek an appropriate protective order
and (ii) to cooperate with the Disclosing Party, at the Disclosing Party’s expense, to obtain such protective order. Each
party agrees that, due to the unique nature of the Confidential Information, the unauthorized disclosure or use of any Confidential
Information of the Disclosing Party may cause irreparable harm and significant injury to the Disclosing Party, the extent
of which may be difficult to ascertain and for which there may be no adequate remedy at law. Accordingly, each party agrees that
the Disclosing Party, in addition to any other available remedies, shall have the right to seek an immediate injunction and other
equitable relief enjoining any breach or threatened breach of this Section 5.9 without the necessity of posting any
bond or other security. The Receiving Party shall notify the Disclosing Party in writing immediately upon the Receiving Party’s
becoming aware of any such breach or threatened breach. Notwithstanding anything to the contrary set forth in this Agreement or
any other Transaction Document, this Section 5.9 shall survive the termination of this Agreement.

 

    	20

    	 

    

 

5.10              Notification of Certain Matters.
Each party shall give prompt notice to the other party of, and shall use their respective commercially reasonable efforts to prevent
or promptly remedy, (i) the occurrence or failure to occur, or the impending or threatened occurrence or failure to occur, of any
event which occurrence or failure to occur would cause any of its representations or warranties in this Agreement or any other
Transaction Document to be untrue or inaccurate in any material respect (or in all respects in the case of any representation or
warranty containing any materiality qualification) at any time after the Effective Date but on or prior to the Closing Date and
(ii) any material failure (or any failure in the case of any covenant, condition or agreement containing any materiality qualification)
on its part to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it under this Agreement
or any other Transaction Document. The delivery of any notice pursuant to this Section 5.10 shall not limit or otherwise
affect the remedies available under this Agreement or any other Transaction Document to any party receiving such notice.

 

5.11              Funding Fee. Company agrees
to pay to Purchaser a funding fee of $20,000.00 if Company borrows the term loan pursuant to Section 2.1 of the Convertible Note.
The funding fee shall be fully earned when it becomes due and payable under this Section and shall not be subject to refund to
Company for any reason, including without limitation any prepayment by Company of outstanding principal under the Convertible Note.

 

5.12              Market Stand-off Agreement.
In the event of a Qualified IPO, Purchaser hereby agrees that it will not, if so requested by the managing underwriter for such
Qualified IPO, without the prior written consent of such managing underwriter, during the period commencing on the date of the
final prospectus relating to such Qualified IPO, and ending on the date specified by such managing underwriter (such period not
to exceed one hundred eighty (180) days, or such other period as may be requested by such underwriter to accommodate regulatory
restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including,
but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or
amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option
or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly,
any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common
Stock (whether such shares or any such securities are then owned by Purchaser or are thereafter acquired) or (ii) enter into any
swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such
securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock
or other securities, in cash, or otherwise. The foregoing provisions of this Section 5.12 shall not apply to the sale of
any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to Purchaser only if all Company officers
and directors are subject to the same restrictions. The underwriters in connection with such Qualified IPO are intended third-party
beneficiaries of this Section 5.12 and shall have the right, power and authority to enforce the provisions hereof as though
they were a party hereto. Purchaser further agrees to execute such agreements as may be reasonably requested by the underwriters
in connection with such Qualified IPO that are consistent with this Section 5.12 or that are necessary to give further effect
thereto.

 

    	21

    	 

    

 

 

ARTICLE
VI

 

bOARD
AND OTHER RIGHTS

 

6.1              Board Rights.

 

(a)         For so long as  Purchaser holds
any combination of Common Stock, Convertible Note (if Company borrows the term loan thereunder), Conversion Shares, Warrants or
Warrant Shares that in the aggregate either represent or entitle Purchaser to acquire at least 2,000,000 shares of Common Stock
(the “Requisite Holder Condition”), (A) Purchaser shall have the right to appoint one (1) representative (the
“Board Observer”) to attend all meetings of the Company Board and any committee thereof in a nonvoting observer
capacity, and (B) Purchaser shall have the right to have one (1) representative (the “Purchaser Director”) nominated
as a member of the Company Board and each committee thereof, including without limitation Company’s compensation committee.
Purchaser shall notify Company in writing in any manner provided in Section 9.6 of this Agreement of its election to appoint
a Board Observer and a Purchaser Director. Any such Purchaser Director shall enter into Company’s standard form of Board
Member Service Agreement on terms no less favorable to such Purchaser Director than required of any other member of the Company
Board prior and as a condition to such Purchaser Director serving on the Company Board.

 

(b)         As of and from the time of Purchaser’s
notification to Company of its election to exercise such right: (1) the Company Board or any committee thereof shall, if necessary,
increase the size of the Company Board or such committee, to accommodate the addition of the Purchaser Director and take all corporate
action required by Law to promptly appoint such Purchaser Director to the Company Board or such committee and (2) the Company Board
shall, for so long as the Requisite Holder Condition is satisfied and unless Purchaser notifies Company of its election to cease
having such Purchaser Director serve on the Company Board or any committee thereof, renominate and reappoint such Purchaser Director
to the Company Board and each committee thereof annually or from time to time at such time as it renominates and reappoints other
members of the Company Board or any such committee (or to the extent that Company in the future submits nominations for directors
to the Company Board to a vote of Company’s stockholders (or action by written consent of stockholders in lieu of a meeting),
Company, the Company Board and any committee of the Company Board that oversees nominations to the Company Board shall use all
commercially reasonable efforts to have the Purchaser Director reelected as to the Company Board by Company’s stockholders
and shall solicit proxies for the Purchaser Director and take any and all such other actions to facilitate such reelection of the
Purchaser Director to the same extent as it does for any of Company’s other nominees to the Company Board); (C) Company shall
reimburse the Board Observer and Purchaser Director for all reasonable costs and expenses customarily incurred in attending meetings
of the Company Board (other than the cost of airfare and hotel accommodations); (D) within one hundred eighty (180) days after
the Closing Date, Company’s certificate of incorporation shall provide for indemnification of the members of the Company
Board, or any committee thereof, to the broadest extent permitted by applicable law; (E) Company shall ensure that the Purchaser
Director is afforded coverage under any Directors and Officers insurance policy then in effect on the same terms as other members
of the Company Board; (F) Company shall enter into an indemnity agreement with the Purchaser Director on terms no less favorable
than those included in the most director-favorable form of indemnity agreement provided to any member of the Company Board; and
(G) Company shall give the Board Observer copies of all notices, minutes, consents and other materials that it provides to its
directors and when so provided; provided, however, that the Board Observer agrees in a written agreement in form
and substance reasonably satisfactory to Company to hold in confidence pursuant to the terms in Section 5.9 with respect
to all information so provided; and, provided further, that Company reserves the right to withhold any information
and to exclude the Board Observer from any meeting or portion thereof if access to such information or attendance at such meeting
could adversely affect the attorney-client privilege between Company and its counsel.

 

    	22

    	 

    

 

(c)         Purchaser shall notify Company in
writing in any manner provided in Section 9.6 of this Agreement of its election to appoint a Board Observer and a Purchaser
Director.

 

Notwithstanding anything
in this Agreement to the contrary, the rights set forth in this Section 6.1 shall survive for so long as the Requisite Holder
Condition is satisfied. Purchaser may assign its rights in this Section 6.1 to one or more Affiliates of Purchaser. Otherwise,
(i) the Purchaser Director rights set forth in this Section 6.1 may not be assigned or transferred to any other Person and
(ii) the Board Observer rights set forth in this Section 6.1 may be assigned or transferred to any other Person in connection
with the sale, assignment or transfer to such Person of all of the Securities then owned beneficially and of record by Purchaser
to the extent it may otherwise assign or transfer such Securities under this Agreement or a related Transaction Document, and any
such assignee shall be treated as the “Purchaser” for purposes of this Section 6.1 relating to the Board Observer.

 

6.2              Vacancies. In the event that
either the Purchaser Director or the Board Observer ceases to serve in his or her capacity as such during his or her term for any
reason, and at such time Purchaser has the right to appoint or nominate a Purchaser Director or appoint a Board Observer, as the
case may be, Purchaser shall have the right to submit a replacement Purchaser Director or Board Observer.

 

6.3              Subscription Rights.

 

(a)              Sale of New Securities. For
so long as the Requisite Holder Condition is satisfied, if Company at any time or from time to time makes any public or non-public
offering of any equity (including Common Stock, Common Stock Equivalent, Capital Stock, Capital Stock Equivalents, preferred stock
and restricted stock), or any other securities, warrants, options or debt that are convertible or exchangeable into equity or that
include an equity component (such as an “equity kicker”) (including any hybrid security) (any such security a “New
Security”), Purchaser shall be afforded the opportunity (provided, in the case of an offering that is not a registered
public offering, that Purchaser satisfies any applicable “accredited investor,” “qualified institutional buyer”
or other investor criteria applicable to such offering) to subscribe for a pro rata share of any New Security so offered for the
same price and on the same terms as such New Security is proposed to be offered to others. Purchaser’s pro rata share, for
purposes of this Section 6.3, is the ratio of the number of shares of Common Stock owned by Purchaser immediately prior
to the issuance of a New Security (assuming all Common Stock Equivalents owned by Purchaser are converted into or exchanged for
shares of Common Stock) to the total number of shares of Common Stock outstanding on a Fully Diluted Basis immediately prior to
the issuance of such New Security. Notwithstanding the foregoing, the subscription rights set forth under this Section 6.3
shall not apply to (1) any offering by Company pursuant to an Exempt Issuance or (2) issuances of any securities issued as a result
of a stock split, stock dividend, reclassification or reorganization or similar event, but solely to the extent such issuance is
made to all holders of Common Stock Equivalents. For the avoidance of doubt, to the extent that Company complies with its obligations
pursuant to this Section 6.3 with respect to any securities that are convertible or exchangeable into (or exercisable for)
Common Stock or other equity, Purchaser shall not have an additional right to purchase pursuant to this Section 6.3 additional
securities as a result of the issuance of New Securities upon the conversion, exchange or exercise of such earlier issued securities
(whether or not such Purchaser exercised its right to purchase such earlier issued securities). Purchaser may assign the right
to exercise the subscription rights set forth in this Section 6.3 with respect to any Securities to the extent it may otherwise
transfer or assign such Securities under this Agreement or a related Transaction Document, and any such assignee shall be treated
as the “Purchaser” for purposes of this Section 6.3.

 

    	23

    	 

    

 

(b)         Notice. In the event Company
proposes to offer New Securities, it shall give Purchaser written notice (or, if such a written notice would be required to be
filed with the SEC, oral notice) of its intention, describing, to the extent then known, the price (or range of prices), anticipated
amount of securities, timing and other terms upon which Company proposes to offer the same (including, in the case of a registered
public offering and to the extent possible, a copy of the prospectus included in the registration statement filed with respect
to such offering) no later than five Business Days, as the case may be, after the initial filing of a registration statement with
the SEC with respect to an underwritten public offering, after the commencement of marketing with respect to a Rule 144A offering
or after Company commences the marketing of any other offering; provided that for purposes of this Section 6.3, in addition
to providing notice to Purchaser in accordance as set forth above, Company shall use its commercially reasonable efforts to effect
actual notice of Purchaser as promptly as practicable, including via telephone and/or electronic mail (provided that Company shall
contact only those persons listed in Section 9.6 of this Agreement and shall have no obligation to use electronic mail if
such electronic mail would be required to be filed with the SEC). Company may provide such notice to Purchaser on a confidential
basis (and Purchaser shall keep the information conveyed by notice confidential) prior to public disclosure of such offering. Purchaser
shall have (i) twenty Business Days from the date of receipt of notice as set forth above but without accounting for any notice
provided pursuant to the proviso above requiring Company to use commercially reasonable efforts to provide notice via telephone
and/or electronic mail or, (ii) in the case or a “shelf takedown” from a shelf registration statement, two days from
the receipt of such notice (such twenty or two day period, as applicable, the “Response Period”) to notify Company
in writing whether it will exercise such subscription rights and as to the amount of New Securities Purchaser desires to purchase,
up to its pro rata share of New Securities being offered. Such notice shall constitute a binding commitment by Purchaser to purchase
the amount of New Securities so specified at the price and other terms set forth in Company’s notice to it and subject to
other customary closing conditions and provided, with respect to a registered offering, that such notice shall not be binding unless
and until Company can accept a binding commitment under applicable Laws. The failure of Purchaser to respond within the Response
Period shall be deemed to be a waiver of Purchaser’s rights under this Section 6.3 only with respect to the offering
described in the applicable notice.

 

    	24

    	 

    

 

(c)         Purchase Mechanism. Subject
to the next sentence, each of Company and Purchaser agrees to use its commercially reasonable efforts to secure any regulatory
or stockholder approvals or other consents, and to comply with any law or regulation necessary in connection with and prior to
the offer, sale and purchase of such New Securities, including calling a meeting of Company’s stockholders to vote on any
matters requiring stockholder approval in connection with the offer, sale and purchase of such New Securities (the “Subscription
Proposals”), recommending to Company’s stockholders that such stockholders vote in favor of any Subscription Proposals
and soliciting proxies for approval of any Subscription Proposals. By the earlier of (i) within one hundred eighty (180) days after
Closing and (ii) twenty (20) Business Days prior to the offer, sale and purchase of New Securities, Company shall amend its certificate
of incorporation in order to permit Purchaser’s exercise of its rights under this Section 6.3 and such amendment shall
be in form and substance reasonably satisfactory to Purchaser.

 

(d)         Failure to Purchase. In the
event Purchaser fails to exercise its subscription rights provided in this Section 6.3 within the Response Period, or, if
so exercised, such Purchaser is unable to consummate such purchase upon the closing of the sale and issuance of New Securities
for any reason, Company shall thereafter be entitled during the period of 60 days following the conclusion of the applicable period
to sell or enter into an agreement (pursuant to which the sale of the New Securities covered thereby shall be consummated, if at
all, within 30 days from the date of said agreement) to sell the New Securities not elected to be purchased pursuant to this Section
6.3 or which Purchaser does not or is unable to purchase, at a price and upon terms no more favorable to purchasers of such
securities than were specified in Company’s notice to such Purchaser. Notwithstanding the foregoing, if such sale is subject
to the receipt of any regulatory or stockholder approval or consent or the expiration of any waiting period, the time period during
which such sale may be consummated shall be extended until the expiration of five Business Days after all such approvals or consents
have been obtained or waiting periods expired, but in no event shall such time period exceed 90 days from the date of the applicable
agreement with respect to such sale. In the event Company has not sold the New Securities or entered into an agreement to sell
the New Securities within said 60-day period (or sold and issued New Securities in accordance with the foregoing within 30 days
from the date of said agreement (as such period may be extended in the manner described above for a period not to exceed 90 days
from the date of said agreement)), Company shall not thereafter offer, issue or sell such New Securities without first offering
such securities to such Purchaser in the manner provided above.

 

(e)         Non-Cash Consideration. In
the case of the offering of securities for a consideration in whole or in part other than cash, including securities acquired in
exchange therefor (other than securities by their terms so exchangeable), the consideration other than cash shall be deemed to
be the fair value thereof as determined by the Board of Directors; provided, however, that such fair value as determined by the
Board of Directors shall not exceed the aggregate market price of the securities being offered as of the date the Board of Directors
authorizes the offering of such securities.

 

(f)         Cooperation. Company and Purchaser
shall cooperate in good faith to facilitate the exercise of such Purchaser’s rights pursuant to this Section 6.3,
including securing any required approvals or consents.

 

    	25

    	 

    

 

6.4              Certain Other Covenants.

 

(a)         At the appropriate time and for so
long as the Requisite Holder Condition is satisfied, Company shall (i) consider in good faith (A) establishing, maintaining and
utilizing governance and oversight committees (including for Affiliate transactions), (B) evaluating compliance plans and policies,
including policies and procedures for monitoring adherence to Company’s non-solicitation and other restrictive covenants,
and (C) hiring a compliance officer to implement and monitor such plans and policies and (ii) maintain and utilize its existing
committees for audit and compensation.

 

(b)         Company shall ensure that (i) Company’s
compensation committee approves all compensation for each officer and director of Company and those Persons who are Subsidiaries
of Company pursuant to clause (i) of the definition of Subsidiary and (ii) no member of Company’s compensation committee
shall vote to approve any of his or her own compensation.

 

ARTICLE
VII

 

CONDITIONS
TO CLOSING

 

7.1              Conditions to Obligations of Purchaser
and Company at Closing. The obligations of Purchaser and Company to consummate the transactions contemplated hereby to be consummated
at the Closing are subject to the satisfaction or waiver at or prior to the Closing Date of each of the following conditions:

 

(a)         no preliminary or permanent injunction
or other Order by any Governmental Authority which prevents the consummation of the transactions contemplated hereby shall have
been issued and remain in effect (each party agreeing to use its commercially reasonable efforts to have any such injunction or
Order lifted);

 

(b)         any Consents, Approvals and Filings
that are necessary for the consummation of the transactions contemplated by this Agreement shall have been made or obtained except
where (i) Company’s failure to make or obtain such Consents, Approvals and Filings would not, individually or in the aggregate,
constitute a Material Adverse Effect or (ii) Purchaser’s failure to obtain such Consents, Approvals and Filings would not
have a material adverse effect on Purchaser’s ability to perform its obligations under this Agreement; and

 

(c)         no suit, claim, investigation, action
or other proceeding shall be pending or, to the knowledge of Company or Purchaser, respectively, threatened against Purchaser or
Company Parties before any Governmental Authority which reasonably could be expected to result in the restraint or prohibition
of any such party, or the obtaining of damages or other relief from any such party, in connection with this Agreement or the other
Transaction Documents or the consummation of the transactions contemplated hereby or thereby.

 

7.2              Additional Conditions to Obligations
of Purchaser at Closing. The obligations of Purchaser to consummate the transactions contemplated hereby to be consummated
at the Closing shall be subject to the satisfaction or waiver at or prior to the Closing Date of each of the following additional
conditions:

 

    	26

    	 

    

 

(a)              each of the representations and warranties
made by Company in ARTICLE III shall be true and correct in all material respects (except to the extent any such representation
or warranty is qualified as to materiality or by Material Adverse Effect, in which case such representation or warranty shall be
true in all respects) on and as of such date with the same effect as if made on and as of such date (except to the extent any such
representation or warranty related to a specific date, in which case such representation or warranty shall be true and correct
in all material respects as of such date (except to the extent any such representation or warranty is qualified as to materiality
or Material Adverse Effect, in which case such representation or warranty shall be true in all respects as of such date));

 

(b)         Company shall have performed, in
all material respects, all of its obligations contemplated herein to be performed by Company on or prior to the Closing Date;

 

(c)         from the Effective Date through the
Closing Date, there shall not have occurred, and be continuing, a Material Adverse Effect;

 

(d)         the Purchase Shares, the Conversion
Shares and the Warrant Shares shall have been duly authorized and reserved for issuance and shall have been authorized for quotation
on the OTCQB, subject only to notice of issuance;

 

(e)         the trading of the Common Stock shall
not have been suspended by the SEC, the OTCQB or any supervising authority over the OTCQB authority;

 

(f)         Company shall have delivered the
following to Purchaser:

 

(i)         an officer’s certificate
certifying as to Company’s compliance with the conditions set forth in clauses (a) through (e) of this Section 7.2;

 

(ii)         the Convertible Note,
executed by a duly authorized officer of Company;

 

(iii)        Certificates Representing
the Purchase Shares, executed by a duly authorized officer of Company and authenticated by Company’s Transfer Agent;

 

(iv)        the Warrants, executed
by a duly authorized officer of Company;

 

(v)         the Guaranty, duly completed
and executed by the Subsidiary Guarantors, in form and substance satisfactory to Purchaser;

 

(vi)        the Registration Rights
Agreement, executed by a duly authorized officer of Company;

 

(vii)       the Shareholders Agreement,
executed by the parties specified therein;

 

(viii)      the portion of the funding
fee, if any, required to be paid to Purchaser on the Closing Date pursuant to Section 5.11; and

 

(ix)         such other documents as
may be required by this Agreement or reasonably requested by Purchaser; and

 

(g)         all conditions precedent for closing
the Credit Agreement shall have been satisfied to the reasonable satisfaction of Purchaser.

 

    	27

    	 

    

 

7.3              Additional Conditions to Obligations
of Company at Closing. The obligations of Company to consummate the transactions contemplated hereby to be consummated at Closing
shall be subject to the satisfaction or waiver at or prior to the Closing Date of each of the following additional conditions:

 

(a)         each of the representations and warranties
made by Purchaser in ARTICLE IV shall be true and correct in all material respects (except to the extent any such representation
or warranty is qualified as to materiality or by Material Adverse Effect, in which case such representation or warranty shall be
true in all respects) on and as of such date with the same effect as if made on and as of such date (except to the extent any such
representation or warranty related to a specific date, in which case such representation or warranty shall be true and correct
in all material respects as of such date (except to the extent any such representation or warranty is qualified as to materiality
or Material Adverse Effect, in which case such representation or warranty shall be true in all respects as of such date));

 

(b)         Purchaser shall have performed, in
all material respects, all of its obligations contemplated herein to be performed by Purchaser on or prior to the Closing Date;

 

(c)         Purchaser shall have delivered the
following to Company:

 

(i)         an officer’s certificate
certifying as to Purchaser’s compliance with the conditions set forth in clauses (a) and (b) of this Section 7.3;

 

(ii)         the purchase price payable
for the Convertible Note and the Purchase Shares;

 

(iii)        the Registration Rights
Agreement, executed by a duly authorized officer of Purchaser;

 

(iv)        the Shareholders Agreement,
executed by the parties specified therein; and

 

(v)         such other documents as
may be required by this Agreement or reasonably requested by Company.

 

(d)         all conditions precedent for closing
the Credit Agreement shall have been satisfied to the reasonable satisfaction of Company.

 

ARTICLE
VIII

 

SURVIVAL;
INDEMNIFICATION

 

8.1              Survival of Representations and
Warranties. All representations and warranties set forth in this Agreement shall survive the transactions contemplated by this
Agreement to be consummated at the Closing (regardless of any investigation, inquiry, or examination made by any party or on its
behalf or any knowledge of any party or the acceptance by any party of any certificate or opinion) for a period of eighteen (18)
months and thereupon shall terminate, unless an Indemnity Notice shall have been delivered with respect thereto with such period.

 

    	28

    	 

    

 

8.2              Indemnification.

 

(a)         Company shall indemnify and hold
harmless Purchaser, its Affiliates, and their respective directors and officers, and each Person, if any, who controls Purchaser
or any of its Affiliates (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) against all
losses, claims, damages, liabilities and expenses (including reasonable attorneys’ and accountants’ fees, disbursements
and expenses, as incurred) (collectively, “Losses”) incurred by such Person entitled to indemnification hereunder
arising out of or based upon any breach of a representation or warranty or breach of or failure to perform any covenant or agreement
on the part of Company contained in this Agreement.

 

(b)         Purchaser shall indemnify and hold
harmless Company, its directors and officers, and each Person, if any, who controls Company (within the meaning of Section 15 of
the Securities Act or Section 20 of the Exchange Act) against all Losses incurred by such Person entitled to indemnification hereunder
arising out of or based upon any breach of a representation or warranty or breach of or failure to perform any covenant or agreement
on the part of Purchaser contained in this Agreement.

 

8.3              Method of Asserting Indemnification
for Third Party Claims. Any Person entitled to indemnification hereunder shall give prompt written notice to the indemnifying
party after the receipt by such indemnified party of any written notice of the commencement of any action, suit, proceeding or
investigation or threat thereof made in writing for which such indemnified party may claim indemnification pursuant to this Agreement,
provided that failure to give such notification shall not affect the obligations of the indemnifying party pursuant to this
ARTICLE VIII except to the extent that the indemnifying party shall have been actually prejudiced as a result of such failure.
In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement
thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with any
other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified
party, and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof,
the indemnifying party shall not be liable to such indemnified party for any legal expenses of other counsel or any other expenses,
in each case subsequently incurred by such indemnified party, in connection with the defense thereof other than reasonable costs
of investigation, unless in the reasonable judgment of any indemnified party, based on the written opinion of counsel, a conflict
of interest is likely to exist between the indemnifying party and such indemnified party and any other of such indemnified parties
with respect to such claim, in which event the indemnifying party shall not be liable for the fees and expenses of more than one
counsel for all indemnified parties selected by such parties (which selection shall be reasonably satisfactory to the indemnifying
party), in each case in connection with any one action or separate but similar or related actions. An indemnifying party who is
not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than
one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment
of any indemnified party, based on the written opinion of counsel, a conflict of interest is likely to exist between the indemnified
party and any other of such indemnified parties with respect to such claim, in which event the indemnifying party shall be obligated
to pay the fees and expenses of such additional counsel. No indemnifying party, in defense of any such action, suit, proceeding
or investigation, shall, except with the consent of each indemnified party, consent to the entry of any judgment or entry into
any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified
party of a release from all liability in respect to such action, suit, proceeding or investigation to the extent such liability
is covered by the indemnity obligations set forth in this Section 8.2. No indemnified party shall consent to entry of any
judgment or entry into any settlement without the consent of each indemnifying party.

 

    	29

    	 

    

 

8.4              Method of Asserting Indemnification
for Other Claims. In the event any indemnified party should have a claim under Section 8.2 against the indemnifying
party that does not involve a third party claim, the indemnified party shall deliver a written notification of a claim for indemnity
under Section 8.2 specifying the nature of and basis for such claim, together with the amount or, if not then reasonably
ascertainable, the estimated amount, determined in good faith, of such claim (an “Indemnity Notice”) with reasonable
promptness to the indemnifying party. The failure by any indemnified party to give the Indemnity Notice shall not impair such party’s
rights under Section 8.2 except to the extent that the indemnifying party shall have been actually prejudiced as a result
of such failure.

 

8.5              Limitations on Indemnification.
The maximum amount that Company or Purchaser can recover for Losses pursuant to this ARTICLE VIII for breaches of representations
and warranties shall not in the aggregate exceed the aggregate purchase price of the Securities. The maximum amount that Company
or Purchaser can recover for Losses pursuant to this ARTICLE VIII for breaches of covenants shall not in the aggregate exceed
the sum of (i) the aggregate purchase price of the Securities plus (ii) an amount equal to twenty percent (20%) per annum
of the aggregate purchase price of the Securities, which amount shall compound on each anniversary of the Closing Date and shall
be treated under clause (i) of this Section 8.5 as part of the aggregate purchase price of the Securities. Neither Company
nor Purchaser shall have any obligation under this ARTICLE VIII to indemnify any Person for lost profits or for indirect,
incidental, punitive, special or exemplary damages. The indemnification provided in this ARTICLE VIII shall be the sole
and exclusive remedy for monetary damages available to Company and Purchaser for matters for which indemnification is provided
under this ARTICLE VIII.

 

ARTICLE
IX

 

MISCELLANEOUS

 

9.1              Fees and Expenses. Except
as otherwise provided in any Transaction Document, each party shall pay its owns expenses incurred in connection with the preparation,
negotiation, execution, delivery, and performance of this Agreement and each Transaction Document and the consummation of the transactions
contemplated hereby and thereby. Company agrees to pay on demand all reasonable out-of-pocket expenses of Purchaser, including
reasonable fees and disbursements of counsel, in connection with: (i) any amendments, supplements, consents or waivers hereto,
the Transaction Documents because of actual or prospective defaults hereunder or Defaults or Events of Default, as such term is
defined in the Convertible Note, and (ii) the enforcement of this Agreement and the other Transaction Documents. In addition, Company
shall pay any and all stamp and other taxes and fees payable or determined to be payable in connection with the execution, delivery,
filing and recording of this Agreement and the other Transaction Documents and agrees to save Purchaser harmless from and against
any and all Liabilities with respect to or resulting from any delay in paying or omission to pay such taxes and fees. It is the
intention of the parties hereto that Company shall pay amounts referred to in this Section 9.1 directly. In the event Purchaser
pays any of the amounts referred to in this Section 9.1 directly, Company will reimburse Purchaser for such advances and
interest on such advance shall accrue until reimbursed at the Default Rate applicable for the Term Loan as defined in the Credit
Agreement.

 

    	30

    	 

    

 

9.2              Independent Contractors. Each
party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give either party the
power or authority to act for, bind, or commit the other party in any way. Nothing herein shall be construed to create the relationship
of partners, principal and agent, or joint-venture partners between the parties.

 

9.3              Specific Enforcement. The
parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed
in accordance with their specific intent or were otherwise breached. It is accordingly agreed that the parties shall be entitled
to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement and to enforce specifically the
terms and provisions hereof, in addition to any other remedy to which they may be entitled by law or equity.

 

9.4              Successors and Assigns. Company
may not assign, delegate, or otherwise transfer (whether by operation of law, by contract, or otherwise) its rights and obligations
under this Agreement or any of the other Transaction Documents or any portion hereof or thereof. Nothing in this Agreement or any
other Transaction Document shall prohibit Purchaser from assigning, delegating or transferring this Agreement and Purchaser’s
rights and obligations under any of the other Transaction Documents to an Affiliate of Purchaser. Otherwise, Purchaser may not
assign, delegate or otherwise transfer (whether by operation of law, by contract or otherwise) its rights and obligations under
this Agreement or any of the other Transaction Documents or any portion hereof or thereof (i) at any time prior to the first anniversary
of the Effective Date and, (ii) thereafter, to any Person whose principal business is providing integrated healthcare services
or who otherwise is a competitor of Company as determined reasonably and in good faith by the Company Board. Subject to the foregoing
and to the second paragraph of Section 6.1, nothing in this Agreement or any other Transaction Document shall prohibit Purchaser
from assigning, delegating, pledging or transferring this Agreement and Purchaser’s rights under any of the other Transaction
Documents, including collateral therefor, so long as any such assignee, delegatee, pledgee or transferee is a “United States
Person” for purposes of Section 7701(a)(30) of the Code. Any attempted assignment, delegation, or transfer in violation of
this Section 9.4 shall be void and of no force or effect.

 

9.5              Entire Agreement. THIS AGREEMENT
AND THE TRANSACTION DOCUMENTS AND INSTRUMENTS EXECUTED AND DELIVERED CONTEMPORANEOUSLY HEREWITH EMBODY THE ENTIRE AGREEMENT AND
UNDERSTANDING BETWEEN THE PARTIES HERETO AND SUPERSEDE ALL PRIOR AGREEMENTS AND UNDERSTANDINGS OF SUCH PERSONS, VERBAL OR WRITTEN,
RELATING TO THE SUBJECT MATTER HEREOF. THIS AGREEMENT AND THE DOCUMENTS AND INSTRUMENTS EXECUTED IN CONNECTION HEREWITH REPRESENT
THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY PRIOR, CONTEMPORANEOUS OR SUBSEQUENT ORAL AGREEMENTS OF
THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.

 

    	31

    	 

    

 

9.6              Notices. All demands, notices,
approvals, consents, requests, and other communications hereunder shall be in writing and shall be deemed to have been given when
the writing is delivered, if given or delivered by hand, overnight delivery service or facsimile transmitter (with confirmed receipt),
or five (5) days after being mailed, if mailed, by first class, registered or certified mail, postage prepaid, to the address or
telecopy number set forth below. If any time period for giving notice or taking action hereunder expires on a day that is not a
Business Day, the time period shall automatically be extended to the Business Day immediately following such day. Such notices,
demands, requests, consents and other communications shall be sent to the following Persons at the following addresses.

 

(i)             if
to Company, to:

 

Apollo Medical Holdings, Inc.

700 N. Brand Blvd., Suite 220

Glendale, California 91203

Attention:
Chief Financial Officer

Telephone:
(818) 396-8050

Fax: (818) 844-3888

 

(ii)            if
to Purchaser, to:

 

NNA of Nevada, Inc.

920 Winter Street

Waltham, Massachusetts 02451

Attention:
Mark Fawcett/Christine Smith

Telephone: (781) 699-2668/(781)
699-9165

Fax: (781) 699-9756

 

Company or Purchaser may, by notice given
hereunder, designate any further or different addresses or telecopy numbers to which subsequent demands, notices, approvals, consents,
requests or other communications shall be sent or persons to whose attention the same shall be directed.

 

9.7              Time Periods; Business Days.
Any action required hereunder to be taken within a certain number of days shall, except as may otherwise be expressly provided
herein, be taken within that number of calendar days excluding the day on which the counting is initiated and including the final
day of the period; provided, however, that if the last day for taking such action falls on a day which is not a Business
Day, the period during which such action may be taken shall automatically be extended to the Business Day immediately following
such day.

 

    	32

    	 

    

 

9.8              Amendments. Any provision
of this Agreement or any other Transaction Document to which Company is a party may be amended if such amendment is in writing
and is signed by Company and Purchaser.

 

9.9              Waiver. The rights and remedies
provided for herein are cumulative and not exclusive of any right or remedy that may be available to any party whether at law,
in equity, or otherwise. No delay, forbearance, or neglect by any party, whether in one or more instances, in the exercise or any
right, power, privilege, or remedy hereunder or in the enforcement of any term or condition of this Agreement shall constitute
or be construed as a waiver thereof. No waiver of any provision hereof, or consent required hereunder, or any consent or departure
from this Agreement, shall be valid or binding unless expressly and affirmatively made in writing and duly executed by the party
to be charged with such waiver. No waiver shall constitute or be construed as a continuing waiver or a waiver in respect of any
subsequent breach, either of similar or different nature, unless expressly so stated in such writing.

 

9.10              Descriptive Headings; No Strict
Construction. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a substantive
part of this Agreement. The parties to this Agreement have participated jointly in the negotiation and drafting of this Agreement.
If an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the
parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any of the provisions of this Agreement. The parties agree that prior drafts of this Agreement shall be deemed not to provide
any evidence as to the meaning of any provision hereof or the intention of the parties hereto with respect to this Agreement.

 

9.11              Governing Law. This Agreement
and, unless otherwise provided in any other Transaction Document, the other Transaction Documents shall be governed by and interpreted
in accordance with the laws of the State of New York (including Sections 5-1401 and 5-1402 of the New York General Obligations
Law, but excluding all other choice of law and conflicts of law rules).

 

9.12              Consent to Jurisdiction; Waiver
of Jury Trial. AS PART OF THE CONSIDERATION FOR NEW VALUE THIS DAY RECEIVED, EACH OF COMPANY AND PURCHASER HEREBY CONSENTS
TO THE EXCLUSIVE JURISDICTION OF FEDERAL COURT SITTING IN THE SOUTHERN DISTRICT OF THE STATE OF NEW YORK AND THE COURTS OF NEW
YORK SITTING IN THE BOROUGH OF MANHATTAN FOR ANY ACTION TO WHICH COMPANY AND PURCHASER ARE PARTIES. TO THE EXTENT PERMITTED BY
LAW, EACH OF COMPANY AND PURCHASER WAIVES TRIAL BY JURY AND WAIVES ANY OBJECTION WHICH IT MAY HAVE BASED ON LACK OF JURISDICTION
OR IMPROPER VENUE OR FORUM NON CONVENIENS TO THE CONDUCT OF ANY ACTION INSTITUTED HEREUNDER OR UNDER ANY OF THE OTHER TRANSACTION
DOCUMENTS, OR ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ANY OF THE OTHER TRANSACTION DOCUMENTS, OR ANY OTHER PROCEEDING
TO WHICH COMPANY OR PURCHASER IS A PARTY, INCLUDING ANY ACTIONS BASED UPON, ARISING OUT OF OR IN CONNECTION WITH ANY COURSE OF
CONDUCT, COURSE OF DEALING OR STATEMENT (WHETHER ORAL OR WRITTEN) OR ACTIONS OF PURCHASER OR COMPANY. COMPANY ALSO CONSENTS TO
THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED APPROPRIATE BY THE COURT.

 

    	33

    	 

    

 

9.13              Severability. In the event
that any provision of this Agreement shall be determined to be invalid or unenforceable by any court of competent jurisdiction,
such determination shall not invalidate or render unenforceable any other provision hereof.

 

9.14              Counterparts. This Agreement
may be executed in several counterparts, each of which shall be an original and all of which, together shall constitute but one
and the same instrument.

 

9.15              Captions. The captions to
the various sections and subsections of this Agreement have been inserted for convenience only and shall not limit or affect any
of the terms hereof.

 

[signature page follows]

 

    	34

    	 

    

 

IN WITNESS WHEREOF, the parties hereto
have caused this Agreement to be duly executed and delivered by their respective duly authorized officers as of the date first
above written.

 

	 	COMPANY:
	 	 
	 	APOLLO MEDICAL HOLDINGS, INC.
	 	 	 
	 	By:	/s/ Kyle Francis
	 	Name:	Kyle Francis
	 	Title:	CFO

 

Signature Page to Investment Agreement
(1 of 1)

 

    	 

    	 

    

 

	 	PURCHASER:
	 	 
	 	NNA OF NEVADA, INC.
	 	 	 
	 	By:	/s/ Mark Fawcett
	 	Name: 	Mark Fawcett
	 	Title:	Vice President and Treasurer

 

Signature Page to Investment Agreement
(2 of 2)

 

    	 

    	 

    

 

EXHIBIT A

 

FORM OF CONVERTIBLE NOTE

 

    	 

    	 

    

 

EXHIBIT B

 

FORM OF WARRANT

 

    	 

    	 

    

 

EXHIBIT C

 

FORM OF REGISTRATION RIGHTS AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]